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Preface: Outline of the thesis 
 
Nuclear medicine offers ideal techniques to visualize inflammatory processes using 
noninvasive methods of whole-body scanning, enabling the determination of both the 
localization and the extent of the inflammatory process throughout the body. Although 
autologous leukocytes, labeled with 111In or  99mTc, is still considered the ‘gold 
standard’ nuclear medicine technique to image infection and inflammation, there is a 
great need for a less cumbersome and less hazardous approach. Over the last few 
decades a series of radiopharmaceuticals to investigate infectious and non-microbial 
inflammatory disorders has been proposed. Radiolabeled monoclonal antibodies and 
antibody-fragments, radiolabeled chemotactic peptides and cytokines, and radiolabeled 
antibiotics are new approaches for this application. Chapter 1 presents an overview of 
these newly developed agents, their potential and their drawbacks.  
Most encouraging results have been obtained with radiolabeled receptor-
specific small proteins and peptides, such as interleukin-1 (IL-1), interleukin-2 (IL-2) 
and interleukin-8 (IL-8). IL-8 is a chemotactic cytokine involved in activation and 
recruitment of neutrophilic granulocytes to areas of infection. This protein binds to 
two types of receptors on neutrophils with high affinity. Previous studies by Van der 
Laken et al. in our group showed excellent infection imaging characteristics of 
radioiodinated IL-8 in a rabbit model of intramuscular infection. However, for clinical 
imaging, 123I is not a very suitable radionuclide: It has a limited availability, it is 
expensive and the adopted labeling method is rather laborious and the specific 
activities obtained were low. For clinical application, a simple and rapid labeling 
procedure, using the radiometal 99mTc, is preferable. The studies presented in this 
thesis focus on the labeling of IL-8 with 99mTc and the suitability of 99mTc-labeled IL-8 
to image infection and inflammation in various animal models.  
IL-8 is labeled with 99mTc using a derivative of hydrazinonicotinamide 
(HYNIC) as a molecule linking protein to radiometal. First, the chemistry of labeling 
proteins with 99mTc via HYNIC is investigated. In chapter 2, the conditions of 
conjugating HYNIC to proteins are varied in order to find the optimal conditions to 
obtain a maximal labeling efficiency while preserving the receptor binding.  
In chapter 3, the contribution of non-specific accumulation of 99mTc-labeled 
proteins in inflammatory foci in rats is studied. Eleven proteins of various molecular 
weights without specific interaction with components in inflammatory sites are labeled 
with 99mTc via HYNIC and studied in rats with intramuscular infection. The question 
which characteristic of a protein determines its nonspecific localization in infectious 
foci is addressed here.   
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Chapter 4 presents the first in vivo characterization of 99mTc-HYNIC-IL-8 in 
rabbits with an intramuscular infection. The results are compared with those obtained 
with radioiodinated IL-8.   
In Chapter 5 a further optimization of the labeling of IL-8 with 99mTc via HYNIC 
is described. Improvement of stability, specific activity and infection imaging 
characteristics are sought in a slight modification of the HYNIC-linker and in the use of 
alternative co-ligand systems.  
In the addendum to chapter 5 the importance of a careful choice of the 
radiolabeling conditions for the imaging characteristics is discussed. 
In chapters 6 and 7 the utility of 99mTc-HYNIC-IL-8 as an imaging agent  in 
rabbit models of colitis and pulmonary infection is explored . 
The pharmacokinetic behavior of 99mTc-labeled IL-8 is studied in chapter 8. 
These studies aim to demonstrate the specificity of uptake of IL-8 in the abscess and to 
elucidate the mechanism of uptake IL-8 in the abscess. 
In chapters 9 and 10 the scope of the study is broadened from IL-8 as infection 
imaging agent to other leukocyte receptor binding proteins. Complement factors C5a 
and C5a-des-Arg74, binding with high affinity to a common receptor on neutrophils, 
are labeled with 99mTc and tested for imaging of infection in a rabbit model (Chapter 
9).  
Several chemokines, closely related to IL-8, are compared for their capabilities 
to image infection in chapter 10. These proteins show various affinities for receptors 
on neutrophils and the relationship between neutrophil receptor affinity and suitability 
for infection imaging is investigated. Special attention is given to Neutrophil-
Activating-Petide-2 (NAP-2) and three NAP-2 variants. 
In chapter 11, the results of the presented studies are discussed and 99mTc-IL-8 
scintigraphy is put in perspective with other new approaches to visualize infection 
scintigraphically such as positron emission tomography (PET) using 18F-
Fluorodeoxyglucose (FDG).  
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Abstract 
In the past century a wide variety in approaches to visualise infections and 
inflammations by gamma scintigraphy has been developed. Autologous leukocytes, 
labelled with 111In or  99mTc, is still considered the ‘gold standard’ nuclear medicine 
technique to image infection and inflammation. The range of radiopharmaceuticals to 
investigate infectious and non-microbial inflammatory disorders is vastly expanding. 
Developments in protein/peptide chemistry and in radiochemistry should lead to 
agents with very high specific activities. Recently, positron emission tomography 
(PET) with 18FDG has been introduced and has been shown to delineate infectious and 
inflammatory foci with high sensitivity. The third millennium will show a gradual shift 
from basal (nonspecific) or cumbersome, even hazardous techniques (radiolabelled 
leukocytes) to more sophisticated approaches. Here a survey is presented of the 
different approaches in use or under investigation.  
 
 
Introduction 
Scintigraphic detection of infection and inflammation allows the determination of both 
the localisation and the number of infectious and inflammatory foci throughout the 
body. Since scintigraphic images are based on functional (physiological and/or 
biochemical) changes of tissues, infectious and inflammatory foci can be visualised in 
their early phases, when anatomical changes are not yet apparent. Over the last 30 
years multiple approaches to visualise infections and inflammations using 
radionuclides and gamma cameras have been developed. Recently, positron emission 
tomography (PET) with 18FDG has been introduced in the field of 
infection/inflammation imaging. To understand the way of action of many of these 
new agents, the pathophysiology of inflammation needs to be elucidated. 
 
 
Infection and inflammation 
Inflammation can be described as the reaction of the body to any kind of injury (1). 
Such injury can vary from trauma to ischaemia, to neoplasm, and also to invasion of 
micro-organisms, in which case we speak of  infection. Infection simply means 
“contamination with micro-organisms”. There can be infection without inflammation, 
as in the case of a severely immunocompromised patient. Especially in such cases it is 
clear that for the purpose of imaging one would need an agent that directly interacts 
with the micro-organisms. There can be inflammation without infection when tissue 
injury is not due to the invasion of micro-organisms but caused by  “stimuli”  as 
trauma, ischaemia, neoplasm or foreign particles (e.g. asbestos).   
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Components of the inflammatory response 
The response to acute infection/inflammation can be characterized by: 
• Locally increased blood supply 
• Increased vascular permeability in the affected area 
• Enhanced transudation of plasma proteins  
• Enhanced influx of leukocytes 
In response to tissue damage powerful defense mechanisms are activated, consisting of 
cells (leukocytes) and plasma proteins (opsonins, antibodies, complement). A complex 
variety of mediators, both vasoactive and chemotactic, is involved in the process. 
These mediators are generated in the focus of inflammation/infection and amplify the 
local response by the recruitment of cells and plasma components from the blood. 
Vasodilatation and increased endothelial permeability are induced to facilitate the 
extravasation of proteins and cells. In addition, the expression of adhesion molecules 
on endothelial cells and leukocytes is stimulated. In this way leukocytes migrate 
actively from the circulation into inflamed tissue. First, they adhere to the vascular 
endothelium due to locally enhanced expression of adhesion molecules (rolling, arrest 
and adhesion). Subsequently, they pass through the endothelium and the basal membrane 
(diapedesis) and migrate into the inflammatory focus (chemotaxis). In acute 
inflammation/infection the infiltrating cells are predominantly polymorphonuclear 
cells (PMN).  
In chronic inflammation/infection the cellular response is different from that of 
acute inflammation/infection. Infiltrating cells are predominantly mononuclear cells: 
lymphocytes, monocytes and macrophages.  
 
 
Non-specific and specific radiopharmaceuticals to image infection 
Non-specific radiotracers of infection  
Increased blood supply, increased vascular permeability and enhanced transudation are 
processes that can be utilized for non-specific accumulation of radiotracers. It must be 
emphasized that all radiopharmaceuticals accumulate to some extent in this non-
specific way at the site of infection. Examples of non-specific radiotracers for 
detection of infection based on increased vascular permeability are:  
• 67Ga-citrate 
• Radiolabelled non-specific immunoglobulins  
• Radiolabelled liposomes  
• Radiolabelled avidin-biotin   
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Table 1.  Strategies in infection imaging with specific radiotracers 
_________________________________________________________________________________ 
A   Target leukocytes moving to and present in the focus of infection: 
-  direct labelling of leukocytes (ex vivo labelling)  
-  indirect labelling of leukocytes (in vivo labelling): 
-  antibody-antigen interactions: radiolabelled antigranulocyte monoclonal                  
   antibodies/antibody-fragments   
      -  binding to receptors on leukocytes: 
             -  radiolabelled chemotactic peptides: formyl-Met-Leu-Phe 
             -  radiolabelled cytokines: the interleukins, platelet factor 4 
      
B   Target mediators that are already present in or migrate to the site of infection by 
radiopharmaca: 
             -  anti-E-selectin antibodies or anti-E-selectin F(ab’)2 fragments  
 
C   Administer radiolabelled mediators that migrate to the site of infection: 
-  radiolabelled mediators binding to leukocytes (see above: indirect labelling of  
   leukocytes) 
 
D   Target the locally present micro-organisms: 
-  radiolabelled ciprofloxacin 
    -  radiolabelled antimicrobial peptides  
 
E   Target the increased glucose uptake of infiltrated granulocytes and tissue  
     macrophages: 
-  18FDG in positron emission tomography (PET) 
_____________________________________________________________________ 
 
Specific radiotracers of infection 
Specific processes of accumulation comprise a number of possible interactions 
between radiopharmaceutical and target, e.g. receptor binding and antibody-antigen 
binding. Several pathways can be distinguished in infection imaging based on specific 
processes of accumulation of the radiopharmaceutical, as shown in table 1. Leukocytes 
preferentially target infection by chemotaxis and can therefore be used to transport 
radionuclides to the infected area (A). They move massively to the site of infection 
and localise there in great numbers. Detection of infection can be accomplished by 
direct labelling of leukocytes (ex vivo labelling) or by labelling leukocytes indirectly, 
i.e. in vivo. Ex vivo labelling requires withdrawal of blood from the patient, 
purification of leukocytes, labelling and reinjection of the radiolabelled cells. 
Autologous leukocytes labelled with 111In or 99mTc can lead to positive imaging due to 
the fact that leukocytes, even after ex-vivo labelling, have the capacity to migrate to 
the inflamed area. In vivo labelling of leukocytes can be based on antibody-antigen 
interactions (e.g. radiolabelled antigranulocyte monoclonal antibodies) or on leukocyte 
receptor binding (e.g. radiolabelled chemotactic peptides and cytokines). With respect 
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to pathway B and C, vasoactive or chemotactic mediators of the inflammatory process 
could either be targeted in vivo by radiopharmaca or could be radiolabelled in vitro 
and injected. So, either we label in vivo a particular component that is already present 
in or goes to the inflamed area, or we inject in a radiolabelled form the mediator itself. 
Pathway D can be said to be truly infection imaging, in the way that 
radiopharmaceuticals are used that specifically target micro-organisms. A completely 
different mechanism of accumulation at the inflammatory site is underlying PET scans 
using 18FDG: Enhanced uptake of radiolabelled glucose by infiltrated granulocytes and 
tissue macrophages with increased metabolic requirements (Pathway E). The 
accumulation of 18FDG in cells with increased glucose metabolism is  specific. 
However, 18FDG is taken up also by e.g. tumour cells. So, accumulation of 18FDG is 
not specific for infection and inflammation processes as such.  
 
Characteristics of  the ideal conditions for infection imaging 
A lot of radiopharmaceuticals for the diagnosis of infection have been developed in the 
last decades, each with its own advantages and disadvantages. Criteria for the ideal 
radiotracer are summarised in Table 2. It will be clear that there exists no 
radiopharmaceutical that meets all these criteria in a perfect way. In clinical practice 
the choice of the imaging agent is based on careful examination of each individual 
case. Early diagnostic imaging is preferable but not always necessary as in the case of 
osteomyelitis or in infected bone/joint prostheses. A one-day protocol is favorable in 
cases of severe and acute illness like lung infections for example. Imaging with high 
radiation doses or the occurrence of minor transient side-effects after administration of 
the radiopharmaceutical is in general unfavorable and should be considered only when 
significant clinical benefit is to be expected. 
 
 
Table 2. Criteria for an ideal radiotracer 
__________________________________________________________________ 
                     
• Efficient accumulation and good retention in inflammatory foci 
• Rapid clearance from the background 
• No accumulation in non-target organs 
• No toxicity 
• Early diagnostic imaging 
• Ready availability and  low cost  
• Easy low-hazard preparation  
• Differentiation between infection and non-microbial inflammation 
• Low radiation burden 
____________________________________________________________________ 
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Developing new radiotracers 
For the development of new infection imaging radiopharmaceuticals the following 
route can be designed. Once a potential new radiopharmaceutical has passed the 
laboratory level of synthesis, purification and quality control, in vitro and in vivo 
testing starts. In case the potential new radiotracer aims at binding to certain cell types 
in vivo (e.g. leukocytes, lymphocytes, bacteria), in vitro binding assays with the target 
cells can give an indication of the potential of the product. Target cells for binding 
studies can be isolated from the blood or cell lines can be generated bearing receptors 
from original cells by cDNA transfection techniques. Reproducibility of receptor 
binding assays is generally better using these cell cultures bearing the desired 
transfected receptors. In binding assays the affinity and specificity of the agent for the 
target cells can be determined. 
Subsequently, the new radiotracer can be tested in one of the simple and easy to 
use animal models of infection. Mice or rats with soft tissue infections induced by 
S.aureus or E.coli can serve as a good model for these first explorations. 
Biodistribution data generated in such a model can give a first impression of the 
imaging potential of the new tracer and allow the first comparison with known agents 
(2,3). Data on accumulation in the target (%ID/g), target/non-target ratios, blood 
clearance and the primary route of clearance (hepatobiliary/renal) can be obtained. 
The next and in most cases last step in preclinical testing will involve more 
advanced models of infection in animals of more closely related species like rabbits 
and dogs. High costs and strict legal regulations will in most cases impede the use of 
primates for these studies. Moreover, the new information that experiments in primates 
could reveal does not outweigh the investments in money and energy in general. 
Besides the soft tissue infection mentioned above, more complicated models of  
infection can be used, which are of more clinical relevance: colitis (4,5), osteomyelitis 
(6,7), endocarditis (8,9), meningitis (10,11) and respiratory tract infections (12,13). In 
many cases these models require more specialised skills and experience. The model of 
choice depends on the intended application of the new radiotracer. In the rabbit and 
dog model(s) a direct comparison between the new radiotracer and the ‘gold standard’ 
111In or 99mTc labelled purified granulocytes can be carried out. 
Once a new radiotracer has successfully passed these stages of laboratory and 
preclinical research, the agent should be tested in clinical trials in patients suspected of 
infectious or inflammatory diseases. 
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Detection of infection by non-specific radiotracers 
 
67Ga-citrate 
67Ga-citrate is used in clinical practice in several pathological conditions, including 
infection and many skeletal disorders (14,15). 67Ga-citrate binds, once injected in the 
circulation, to circulating transferrin. This complex extravasates at the site of infection 
due to the locally enhanced vascular permeability (16), and is partly bound there to 
lactoferrin excreted by leukocytes or to siderophores produced by microorganisms 
(17). The agent is excreted partly via the kidneys (especially during the first 24 hours 
after injection), and via the gastrointestinal tract. Physiological uptake of the radiolabel 
occurs in liver, bone, bone marrow and bowel. Although 67Ga-citrate scintigraphy has 
high sensitivity for both acute and chronic infection and noninfectious inflammation (18), 
there are several shortcomings that limit its clinical application. The specificity of the 
technique is low, due to physiological bowel excretion and accumulation in malignant 
tissues and areas of bone modeling (19-21). In addition, the radiopharmaceutical has 
unfavourable imaging characteristics (long physical half-life and high energy gamma 
radiations), causing high radiation absorbed doses. Furthermore, optimal imaging often 
requires delayed recordings up to 72 hours. These unfavorable characteristics, in 
combination with the development of newer radiopharmaceuticals, have narrowed the 
clinical indication for gallium scintigraphy to certain conditions such as lung infections 
and chronic osteomyelitis (18,21).  
 
Non-specific immunoglobulins  
Initially it was hypothesized that human polyclonal immunoglobulin (HIG) was retained 
in infectious foci due to the interaction with Fc-γ receptors as expressed on infiltrating 
leukocytes (22). Later studies have shown that radiolabelled HIG accumulates in 
infectious foci by nonspecific extravasation due the locally enhanced vascular 
permeability (23).  
For clinical use HIG has been labelled with 111In as well as 99mTc. Both agents 
have slow blood clearance and physiological uptake in the liver, the spleen and the 
kidneys. The 99mTc-labelled preparation has the known ideal radiation characteristics, 
while the 111In-labelled preparation allows imaging at time points beyond 24 h 
postinjection. 111In or 99mTc-labelled HIG has been extensively tested in a large number 
of clinical studies. It has shown excellent performance in the localisation of 
musculoskeletal infection and inflammation (24). In addition, good results have been 
reported in pulmonary infection - particularly in immunocompromised patients – (25,26), 
and abdominal inflammation (27). In a comparative study, Dams et al. showed that 
99mTc-HIG labelled with the Tc-99m chelator hydrazinonicotinamid (HYNIC), has in 
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vivo characteristics highly similar to those of 111In-HIG, and in most cases can replace 
the 111In-labelled compound (28). Poor sensitivity of radiolabelled HIG is found in the 
diagnosis of endocarditis and vascular lesions in general, due to long lasting high levels 
of circulating activity. A general limitation is the long time span between injection and 
final diagnosis (24-48 h). 
 
Liposomes 
Liposomes are spheres consisting of one ore more lipid bilayers surrounding an 
aqueous space. They were proposed as vehicles to image infection some 20 years ago, 
but the preparations used in those early years were cleared from the circulation very 
rapidly by the mononuclear/phagocyte system (MPS). However, if the surface of the 
liposomes is coated with a hydrophylic polymer such as polyethyleneglycol (PEG), 
they circumvent recognition by the MPS, leading to a prolonged residence time in the 
circulation and enhanced uptake in pathological sites by extravasation due to locally 
enhanced vascular permeability (29). Such stabilized PEG-liposomes can be labelled 
with 111In-oxinate and with 99mTc using either HMPAO as an internal label or via 
HYNIC as an external chelator. Labelling is easy and takes only minutes (30). The 
first clinical evaluation showed good imaging of focal infection (31). In patients 
suspected of infectious or inflammatory disease, 99mTc-PEG-liposomes were directly 
compared to 111In-IgG-scintigraphy. 99mTc-PEG-liposomes scintigraphy showed high 
sensitivity (94%) and specificity (89%). Visualization of muscuskeletal and abdominal 
pathology was better than with 111In-IgG.  Unfortunately, in another clinical study self-
limiting side-effects were observed in three out of nine patients (32). 
 
The avidin-biotin system 
Avidins are a family of proteins present in the eggs of amphibians, reptiles and birds; 
streptavidin is a member of the same family. Avidin and streptavidin (MW 64-60 kDa) 
bind to biotin with extremely high affinity (Kd = 10-15 M). Biotin is a compound of low 
molecular weight that can be radiolabelled. The avidin-biotin approach is based on the 
fact that avidin (or streptavidin) will non-specifically localise at sites of infection due 
to increased vascular permeability. Avidin (or streptavidin) is injected as a pretargeting 
agent, followed hours later by a second injection with radiolabelled biotin (33). Good 
diagnostic accuracy was demonstrated in a study of vascular infection (34) and of 
chronic osteomyelitis (35).  
 
Limitations in the use of non-specific radiotracers to image infections 
Infectious foci can be visualised with radiotracers without a specific interaction 
between the agent and a tissue component in the infectious focus, in a non-specific 
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process of localisation due to the locally enhanced vascular permeability. 
Extravasation of (macro)molecules via diffusion is a slow process. Prolonged high 
blood levels are needed to allow (sufficient) diffusion into the target tissue. However, 
high blood levels implicate relatively high background levels, especially in well-
perfused tissues. Secondly, in chronic inflammation the vascular permeability tends to 
normalize. Furthermore, because nonspecific agents accumulate due to a common 
feature of infection and inflammation, these agents cannot distinguish between 
infection and inflammation. As a result, non-specific radiotracers are principally 
limited in their ability to detect (and discriminate between) infections and 
inflammations. In this 67Ga-citrate, radiolabelled HIG, radiolabelled liposomes and the 
avidin-biotin approach face the same inherent limitations. 
 
 
Detection of infection by specific radiotracers 
As outlined in Table 1, different strategies in imaging infection using specific 
radiotracers can be employed. These agents will be presented in more detail. An 
overview of agents that are currently being developed for infection imaging is 
presented in Table 3.  
 
 
Table 3. Overview of studies in infection imaging with new specific radiotracers (including 
18FDG). 
_____________________________________________________________________ 
 
    Agent              Number of patients studied    Year of publication    Ref.  
_____________________________________________________________________ 
Antigranulocyte antibodies: 
   Anti-NCA-95: BW 250/183  >300            1989-2000          42-48 
   Anti-CD66: LeukoScan            >100   1994-2000      49-51 
   Anti-CD15: LeuTech   >200    1996-2000          52-55 
Chemotactic peptide analogs  preclinical  1991-1997      59-63 
Interleukin-1ra        5   2000          66 
Interleukin-2     >400     1999,2000      69-71 
Interleukin-8            8   1996-2000       3,72-74 
PF-4 derivative: P483H       30   1996,1999      75,76 
Anti E-selectin antibodies       25   1996-1997      80,81 
Ciprofloxacin: Infecton   >1000   1996-2000      82,83 
Neutrophil defensins: HNP-1  preclinical  1998,1999      84,85 
18FDG (PET)      >250   1996-2000       91-98 
_____________________________________________________________________ 
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Detection of infection by direct labelling of leukocytes 
 
Ex vivo labelled leukocytes 
Radiolabelled autologous leukocytes have been developed in the seventies and eighties 
(36-38) and are still considered the “gold standard” nuclear medicine technique for 
infection and inflammation imaging. After intravenous administration, there is initial 
sequestration of the labelled leukocytes in the lungs with subsequent rapid clearance of 
the activity from the lungs. The radiolabel rapidly clears from the blood and in most 
cases there is high uptake in granulocytic infiltrates, while a substantial portion of the 
leukocytes (presumably the damaged cells) accumulate in the spleen. Thus, as a 
radiopharmaceutical, radiolabelled leukocytes are a specific indicator for leukocytic 
infiltration, but not for infection. McAfee et al. developed a technique to label autologous 
leukocytes with 111In using oxinate as a chelate to transfer the radiolabel into the cell 
(36). Peters et al. developed a labelling technique using HMPAO, a lipophilic chelator, 
that allows efficient labelling of white blood cells with 99mTc (37). In contrast to 111In-
oxinate some of the 99mTc-HMPAO is released from the leukocytes after injection and 
subsequently excreted renally (within minutes) and hepatobiliary (after hours) (38). Due 
to the more optimal radiation characteristics 99mTc-labelled leukocytes have replaced 
111In-labelled leukocytes for most indications. For evaluation of kidney, bladder and gall 
bladder infections the use of leukocytes labelled with 111In is preferred. The excellent 
performance of radiolabelled leukocytes for imaging infection and inflammation was 
demonstrated in a series of studies: for imaging infectious/inflammatory foci 
sensitivity exceeded 95% (38,39). There was some concern that more chronic 
infections could be missed with labelled leukocyte scans, because such infections 
generate a smaller granulocyte response than acute infections. However, a study in 155 
patients showed that the sensitivity of labelled leukocytes for acute infections (90%) 
was not significantly different from the sensivity for detection chronic infections 
(86%) (40). With regard to diagnostic accuracy there is no need for a better imaging 
agent than labelled autologous leukocytes. However, the preparation of this 
radiopharmaceutical is laborious, requires specialized equipment and could be 
hazardous. Isolating and labelling a patient’s white blood cells takes a trained 
technician approximately 3 hours. In addition, the need to handle potentially 
contaminated blood could lead to transmission of blood-born pathogens such as HIV 
and HBV  (41).  
 
Detection of infection by in vivo labelling of leukocytes 
A gross division can be made in radiotracers that bind leukocytes by receptor-binding 
(relatively small molecules; MW < 20 kDa) and radiotracers that bind leukocytes by 
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antibody-antigen interaction (relatively large molecules). The antibodies range in 
molecular weight from 50 kDa (antibody fragments) via 150 kDa (IgG) to 900 kDa 
(IgM). 
 
Antigranulocyte antibodies and antibody fragments 
Ever since it became clear that radiolabelled autologous leukocytes could visualise 
infectious foci, investigators have tried to develop a method that would label 
leukocytes in the circulation or in the infectious foci. Instead of isolating the white 
blood cells from a patient and labelling the cells ex vivo, these methods aimed to label 
white blood cells in vivo. Labelling procedures are easier and do not require handling 
of potentially contaminated blood. The use of radiolabelled monoclonal antibodies 
against surface antigens as present on granulocytes was one of the first attempts to 
accomplish in vivo labelling of leukocytes. Several monoclonal antibodies reactive 
with antigens expressed on granulocytes (NCA, CD15, CD66 and CD67) have been 
developed. At least three anti-granulocyte antibodies have been tested for infection 
imaging: anti-NCA-95 IgG (BW250/183) (42-48), anti-NCA-90 Fab' (Immu-MN3, 
leukoscan®: anti-CD66) (49-51), and anti-SSEA-1 IgM (LeuTech®: anti-CD15) (52-
55). Each of these anti-granulocyte antibodies labelled with 99mTc or 123I allowed 
accurate delineation of infection.  
 It was soon realized that the in vivo behavior of these labelled anti-granulocyte 
antibody preparations, did not mimick the behavior of radiolabelled leukocytes. In 
general, blood clearance of the IgG preparations was much slower, giving a high 
background radioactivity that decreases slowly with time. For that reason the time 
interval between injection of the labelled antibodies and the acquisition of images is 
relatively long in order to get good target-background ratios. Furthermore, no initial 
lung entrapment was seen and splenic uptake was much lower, while the preparations 
based on antibody fragments (Fab, Fab') had a much higher renal excretion. Similarly, 
the IgM antibody had a much higher liver uptake as compared to the ex vivo labelled 
white blood cells. Becker et al. showed that less than 10% of the radiolabelled 
BW250/183 antibody as present in the blood was actually associated with granulocytes 
(42). These observations indicated that the anti-granulocyte antibody approach for 
infection imaging, although feasible did not represent a method to label white blood 
cells in vivo. It is now generally accepted that radiolabelled anti-granulocyte 
antibodies localise in infectious foci mainly by nonspecific extravasation due to the 
locally enhanced vascular permeability, and that binding of the antibody to infiltrated 
leukocytes in the inflamed tissue may contribute to the retention of the radiolabel in 
the focus. Perhaps an exception should be made for anti-SSEA-1 IgM (LeuTech®: 
anti-CD15) (52). This antibody recognizes CD-15 antigens on PMNs with high affinity 
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(Kd = 10-11M) and the in vivo PMN binding exceeds 50%, pointing towards more 
specific processes in infected tissue accumulation. Recently, a 99mTc-labelled anti-
CD15 IgM monoclonal antibody has shown promising results in patients with 
equivocal appendicitis (53). 
The anti-granulocyte antibody-based radiopharmaceuticals visualised infectious 
foci in patients with a sensitivity between 80 and 90% (56). 99mTc-BW250/183 
scintigraphy was useful in the evaluation of vascular graft infection and prosthetic 
heart valve infection. Good results were also obtained in the evaluation of patients 
with inflammatory bowel disease (43,56), although the agent appeared to be less 
accurate compared to labelled leukocytes (45,46). Pulmonary infections -  with the 
exception of lung abscesses - were not visualised. Peripheral bone infections were 
adequately visualised, but the sensitivity decreased in case the focus was located closer 
to the spine (50). Due to the relatively slow blood clearance of the agent, a 24-hour 
postinjection scan is generally necessary for correct localisation of the inflammatory 
focus. A major disadvantage of the murine monoclonal antibodies is that they may 
induce human antimouse antibodies (HAMA), which can result in altered 
biodistribution after subsequent injections (56,57). In this respect, the use of antibody 
fragments instead of the whole antibody seems to be more advantageous, since such 
fragments appeared to be less immunogenic (56). In addition, antibody fragments 
show faster blood clearance and may thus provide earlier diagnosis. The 99mTc-labelled 
antigranulocyte Fab'-fragment (Leukoscan®) has been registered in Europe as an 
infection imaging agent (49). Further clinical studies will help to define the utility of 
these new agents in clinical practice. 
 
Chemotactic peptides 
Like anti-granulocyte antibodies, peptides with high affinity for receptors expressed 
preferentially on granulocytes, could be suitable for targeting granulocytes in vivo. A 
wide variety of peptides that bind to receptors as expressed on white blood cells has been 
tested for the detection of infection. One of the first receptor-binding peptides that was 
tested for its ability to image infectious foci was the chemotactic peptide formyl-Met-
Leu-Phe. This tripeptide that is N-terminally formylated, is a chemotactic factor 
produced by bacteria. It binds to receptors on granulocytes and monocytes with high 
affinity (Kd = 10-30 nM). The first work on this radiolabelled chemotactic peptide was 
reported almost twenty years ago. Zoghbi et al. and later McAfee et al. labelled f-Met-
Leu-Phe and investigated its in vivo characteristics (58). They found that even low doses 
of peptide induced a transient granulocytopenia. In 1991, Fischman et al. described the 
synthesis of four DTPA-derivatized chemotactic peptide analogs and their labelling with  
111In (59). All peptides maintained biologic activity and receptor binding affinity. The 
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peptides were tested in rats with Escherichia coli infections. All analogs showed 
preferential localisation in the focal infection within one hour after injection. In a 
comparative study in rabbits with E. coli infections, it was demonstrated that localisation 
of infection using 99mTc-labelled f-Met-Leu-Phe was superior to that of 111In-labelled 
leukocytes (60). However, although a high specific activity 99mTc-labelling method was 
applied, a peptide dose as low as 10 ng/kg still had an effect on the peripheral leukocyte 
counts (61). Several antagonists were developed to circumvent this undesirable biologic 
activity of the radiolabelled chemotactic peptide. However, these antagonists had lower 
uptake in the infectious focus, most likely due to reduced affinity for the receptor (62,63). 
In summary, rapid imaging of infection and inflammation is feasible with radiolabelled 
chemotactic peptides, however, the undesired biologic side-effects of these peptides seem 
to impede further clinical development. 
 
Cytokines 
Labelled cytokines are an interesting class of protein radiopharmaceuticals of small 
molecular weight (< 20 kDa). Cytokines act through an interaction with specific cell-
surface receptors expressed on known cell populations. Binding affinities are usually 
high (nanomolar range). Cytokine receptors are expressed at low levels on non-
excitated cells, but their expression can be upregulated during activation. 
  
 Interleukin-1 (IL-1) 
IL-1 binds receptors as expressed mainly on granulocytes, monocytes and lymphocytes, 
with high affinity. Studies in mice with focal Staphylococcus aureus infections showed 
specific uptake of radioiodinated IL-1 at the site of infection (2). Using IL-1 receptor 
blocking antibodies, it could be demonstrated that accumulation of the agent in the 
infectious foci was due to binding to the IL-1 type II receptor (64). Unfortunately, the 
biologic effects (e.g., hypotension, headache) of IL-1 even at very low doses (10 ng/kg) 
precluded clinical application of radiolabelled IL-1. Therefore, the naturally occurring 
IL-1 receptor antagonist (IL-1ra) was tested as an imaging agent. This equally-sized (17 
kDa) protein binds IL-1 receptors with similar high affinity but lacks any biologic 
activity. In a comparative study in rabbits with focal E. coli infections, the abscess uptake 
of radioiodinated IL-1ra was half that of radioiodinated IL-1 (65). 123I-IL-1ra was tested 
in patients with rheumatoid arthritis. In these patients, inflamed joints were nicely 
visualised, however, major retention of the radiolabel in the intestinal tract indicated that 
this agent can not be used to visualise infectious and inflammatory lesions in the 
abdomen (66). 
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  Interleukin-2 (IL-2) 
Chronic inflammation is characterized by infiltration of the target tissue by lymphocytes. 
These infiltrates have been successfully targeted with radiolabelled IL-2. The IL-2 is 
considered to bind specifically to IL-2 receptors as expressed on activated T-
lymphocytes. In a study in an animal model of human autoimmune diabetes mellitus, 
Signore et al. showed that lymphocytic infiltration in the pancreas could be visualised 
with 123I-labelled IL-2 between five and fifteen minutes after injection (67). A method 
was developed that allowed the preparation of a 99mTc-IL-2 preparation with a high 
specific activity (68). Studies in patients with chronic inflammatory conditions, including 
insulin-dependent diabetes, Hashimoto thyroiditis, Graves’ disease, Crohn’s disease, 
coeliac disease and other autoimmune diseases, demonstrated localisation of 123I- or 
99mTc-labelled IL-2 at the site of lymphocytic infiltration (69-71). These results suggest 
that  radiolabelled IL-2 might be a suitable agent for in vivo targeting of mononuclear 
cell infiltration as present in autoimmune diseases. 
 
  Interleukin-8 (IL-8) 
IL-8 is a small protein (8.5 kDa) belonging to the CXC subfamily of the chemokines, or 
chemotactic cytokines, in which the first two cysteine residues are separated by one 
aminoacid residue. IL-8 binds to receptors on neutrophils with high affinity (0.3 – 4 nM). 
Hay and collegues (72) studied the in vivo behaviour of  radioiodinated IL-8 in a rat 
model with carrageenan-induced sterile inflammations. The uptake peaked at 1-3 hours 
after injection and declined thereafter. Target-to-background ratios remained relatively 
low. In a pilot study in 8 patients these investigators showed that a 123I-IL-8 could 
visualise inflammatory foci (73). The labelling method appeared to have major effects 
on the in vivo biodistribution of radioiodinated IL-8. The scintigraphic imaging 
characteristics of IL-8 labelled via the Bolton-Hunter method were clearly superior to 
IL-8 labelled via the iodogen method, despite similar in vitro cell binding 
characteristics (3). In rabbits with focal E. coli infection, accumulation of 123I-labelled 
IL-8 in the abscess was rapid and high. The specific activity of this IL-8 preparation was 
relatively low resulting in a transient drop of peripheral leukocyte counts to 45% after a 
dose of 25 µg/kg 123I-IL-8, followed by a leukocytosis (170 % of preinjection level) 
during several hours. Recently,  a 99mTc-labelled IL-8 preparation was developed using 
HYNIC as a chelator. In rabbits with E. coli infection, high abscess uptake of  99mTc-
HYNIC-IL-8 and high abscess-background ratios were obtained compared to those using 
the radioiodinated preparation (74). The higher specific activity of the 99mTc-labelled 
IL-8 preparation ameliorates concerns about the influence on WBC counts. 
  
  
  
Infection imaging reviewed     25 
  Platelet Factor 4 (PF-4) 
PF4 is like IL-8 a member of the CXC chemokines.  PF4  binds the CXC type II (= IL-8 
type B) receptors expressed on neutrophils and monocytes. PF4 has been called the 
“body’s heparin neutralizing agent”.  At Diatide Inc. the peptide P483H was synthesized. 
This peptide contains the heparin-binding region of PF4 - complexed with heparin - and a 
lysine-rich sequence to facilitate rapid renal clearance. In a rabbit model of infection, 
99mTc-P483H clearly delineated the infectious foci as early as 4 hours after injection. No 
systemic side effects were observed: the transient neutropenia observed with  IL-8 and f-
Met-Leu-Phe was not encountered after i.v. injection of P483H (75). 99mTc-P483H has 
been studied in patients to test its applicability as imaging agent for scintigraphic 
detection of infection and inflammation with fair results (82% sensitivity, 77% 
specificity) (76). However, in some patients excessive thyroid uptake was observed, 
suggesting the release of  99mTc from the agent in vivo. 
 
Detection of infection by targeting adhesion molecules 
 
Anti-E-selectin antibodies or anti-E-selectin F(ab’)2 fragments  
E-selectin is an endothelial adhesion molecule exclusively expressed on the luminal 
surface of activated endothelial cells and capable of binding to leukocytes. 
Radiolabelled anti-E-selectin monoclonal antibodies (77) or anti-E-selectin F(ab’)2 
fragments (78) have been successfully used to image arthritis and chronic 
inflammatory bowel disease (79-81). To overcome the possible induction of human 
anti-mouse antibodies, a bioengineered single-chain antibody construct has been 
developed. 
 
Detection of infection by radiolabelled antibiotics  
 
Ciprofloxacin (Infecton) 
None of the agents discussed above can make a differential diagnosis between 
infection and inflammation as they accumulate in the focus due to a common feature 
of infection and inflammation. Ciprofloxacin, a fluoroquinolone antimicrobial agent, 
binds to the DNA gyrase enzyme present in all dividing bacteria, even to those 
resistant to ciprofloxacin. Fluoroquinolones are thought not to bind to dead bacteria 
nor to accumulate in non-microbial inflammatory processes such as Crohn’s disease. It 
is claimed that with these 99mTc-labelled agents it is possible to discriminate between 
infection and sterile inflammation (82). First clinical studies in several centers so far 
show high accuracy in the detection of bacterial infection. Data on the efficacy of 
99mTc-Infecton imaging in 90 patients with suspected infective disorders reveal a 
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sensitivity of 70% and a specificity of 93% (83). Since this agent is not taken up in 
bone marrow it could be very helpful in the evaluation of infection of orthopaedic 
prostheses.  
 
Antimicrobial peptides 
Neutrophil defensins (human neutrophil peptides, HNP) are stored in the granules of 
neutrophils. In addition to their direct antimicrobial activity, the peptides have chemo-
attractive activity for various monocytes and lymphocytes. It has been hypothesized 
that their cationic charge  facilitates binding of these peptides to various micro-
organisms. HNP-1 was labelled with 99mTc using a direct method by reducing the 
disulfide bridges of the molecule. Using this agent in experimental thigh infections in 
mice abscess-to-background ratios were low and decreasing with time (84,85). In the 
peritoneal cavity of the infected mice, 99mTc-HNP-1 bound to bacteria rather than to 
leukocytes. However, this agent needs extensive optimisation and tailoring to become 
able to distinguish between bacterial infection and sterile inflammation. 
 
Detection of infection by positron emission tomography (PET) using 18FDG 
The use of 18F fluorodeoxyglucose positron emission tomography (FDG-PET) has 
become increasingly important for differentiating malignant from benign tumours, for 
tumour staging, and for evaluating treatment efficacy in cancer patients (86,87). As 
early as 1931, Warburg has demonstrated an increased glucose metabolism in 
malignant tumours in vitro (88). FDG accumulates quantitatively in malignant tumours 
in vivo mainly due to their increased glucose metabolism. However, during staging 
and follow-up of malignant tumours, false-positive findings occasionally occurred, 
mainly due to infectious or granulomatous processes (89). Ever since Tahara et al. first 
demonstrated high FDG uptake in human abdominal abscesses in 1989 (90), FDG has 
been reported to accumulate in various inflammatory processes. Infection imaging 
with FDG-PET is based on the fact that granulocytes and macrophages use glucose as 
an energy source. When activated through infection, metabolism and thus FDG-uptake 
increases. The usefulness of FDG-PET to image infections has recently been 
demonstrated in several patient studies (Table 3) (91-98). FDG-PET has been studied 
in a wide variety of infections, including lesions of baterial, tuberculous and fungal 
origins, soft tissue infections as well as bone infections. Sensitivities and specificities 
generally exceeded 90%. FDG-PET has been especially successful in cases of 
osteomyelitis (93,95-98). The high spatial resolution allows differentiation between 
osteomyelitis or inflammatory spondylitis and infection of the soft tissue surrounding 
the bone (97). High spatial resolution and rapid accumulation into infectious foci are 
significant advantages over conventional imaging techniques as labelled leukocytes. 
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However, the high degree of unspecificity due to uptake in any cell type with high 
glycolytic activity is a serious limitation of the use of FDG-PET for infection imaging. 
E.g., FDG-PET does not allow the discrimination between tumour lesions and 
inflammatory  lesions. Depending on the clinical setting, this may restrict the 
usefulness of FDG-PET in the imaging of infection. Moreover, FDG uptake in 
infectious foci is affected by serum glucose levels and by conditions as diabetes 
mellitus. Cost is another issue. FDG-PET is a rather expensive imaging modality and 
prospective studies in various patient populations will have to show the cost-
effectiveness of FDG-PET for imaging of inflammatory and infectious diseases.   
 
Conclusion 
In the third millennium we will face a gradual shift in the field of nuclear medicine 
from the basal (non-specific) and cumbersome, even hazardous techniques 
(radiolabelled leukocytes) to more intelligent approaches based on small agents 
binding their targets with high affinity. Classes of agents will be designed to 
specifically distinguish between infection and non-infectious inflammation and 
between acute and chronic processes. The advantages of 99mTc as radionuclide will be 
fully explored. Labelling with high specific activity will reduce doses to be used, so 
that undesirable agonistic activities will be non-existent. In a totally different 
approach, undesirable agonistic activities will be coped with by chemical modification 
of the agonist. Furthermore, 18FDG-PET may prove to be as useful in the rapid 
detection and management of human infections, as it is for management of malignant 
diseases.  
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ABSTRACT 
 
At present there is considerable interest in labeling peptides with Tc-99m for the 
development of target specific radiopharmaceuticals for imaging purposes. In the 
present study the conjugation of the bifunctional coupling agent succinimidyl-
hydrazinonicotinamide (S-HYNIC) was studied and optimized in  a series of peptides 
(MW 6.5 – 14.3 kDa).  
Methods: Aprotinin (MW 6.5 kDa), cytochrome C (MW 12.4 kDa), α-lactalbumin 
(MW 14.2 kDa) and lysozyme (MW 14.3 kDa) were conjugated with S-HYNIC via 
the ε-aminogroups of their lysine-residues. The effects of molar conjugation ratio, 
reaction temperature, pH and protein concentration were studied. Reaction products 
were analyzed both with respect to the HYNIC-substitution ratio 
(spectrophotometrically) as well as to the labeling efficiency (SG-ITLC) and 
molecular size (FPLC). The effects of conjugation on biological activity were studied 
in three proteins binding to receptors on leukocytes: interleukin-8 (MW 8.5 kDa), 
interleukin-1α (MW 17 kDa) and interleukin-1 receptor antagonist (MW 17 kDa). 
Results: The labeling efficiency of aprotinin, cytochrome c, α-lactalbumin and 
lysozyme  conjugated under optimal conjugation conditions exceeded 90%. Specific 
activities obtained were up to 7.5 MBq/µg. Conjugation was most efficient at 0 0C (as 
compared to 20 and 40 0C), at pH 8.2 (as compared to 6.0, 7.2 and 9.5) and at protein 
concentrations ≥ 2.5 mg/ml. In general, efficiency increased with increasing molar 
conjugation ratio (protein-HYNIC-ratio 1:3 < 1:6 < 1:15 < 1:30). For the  receptor 
binding proteins, biological activity was preserved only under mildest conjugation 
conditions. For each of these proteins an inverse relation between labeling efficiency 
and receptor binding capacity was found.  
Conclusion:  Labeling proteins with 99mTc using S-HYNIC is easy, rapid and efficient 
and preparations  with high specific activity can be obtained. However, biological 
activity of proteins may be lost at high HYNIC-substitution ratios. With the proteins 
tested here a careful balancing of reaction conditions resulted in acceptable, be it 
suboptimal, labeling efficiencies and preservation of biological activity. 
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INTRODUCTION 
 
Nowadays there is considerable interest in labeling proteins and peptides with 99mTc 
for the development of target specific imaging agents. Three main strategies for 
labeling proteins with 99mTc can be distinguished: (i) direct labeling, (ii) preformed 
chelate approach, and (iii) indirect labeling using a bifunctional coupling agent (BCA) 
(1;2). The direct labeling approach uses a reducing agent to convert the cystine 
disulfide bridges of a protein into free thiols, which are able to bind 99mTc in a very 
efficient way. However, this method applies only to proteins with disulfide bonds. 
More importantly, these bonds are often critical for maintaining the biological 
properties of the protein. In the preformed chelate approach first a complex of 99mTc 
with a bifunctional coupling agent (BCA) is formed. In a second step the 99mTc-BCA 
complex is conjugated to a protein. However, a two-step radiochemical synthesis is not 
very suitable for routine clinical applications. In the indirect labeling approach the 
BCA is attached first to a protein to form a BCA-protein conjugate. Secondly, the 
conjugate is labeled with 99mTc either directly by reduction of 99mTcO4- or indirectly by 
ligand exchange with an intermediate 99mTc-complex (such as 99mTc-glucoheptonate, 
99mTc-diphosphonate or 99mTc-tricine). In general, the latter approach is easy to carry 
out and has a well-defined chemistry. Succinimidyl-hydrazinonicotinamide (S-
HYNIC) as developed by Abrams and coworkers (3) appears to be an ideal BCA for 
99mTc-labeling, because it allows rapid and efficient labeling of proteins. In addition, it 
can be used in relatively low concentrations. Thus, preparations can be produced with 
high specific activities. The S-HYNIC approach consists of a conjugation step and a 
labeling step. In the conjugation step S-HYNIC reacts with ε-amino groups of lysine-
residues in the protein, resulting in a HYNIC-protein conjugate. This conjugate can be 
labeled with 99mTc in the second step. In our study, tricine (N-[Tris(hydroxymethyl)-
methyl]glycine) was used as co-ligand. In the resulting 99mTc-HYNIC-protein complex 
the 99mTc species is coordinated by two tricine molecules and the terminal N-atom of the 
hydrazine-group of HYNIC (4). 
The aim of the present study was to characterize and optimize the labeling of 
small-sized proteins using S-HYNIC. In our laboratory we develope and test new 
agents for scintigraphic imaging of infections (5;6). 99mTc-labeled small-sized proteins 
binding to leukocyte receptors are most attractive candidates in this, for leukocytes are 
abundantly present in the area of infection. Receptors for interleukin-1 and interleukin-
8 are highly expressed on activated leukocytes. In this study we used three leukocyte 
receptor binding proteins: interleukin-8 (MW 8.5 kDa) binding to interleukin-8 
receptors; interleukin-1α (MW 17 kDa) and interleukin-1 receptor antagonist (MW 17 
kDa) both binding to interleukin-1 receptors. To study and optimize the conjugation of 
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S-HYNIC to proteins we selected four easily available proteins of similar molecular 
weight (6.5 – 14.3 kDa): Aprotinin, cytochrome c, α-lactalbumin and lysozyme. The 
effects of  the six reaction parameters of the reaction were investigated: molar 
conjugation ratio S-HYNIC to protein, reaction temperature, S-HYNIC administration 
mode, pH,  protein concentration and duration of the conjugation reaction. The effects 
of each of the parameters on HYNIC substitution ratio and on labeling efficiency were 
studied. Next, the three leukocyte receptor binding proteins were studied for effects of 
conjugation on labeling efficiency and receptor binding capacity.  
 
 
MATERIALS AND METHODS 
 
Seven proteins were selected for these studies. Four proteins were purchased from 
Sigma (St. Louis, MO): Aprotinin (from bovine lung, molecular weight (MW) 6.5 
kDa); cytochrome c (from horse heart, MW 12.4 kDa), α-lactalbumin (from bovine 
milk, MW 14.2 kDa); lysozyme (from chicken egg white, MW 14.3 kDa). Human 
recombinant interleukin-8 (IL-8, MW 8.5 kDa), human recombinant interleukin-1α 
(IL-1α, MW 17 kDa) and interleukin-1 receptor antagonist (IL-1ra, MW 17 kDa)  
were kindly provided by Dr I. Lindley (Novartis, Vienna, Austria), Dr P.T. Lomedico 
(Hoffman-La Roche, Nutley, NJ) and Dr R.C. Thompson (Synergen, Boulder, CO), 
respectively. Succinimidyl-hydrazino-nicotinamide (S-HYNIC,  MW 286 Da) was 
synthesized as described by Abrams et al. (3). 
 
Conjugation of S-HYNIC to protein 
The proteins were conjugated to S-HYNIC essentially as described by Abrams et al. 
(3). Briefly, in a 1.5 ml vial 10% (v/v) of buffer solution was added to the solution of the 
protein under investigation. Buffer solutions to adjust the pH of the protein solution were: 
1.0 M NaAc pH 6.0, phosphate-buffered saline (PBS) in 10-fold concentration pH 7.2, 
1.0 M NaHCO3 pH 8.2 and 1.0 M  Na2CO3/NaHCO3 pH 9.5. Subsequently an excess of 
S-HYNIC in DMSO  was added dropwise to the solution. Reactions with durations 
shorter than 60 minutes were stopped by addition of an excess of 1.0 M glycine (Merck, 
Darmstadt, Germany) in PBS. Finally, precooled PBS was added to all reaction mixtures. 
To remove excess unbound S-HYNIC the mixture was extensively dialyzed against PBS 
(0.1-0.5 ml dialysis cell 3.5 MWCO, Pierce, Rockford, IL). Dialyzed samples were 
stored at –20 0C. Six reaction parameters of the conjugation reaction were investigated: 
• The amount of S-HYNIC added to the reaction mixture was varied: from a 1 to 1 
molar ratio S-HYNIC to protein, to a 30-fold excess S-HYNIC; 
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• The S-HYNIC solution was added to the protein preparation either dropwise (1 drop 
per minute) or as a single bolus; 
• The reaction temperature was varied: from 0°C to 40°C; 
• The pH of the reaction was varied: from pH 6.0 to 9.5; 
• The protein concentration was varied: from 0.5 mg/ml to 10 mg/ml; 
• The reaction time was varied; from 3 minutes to 60 minutes. 
The various conjugation reaction conditions are summarized in table 1 and 2. All 
conjugation reactions were performed on a microgram scale of 40 to 200 µg protein per 
reaction. The number of HYNICs incorporated in the HYNIC-protein conjugate was 
determined spectrophotometrically by converting the hydrazine group of HYNIC into a 
hydrazone using o-sulfonic benzaldehyde (7). In brief, samples of HYNIC-protein 
conjugate (10-20 µg) to be analyzed were diluted into 0.1 ml of o-sulfonic benzaldehyde 
(Aldrich, Zwijndrecht, Netherlands; 1 mg/ml, 0.1 M NaAc, pH 4.7). The reaction was 
incubated at room temperature in the dark overnight. Samples of unconjugated protein 
were taken as a negative control. The absorption of the hydrazone adduct was read at 343 
nm. The hydrazine concentration was calculated using a molar extinction coefficient of 
ε343nm = 17000 mol-1.l.cm-1 for the adduct.   
 
Technetium-99m labeling of HYNIC conjugated protein  
Tricine-SnSO4-kits were prepared containing  20 mg tricine (N-[Tris(hydroxymethyl)-
methyl]glycine, Fluka, Buchs, Switzerland) and 0.01 mg SnSO4 (Merck) in 0.2 ml PBS 
pH 7.0. Stannous sulphate dissolved in 2 M HCl was added to a solution of tricine in 
PBS and  the pH was subsequently adjusted to 7.0 with 1.0 M NaOH. To a thawed 
protein-HYNIC vial (5 µg) a 0.2 ml tricine-SnSO4-kit and 0.1-0.3 ml 20-30 MBq 
99mTcO4-  in saline were added. The mixture was then incubated at room temperature for 
30 minutes.  
The radiochemical purity was determined by instant thin-layer chromatography  (ITLC) 
on ITLC-SG strips (Gelman Laboratories, Ann Arbor, MI) with 0.1 M citrate, pH 6.0, as 
the mobile phase.  
Analytical FPLC was carried out on a Pharmacia (Roosendaal, Netherlands) Superdex 75 
HR 10/30 column using 0.05 M phosphate buffer with 0.15 M NaCl, pH 7.0 as eluens.  
 
Receptor binding assays 
The receptor binding fraction (RBF) of the various 99mTc-HYNIC-IL-8, 99mTc-HYNIC-
IL-1α and 99mTc-HYNIC-IL-1ra preparations was determined in receptor binding assays 
essentially as described by Lindmo et al. (8). First the radiolabeled conjugates were 
purified on a Sephadex G-25 column (PD-10; Pharmacia) with 0.5 % BSA in PBS as 
eluens in order to remove non protein-bound label.  
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 For 99mTc-HYNIC-IL-8 a receptor binding assay with human leukocytes was used. 
Heparinized human whole blood (10 ml) was mixed with 2.5 ml 5% Dextran (Sigma). 
Following red blood cell sedimentation for 1 hr at room temperature, the blood free of 
red blood cells, was washed in incubation buffer (1 mM NaH2PO4, 5 mM Na2HPO4, 140 
mM NaCl, 0.5 mM MgCl2, 0.15 mM CaCl2, 0.5% (w/v) BSA, pH 7.4) and centrifuged at 
500xg for 20 min. The cell pellet was then resuspended in 7 ml incubation buffer and 
layered on 5 ml Ficoll-Hypaque (Pharmacia), followed by centrifugation at 500xg for 20 
min. Contaminating erythrocytes were removed from the pellet, rich of 
polymorphonuclear cells (PMNs), by hypotonic lysis. The PMN pellet was washed once 
and subsequently resuspended in incubation buffer supplemented with 0.5% BSA. A 
series of serially diluted PMN suspension (0.5 - 8 x 106 PMN/ml) was incubated with 
10,000 cpm of  99mTc-labeled IL-8. A duplicate of the lowest cell concentration was 
incubated in the presence of a 100-fold molar excess of unlabeled IL-8 to correct for 
nonspecific binding. After 3 hr incubation at 4 0C, PMNs were centrifuged (5 min, 
2000xg) and the radioactivity in the pellet (total bound activity) was measured in a 
shielded well-type gamma counter (Wizard; Pharmacia). The data were graphically 
analyzed in a modified Lineweaver-Burk plot: a double inverse plot of the conventional 
binding plot (specifically bound fraction versus cell concentration). The receptor-binding 
fraction at infinite cell excess was calculated by linear extrapolation to the ordinate. 
 The murine cell line EL-4-6.1, a variant subline of EL-4 thymoma cells (9), a kind 
gift of Dr H.R. MacDonald (Ludwig Institute for Cancer Research Epalinges, 
Switzerland), was used for determination of the receptor binding capacity of the 99mTc-
HYNIC-IL-1α and 99mTc-HYNIC-IL-1ra preparations. The cell line was cultured at 37oC 
in a humidified atmosphere of air/CO2 (95:5) in RPMI 1640 medium (GIBCO, 
Gaithersburg, MD) containing 10% fetal calf serum. Live EL-4-6.1 cells were washed 
once with cold medium. A series of serially diluted cell suspension (0.2-3 x 107 cells/ml) 
was incubated with 10,000 cpm of 99mTc-HYNIC-IL-1α or 99mTc-HYNIC-IL-1ra in 
assay buffer (RPMI 1640, 0.5% BSA, 0.05% NaN3). A duplicate of the lowest cell 
concentration was incubated in the presence of at least a 100-fold molar excess of 
unlabeled IL-1α or IL-1ra to correct for non-specific binding. After 30 minutes 
incubation at 37oC, cells were centrifuged (5 min, 2000xg) and the radioactivity in the 
pellet (total bound radioactivity) was measured in a shielded well-type gamma counter 
(Wizard; Pharmacia). Data analysis was similar to that of  the leukocyte receptor binding 
assay.  
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RESULTS 
 
Optimization of the conjugation reaction: effects on HYNIC substitution and 
labeling efficiency   
The number of HYNIC-groups incorporated in the HYNIC-protein conjugates as 
determined by the hydrazine assay and the labeling efficiencies of the 99mTc-labeled 
HYNIC-protein conjugates is presented in table 1 and figure 1. Labeling efficiencies of 
all proteins conjugated under optimal conjugation conditions exceeded 90%. Specific 
activities of up to 7.5 MBq/µg were obtained.  
 
 
 
Table 1.  Schematic presentation of the reaction conditions of the conjugation reaction of S-
HYNIC with four different proteins. For labeling experiments 5 µg of HYNIC-conjugated protein 
was labeled with 20-30 MBq 99mTc. The resulting HYNIC-substitution ratios and labeling 
efficiencies are presented.  
 
_________________________________________________________________________________________________ 
 
                                    Reaction conditions                                                            Results                             
________________________________________________________________   _______________________________ 
  Conjugation ratio 
S-HYNIC:protein 
S-HYNIC 
Admininistration 
Mode * 
Reaction 
Temperature 
Reaction 
pH 
Protein 
Concentration 
Substitution ratio 
HYNIC:protein 
Apr Cyt  Lac Lys 
Labeling 
Efficiency % 
Apr Cyt  Lac Lys 
1 1 : 1 d 20°C 8.2 5 mg/ml 0.1   0.3   0.4   0.1 49    70    79    26 
2 3 : 1 d 20°C 8.2 5 mg/ml 0.9   1.0   0.6   0.6 76    89    88    58 
3 6 : 1 d 20°C 8.2 5 mg/ml 1.5   1.8   2.0   0.9 86    92    84    78 
4 15 : 1 d 20°C 8.2 5 mg/ml 2.0   2.2   4.6   2.3 94    91    88    90 
5 30 : 1 d 20°C 8.2 5 mg/ml 3.6   3.9   7.8   2.4 83    88    92    85 
6 6 : 1 d 0°C 8.2 5 mg/ml 1.9   1.8   2.4   1.4 87    92    85    81 
=3 6 : 1 d 20°C 8.2 5 mg/ml 1.5   1.8   2.0   0.9 86    92    84    78 
7 6 : 1 d 40°C 8.2 5 mg/ml 0.8   0.7   1.8   0.7 80    88    84    58 
8 6 : 1 b 0°C 8.2 5 mg/ml 1.3   1.7   2.2   1.3 87    90    87    75 
9 6 : 1 b 20°C 8.2 5 mg/ml 1.1   1.7   1.4   0.8 87    91    79    59 
10 6 : 1 b 40°C 8.2 5 mg/ml 0.6   1.1   1.0   0.5 77    89    63    43 
11 6 : 1 d 20°C 6.0 5 mg/ml 0.4   0.1   0.2   0.3 69    60    39    33 
12 6 : 1 d 20°C 7.2 5 mg/ml 1.0   1.0   1.0   1.0   82    84    66    72 
=3 6 : 1 d 20°C 8.2 5 mg/ml 1.5   1.8   2.0   0.9 86    92    84    78 
13 6 : 1 d 20°C 9.5 5 mg/ml 1.2   1.0   2.1   0.5 86    80    72    45 
14 6 : 1 d 20°C 8.2 0.5 mg/ml 0.1   0.1   0.1   0.0 10    25    17    10 
15 6 : 1 d 20°C 8.2 2.5 mg/ml 0.9   1.1   2.1   0.7 84    75    30    58 
=3 6 : 1 d 20°C 8.2 5 mg/ml 1.5   1.8   2.0   0.9 86    92    84    78 
16 6 : 1 d 20°C 8.2 10 mg/ml 1.7   0.8   1.8   1.2 87    86    80    82 
  _________________________________________________________________________________________________         
Reaction time = 60 minutes. Apr: aprotinin; Cyt: cytochrome c; Lac: α-lactalbumin; Lys: 
lysozyme. * d = dropwise addition of 10 drops (1 drop/minute); b = addition as a single 
bolus. 
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   At increasing conjugation ratio HYNIC to protein an increasing number of 
HYNICs was conjugated per protein molecule (Fig. 1A). At increasing conjugation ratios 
labeling efficiency increased as well but stabilized at higher ratios (Fig. 1B). The FPLC 
patterns of labeled cytochrome c (Fig. 2A) showed higher molecular weight species 
appearing at increasing conjugation ratio. This formation was found for cytochrome c 
only; for aprotinin, α-lactalbumin and lysozyme higher conjugation ratios did not result 
in the formation of high molecular weight species (demonstrated for aprotinin in Fig. 
2B). It should be noted that highest conjugation ratios (30:1) occasionally resulted in 
precipitation. 
 The reaction temperature clearly affected the HYNIC substitution ratio (Fig. 1C) 
and labeling efficiency  (Fig. 1D): most efficient conjugation and highest labeling 
efficiency were obtained at 00C. Additionally, adding S-HYNIC to the protein as a 
single bolus appeared less effective than a dropwise addition (Fig. 1C, 1D). 
  At pH 6.0 conjugation and labeling was less efficient (Fig. 1E, 1F). Best results 
were obtained at pH 8.2 with each of the four proteins tested.    
  At lowest protein concentrations (0.5 mg/ml) hardly any HYNIC was conjugated 
to the protein and thus labeling efficiencies were very low (Fig. 1G, 1H). More 
efficient conjugation and subsequent labeling was obtained at higher concentrations 
(≥2.5 mg/ml).    
 
Optimization of the conjugation reaction: effects on biological activity 
Table 2 summarizes the results of the conjugation reactions with three receptor binding 
proteins. Labeling of IL-8, IL-1α and IL-1ra was more efficient at higher molar 
conjugation ratios. At  a fixed  molar conjugation ratio a higher labeling efficiency was 
obtained  with longer reaction times. The capacity of 99mTc-labeled IL-8, IL-1α and IL-
1ra to bind their receptors on leukocytes (IL-8) or EL-4-6.1 cells (IL-1α and IL-1ra) was 
clearly affected by the conjugation reaction conditions. Milder conjugation conditions 
(low conjugation ratio S-HYNIC to protein and/or short reaction time) resulted in a 
higher receptor binding capacity. Increasing conjugation ratios and/or increasing reaction 
times resulted in higher labeling efficiency and a decrease of  the receptor binding 
fraction. For each of the three proteins most optimal preparations were obtained when the 
protein was reacted five minutes at an 3:1 S-HYNIC:protein ratio. These conditions 
revealed preparations with a good receptor binding capacity (≥65%) with a reasonable 
labeling efficiency (20-52%). 
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Figure 1.  Effects of varying reaction conditions of the conjugation reaction of S-HYNIC with 4 
different proteins on: i) the number of substituted HYNIC-groups per  molecule of  protein 
conjugate; and ii) the labeling efficiency of the labeled protein conjugate. Data are taken 
directly from Table 1. 
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Figure 2.  HPLC radioactivity profiles of preparations 99mTc-labeled cytochrome c and 
aprotinin. Effect of  increasing conjugation ratios S-HYNIC : protein. 
 
 
 
 
Table 2.  Schematic presentation of the reaction conditions of the conjugation reaction of S-
HYNIC with interleukin-8 (IL-8), interleukin-1α (IL-1α) and interleukin-1 receptor antagonist 
(IL-1ra). For labeling experiments 5 µg of HYNIC-conjugated protein was labeled with 20-30 
MBq 99mTc. The resulting labeling efficiencies and binding capacities to receptors on human 
granulocytes (IL-8) or EL-4-6.1 cells (IL-1α, IL-1ra) are presented. 
 
__________________________________________________________________________________________ 
 
                   Reaction conditions                                     Results  
     ___________________________    ____________________________________ 
                     
 Conjugation ratio 
S-HYNIC:protein 
Reaction 
Time 
Labeling 
Efficiency 
IL8      IL1α    IL1ra 
Receptor Binding 
Fraction 
IL8     IL1α   IL1ra 
1 1 : 1 5 min. 15%    16%     24% 65%    98%   84% 
2 1 : 1 60 min. 87%    44%     29% 31%    62%   71% 
3 3 : 1 5 min. 20%    35%     52% 65%    70%   65% 
4 3 : 1 10 min. 71%    43%     61% 37%    54%   56% 
5 3 : 1 60 min. 95%    57%     83% 21%    54%   18% 
6 10 : 1 60 min. 97%    82%     94% 16%    38%   17% 
__________________________________________________________________________________________ 
IL8: interleukin-8; IL1α: interleukin-1α; IL1ra: interleukin-1 receptorantagonist. S-HYNIC 
admininistration mode = dropwise; reaction temperature = 20°C; reaction pH = 8.2; protein 
concentration = 5 mg/ml. 
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DISCUSSION 
 
The aim of this study was to characterize and optimize the conjugation of S-HYNIC to 
proteins in order to obtain a conjugate that could be labeled efficiently with 99mTc. In 
addition, the effects of conjugation on receptor binding capacity of proteins were 
studied for three proteins. The effects of  six conjugation reaction parameters on 
HYNIC substitution and labeling efficiency were investigated. Higher conjugation 
ratios S-HYNIC to protein resulted in increasing efficiency on the one hand, but could 
lead to the formation of higher molecular weight aggregates and even to precipitation. 
The influence of the conjugation ratio on the number of introduced HYNIC-groups per 
protein molecule has been investigated in earlier studies for larger proteins like 
polyclonal IgG (MW 150 kDa) (10) and for human serum albumin (HSA, MW 67 
kDa) (11). A fourfold molar excess of S-HYNIC was required in order to incorporate 
one HYNIC-group per IgG-molecule or HSA-molecule at protein concentrations of 
4.6 mg/ml (IgG) or 20 mg/ml (HSA). This is in line with our results with smaller 
proteins. Also, incorporation of  more than ten  HYNIC-groups per IgG-molecule 
resulted in precipitation of  the protein (10).  
 Conjugation of small proteins was most efficient at 0 0C as compared to 20 and 
40 0C. This could be due to the fact that S-HYNIC can either be conjugated to the 
protein or be hydrolysed. Lower reaction temperatures might favor the conjugation 
reaction, while at higher temperatures hydrolysis dominates. The effect of reaction 
temperature on conjugation has not been reported so far. Conjugations are routinely 
carried out at room temperature (3;10;11).  
 It was found that a protein concentration of at least 2.5 mg/ml resulted in 
efficient conjugation and labeling. A low protein concentration of 0.5 mg/ml appeared 
to be too low for efficient conjugation. Protein concentrations as high as 50 mg/ml (3) 
and 20 mg/ml (11) have been reported. Schwartz et al. (10) varied IgG concentrations 
from 4.6 mg/ml up to 37 mg/ml. Increasing concentrations resulted in increasing 
efficiencies of the conjugation reaction. Our study with small proteins demonstrated no 
substantial gains at protein concentrations exceeding 5 mg/ml.  
 The effect of the duration of the reaction was studied with the leukocyte receptor 
binding proteins: longer reaction time resulted in higher labeling efficiency. The 
addition of an excess of glycine to stop the conjugation reaction was highly effective. 
The biological characteristics of IL-8, IL-1α and IL-1ra were clearly affected by the 
conjugation conditions. Preservation of receptor binding capacity was obtained only at 
low conjugation ratios and/or short reaction times. A possible explanation for the loss 
of receptor binding capacity might be that the most susceptible lysine ε-amino groups 
for reaction with S-HYNIC are not located in the receptor binding region of the 
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molecule. The results of our experiments in conjugating, labeling and receptor binding 
of IL-8, IL-1α and IL-1ra present a dilemma: optimal labeling efficiency can be 
obtained only at the expense of receptor binding. If, on the other hand, receptor 
binding is to be preserved, labeling efficiency will be lower. A careful balancing of 
reaction conditions will result in acceptable, be it suboptimal, labeling efficiencies and 
receptor binding. 
  In conclusion, labeling proteins with 99mTc using S-HYNIC is easy, rapid and 
efficient and preparations with high specific activity can be obtained. However, if 
biological activity has to be preserved, the conjugation conditions will need to be fine-
tuned in case lysine-residues critical for biological activity are affected by conjugation 
with S-HYNIC. 
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ABSTRACT 
 
Although several proteins have been proposed and tested for scintigraphic detection of 
infection, the most optimal characteristics of a protein for this application have not yet 
been determined. Molecular weight (MW) of the protein, its charge, shape, 
carbohydrate content, characteristics of the radionuclide and receptor interactions are 
factors that could affect the in vivo behavior of the infection imaging agent. The effect 
of molecular weight on nonspecific accumulation of 99mTc-labeled proteins in 
inflammatory foci was studied in a rat model.  
Methods: Eleven proteins whose MWs ranged from 2.5 kDa up to 800 kDa were 
labeled with 99mTc using the hydrazinonicotinamide (HYNIC) chelator. Rats with S. 
aureus infection were injected i.v. with 15 MBq  99mTc-labeled protein. Gamma camera 
images were acquired and biodistribution of the radiolabel was determined ex vivo.  
Results: From biodistribution data no significant correlation was found between 
abscess uptake and molecular size of the 99mTc-labeled proteins that were studied. Fast 
blood clearance with predominant uptake in liver and spleen was found for the largest 
proteins (MW 669 kDa - 800 kDA). For proteins of intermediate size (MW 66 kDa – 
206 kDa) we found relatively slow blood clearance with relatively moderate uptake in 
liver and spleen. For smaller proteins (MW 2.5 kDa – 29 kDa) rapid blood clearance 
with predominant kidney uptake was observed. The abscess uptake of the 99mTc-
labeled proteins (%ID/g, 24 h p.i.) was highest for serum proteins IgG and BSA. 
Abscess uptake correlated well with blood levels: r=0.95 and 0.84 at 4 and 24 h 
respectively (P<0.005). The abscess-to-muscle ratios varied from 2.1 to 17.8 at 24 h 
p.i. with highest values for α-2 macroglobulin (MW  725 kDa) and the intermediate 
sized proteins (MW 66-206 kDa). Gamma camera imaging showed localization of  all 
radiotracers at the site of infection with abscess-to-background ratios (A/B) ranging 
from 1.4 to 7.0 (IgG) at 20 h p.i. The serum proteins IgG and BSA showed highest 
blood levels and best infection imaging characteristics.  
Conclusion: Not molecular weight but blood residence time is the principal factor that 
determines localization of a nonspecific tracer protein in infectious foci. The ideal 
nonspecific infection imaging agent is a protein with a long circulatory half-life. From 
the proteins tested here IgG and albumin showed the best characteristics for an 
infection imaging agent.  
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INTRODUCTION 
 
Localization of radiolabeled proteins in infectious and inflammatory foci is driven by 
specific and/or nonspecific interactions. At present, multiple new agents are under 
study for infection imaging and the main interest is focussed on proteins that are easy 
to prepare and bind specifically to receptors or antigens present in inflammatory foci 
(1-5). Small molecules, like chemotactic peptides, have been shown to localize rapidly 
in infectious foci, but their absolute uptake in infectious foci is low (6). In addition, 
these molecules are biologically active and can evoke undesirable side-effects. 
Therefore, biologically inert compounds have some advantages. It is now well 
established that the preferential localization of proteins without specific receptor 
interaction in infectious and inflammatory foci is mainly the result of locally enhanced 
vascular permeability (7-9). Such proteins, labeled with In-111 or Tc-99m have been 
applied successfully for the scintigraphic detection of infection and inflammation (10-
12).  
 In this study we focussed on radiolabeled proteins with no known interaction 
with receptors at the site of infection. The most optimal characteristics of these 
proteins for infection imaging have not yet been determined. Molecular weight (MW) 
of the protein involved, pI (13;14), shape (15), carbohydrate content (16;17) and 
characteristics of the chelating system and radionuclide (18) are  factors that could 
affect the in vivo behavior of the infection imaging agent.  
 We studied the effect of molecular weight on nonspecific accumulation of  99mTc-
labeled proteins in inflammatory foci in a rat model of infection. To our knowledge, this 
has not been studied systematically yet. Eleven 99mTc-labeled proteins in a broad MW 
range from 2.5 kDa up to 800 kDa were tested. In order to eliminate the effect of 
glycosylation, a series of nonglycosylated proteins was selected for these studies. The 
pI values of these proteins ranged from 4.5 to 7.2. Polyclonal human IgG, a clinically 
used infection imaging agent, was included in the study as a reference. 
  
 
MATERIALS AND METHODS 
 
Radiopharmaceuticals 
Eleven  proteins and peptides were selected for these studies. All proteins were 
obtained from Sigma Chemical Company (St. Louis, Mo) unless stated otherwise: α-
crystallin molecular weight (MW) 800 kDa (a kind gift of Prof. Dr. W.W. de Jong, 
Dept of Biochemistry, University Hospital Nijmegen, The Netherlands), α-2 macro-
globulin MW 725 kDa (ICN, Costa Mesa, CA), thyroglobulin MW 669 kDa, amylase 
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(sweet potatoes) MW 206 kDa, aldolase (rabbit muscle) MW 158 kDa (Boehringer, 
Mannheim, Germany), human polyclonal immunoglobulin G  (IgG) MW 150 kDa 
(Baxter/Hyland Gammagard S/D, Lessines, Belgium), phosphorylase b (rabbit muscle) 
MW 97 kDa, bovine serum albumin (BSA) MW 66 kDa, carbonic anhydrase MW 29 
kDa, myoglobin MW 17 kDa and insulin-A-chain MW 2.5 kDa. None of  these 
proteins (with the possible exception of IgG) has any known specific interaction at the 
site of infection. To exclude the effects of carbohydrate groups, only non-glycosylated 
proteins were selected for these studies. The proteins had pI-values ranging from 4.5 to 
7.2. 
 The proteins were conjugated with S-HYNIC, essentially as described by 
Abrams et al. (19). Briefly; a 3-60 fold molar excess of freshly dissolved succinimidyl 
6-hydrazino nicotinate hydrochloride (in dry DMSO) was added dropwise to a 
solution of each protein (5-10 mg/ml in 0.1 M NaHCO3 buffer, pH 8.2) under constant 
stirring. The added volume did not exceed 10% of the total reaction volume. The 
solution was incubated for 30 min at room temperature, protected from light. The 
reaction was stopped by adding 100 µl of precooled phosphate buffered saline (PBS), 
pH 7.4 (4oC). Following extensive dialysis (Slide-A-Lyser Cassette; molecular weight 
cut-off 3.5 kDa, Pierce, Rockford, IL) against PBS (overnight, 4oC, protected from 
light, four buffer changes) the mixture was diluted with PBS to a final concentration of 
1 mg/ml, divided into 0.2 – 1 ml aliquots and stored at -20oC. 
 For 99mTc-labeling of HYNIC conjugated proteins, tricine (N-
[Tris(hydroxymethyl)-methyl]glycine, Fluka, Buchs, Switzerland) was used as co-
ligand. Twenty milligrams of tricine and 10 µg of stannous chloride in 0.2 ml PBS 
were added to vials containing HYNIC-protein. Subsequently, 99mTcO4- was added and 
the mixture was incubated at room temperature for 15 min. Following the labeling 
reaction the reaction mixture was applied on a Sephadex G-25 column (PD-10; 
Pharmacia, Uppsala, Sweden) and eluted with 0.5% BSA in PBS to remove unbound 
99mTc-pertechnetate. 
 
Radiochemical purity and in vitro stability 
The radiochemical purity of the preparations was determined by instant thin-layer 
chromatography (ITLC) on Gelman ITLC-SG strips (Gelman Laboratories, Ann 
Arbour, MI) with 0.15 M sodium citrate (pH 6.0) as mobile phase. In addition, 
samples of 99mTc-labeled proteins and peptides (except insulin A-chain) were analyzed 
by size exclusion FPLC using Biosep SEC S-3000 (300x7.8 mm, Phenomenex, 
Torrance, CA), Superdex 75 HR 10/30 (Pharmacia, Uppsala, Sweden) or Shodex 
Protein KW 802.5 (300x8 mm, Showa Denko, Japan) columns. 99mTc-HYNIC-insulin-
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A-chain was analyzed on a reversed phase chromatography column (Zorbax Rx-C18, 
250x4.6 mm, Atas, Veldhoven, The Netherlands). 
 The in vitro stability of the radiolabeled proteins was monitored in rat serum.  A 
sample of 0.2 ml 99mTc-HYNIC-protein solution (15 MBq, 20-100 µg protein) was 
diluted 1:5 in rat serum and incubated for 4 hours at 37oC. After 1, 2 and 4 hours 
aliquots of the mixture were diluted 5x with PBS and analyzed by ITLC as described 
above. 
 
Animal studies 
Abscesses were induced under ether anaesthesia in male Wistar rats (weighing 200-
240 g) by intramuscular injection of 2x109 colony forming units of Staphylococcus 
aureus in 100 µl 50:50% suspension of autologous blood and saline in the left calf 
muscle. Twenty-four hours after inoculation of bacteria the radiolabeled proteins were 
injected via the tail vein (0.2 ml of solution, 15 MBq, 20-100 µg protein).  
   
Biodistribution 
Four and twenty-four hours after injection, groups of five animals were killed by 
carbon dioxide suffocation. Blood was collected by cardiac puncture. Samples of 
normal muscle, abscess, lung, spleen, kidney, liver and small intestine were dissected 
and weighed. The radioactivity in the tissues was measured in a shielded well-type 
gammacounter (Gamma-Wizard, Pharmacia LKB, Uppsala, Sweden). To correct for 
radioactive decay and permit calculation of the uptake of the radiopharmaceuticals in 
each organ as fraction of the injected dose, aliquots of the injected doses were counted 
simultaneously. The activity in the tissues was expressed as percentage of injected 
dose per gram of tissue. 
 
 
Gamma camera imaging 
Separate sets of three animals with S. aureus infection were injected with each of the 
99mTc-labeled proteins (0.2 ml, 15 MBq,  20-100 µg per rat). Scintigraphic images of 
anaesthetized rats (oxygen/nitrous oxide/enflurane) were obtained with a Siemens 
Orbiter γ-camera connected to an ICON computer system (Siemens Inc., Hoffman 
Estates, IL). Rats were imaged immediately after injection and 1, 2, 4, 8 and 20 h p.i. 
All images were acquired with a LEAP-collimator and 15% symmetric window 
centered on the 140 keV 99mTc γ-radiation peak and stored in 256x256 matrix. Regions 
of interest were drawn over the infectious focus and a symmetrical region over the 
contralateral muscle. Abscess-to-background ratios were calculated. 
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Statistical analysis 
The biodistribution and imaging data are presented as the mean ± SD. Correlation was 
tested using the nonparametric Spearman rank correlation test. r and P values were 
computed for biodistribution data at four and twenty-four hours post injection for 
every pair of the following variables: Activity in the infect as percentage of injected 
dose per gram of tissue (%ID/g), molecular weight of the radiolabeled protein, activity 
in the blood (%ID/g), kidney uptake (%ID/g) and liver uptake (%ID/g).  
 
 
RESULTS 
 
Radiopharmaceuticals 
Radiochemical purity of all preparations exceeded 92%. FPLC analysis revealed 
monomeric radioactivity peaks concordant with protein peaks measured at 280 nm for 
all preparations except BSA which showed two peaks with approximately 11% of 
activity in a higher MW peak. All preparations were stable up to 4 h in rat serum as 
determined by ITLC. In no preparation the percentage of free pertechnetate during 
incubation increased by more than 2%. 
 
Biodistribution 
The biodistribution data of  the 99mTc-HYNIC-proteins for liver, abscess, blood and 
kidneys at 4 and 24 h post injection are depicted in Figure 1. Relatively high hepatic 
uptake was observed with proteins of molecular weight greater than that of BSA, 
especially the very large proteins α-crystallin and thyroglobulin. Relatively high renal 
uptake was observed with proteins of molecular weight smaller than that of BSA. 
Proteins of intermediate size like aldolase, IgG, phosphorylase and BSA showed 
moderate hepatic and renal uptake.  
 99mTc-HYNIC-IgG had the highest abscess uptake (1.29 ± 0.13 and 1.39 ± 0.32 
%ID/g at 4 and 24 h p.i. respectively). Abscess uptake of all other 99mTc-HYNIC-
proteins (except aldolase) decreased from 4 to 24 hrs. There was no significant 
correlation between abscess uptake and MW within the agents studied. In contrast, 
there was a highly significant correlation between abscess uptake and blood level of 
tested proteins as illustrated in figure 2 (r=0.95 and 0.84 at 4 and 24 h, respectively; 
P<0.005). Significant correlation was found between muscle uptake and blood level at 
4 h (r=0.76; P<0.01). No significant correlations were found between blood level and 
renal or hepatic uptake (P>0.05 at all time points). In addition, there was a highly 
significant correlation between MW and hepatic uptake (r=0.89 and 0.94 at 4 and 24 
h; P<0.005) but no significant correlation between MW and renal uptake. 
 
 
Infection imaging with nonspecific tracers      51 
0
2
4
6
8 Liver
Abscess
Blood
 Kidney
10
15
20
25
30
%
ID
/g
Aldolase
Phosphorylase b
Insulin A-chain
Thyroglobulin
Amylase
IgG BSA
Carbonic anhydrase
Myoglobin
Macroglobulin
Crystallin
%ID/g at 4 h p.i.
0
2
4
6
8 Liver
Abscess
Blood
Kidney
10
15
20
25
30
%
ID
/g
Aldolase
Phosphorylase b
Insulin A-chain
Thyroglobulin
Amylase
IgG BSA
Carbonic anhydrase
Myoglobin
Macroglobulin
Crystallin
%ID/g at 24 h p.i.
%
ID
/g
%
ID
/g
Figure 1.  Selected data from the biodistribution of  99mTc-labeled protein in rats with S. 
aureus infection at 4 and 24 h p.i. in diagram form (%ID/g, mean of 5 values per protein per 
time point, error bars indicate SD). 
  
Scintigraphy 
The scintigraphic images obtained with each 99mTc-labeled protein at 20 h p.i. are 
shown in figure 3. Figure 4 presents data from quantitative analysis of the 
scintigraphic images of groups of three rats at 0, 1, 2, 4, 8 and 20 h p.i. The 20 h p.i. 
scintigrams show relatively high hepatic uptake for proteins of molecular weight ≥ 66 
kDa. However, there is no linear relationship between molecular weight and hepatic 
uptake: for instance 99mTc-HYNIC-phosphorylase b (97 kDa) cleared predominantly 
via the hepatobiliary route whereas similarly sized proteins like IgG (150 kDa) and 
BSA (66 kDa) showed only moderate uptake in the liver. Proteins smaller than BSA 
showed high kidney uptake as is clearly demonstrated in the scintigrams of 99mTc-
HYNIC-carbonic  anhydrase,  myoglobin  and  insulin-A-chain.  
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Figure 2.  Correlation between blood level (%ID/g) and abscess uptake (%ID/g) of  99mTc-
labeled protein in rats with S. aureus infection at 4 and 24 h p.i. 
 
 
Inflammatory  foci  were  well visualized with all proteins except 99mTc-HYNIC-α-
crystallin, thyroglobulin, myoglobin and insulin-A-chain. Furthermore, the abscess 
visualization did not correlate with molecular weight: for instance 99mTc-HYNIC-α-
crystallin, α-2-macroglobulin and thyroglobulin are proteins of similar weight; only α-
2-macroglobulin showed good visualization of the abscess, whereas the other proteins 
did not. Quantitative analysis of the scintigrams revealed that particularly the small 
peptide 99mTc-HYNIC-insulin-A-chain cleared rapidly from the body (data not shown). 
Retention of the radiolabel at the site of infection increased with time for 99mTc-
HYNIC-amylase, aldolase, IgG, phosporylase b, BSA and carbonic anhydrase. Highest 
percentage of residual activity retained in the abscess was obtained with 99mTc-
HYNIC-IgG: up to 13.3 ± 1.5% of the whole body activity was found in the abscess at 
20 h p.i. 
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Figure 3. Images of rats with S. aureus infection at 20 h post injection of  99mTc-labeled 
protein 
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Figure 4.  Abscess-to-background ratios as determined by quantitative analysis of the images 
of rats with S. aureus infection injected with 99mTc-labeled protein (mean of 3 values per 
protein per time point, error bars indicate SD). 
 
 
DISCUSSION 
 
In the present study, the effect of molecular size of proteins with no known specific 
receptor interactions on accumulation in foci of acute inflammation was investigated. 
No significant correlation was found between abscess uptake and molecular size for 
the eleven 99mTc-labeled proteins in this study. Data from biodistribution and γ-camera 
imaging demonstrated fast blood clearance with predominant uptake in liver and 
spleen for the largest proteins in study (MW 669 kDa - 800 kDa). Proteins of 
intermediate size (MW 66 kDa – 206 kDa) had relatively slow blood clearance with 
relatively moderate uptake in liver and spleen. For smaller proteins (MW 2.5 kDa – 29 
kDa) rapid blood clearance with predominant renal uptake was observed. Serum 
proteins IgG and BSA revealed the highest abscess uptake (%ID/g, 24 h p.i.). These 
proteins showed the best infection imaging characteristics. Interestingly, there was a 
highly significant correlation between abscess uptake and blood level. This finding 
suggests that the process of abscess accumulation of non receptor binding proteins is 
mainly driven by sustained blood levels. However, there was no significant correlation 
between molecular weight and circulatory half-life: for instance, IgG and aldolase 
have similar molecular weights (150, 158 kDa respectively), but IgG had much higher 
blood levels at both time points (4 and 24 h p.i.), whereas aldolase cleared from the 
blood very rapidly. There are similarities in blood clearance patterns of non-protein 
polymeric molecules as compared to those of the proteins presented here. Molecular 
weight dependent tissue accumulation has been systematically investigated for 
dextrans (20) and polyethyleneglycols (PEGs) (21). For PEGs it was found that the 
 
Infection imaging with nonspecific tracers      55 
circulatory half-life of PEG increased from 18 min to 1 day as the PEG MW increased 
from 6 to 190 kDa. Renal clearance decreased and hepatic clearance increased with 
increasing PEG MW. For dextrans in a MW range of 4 to 150 kDa, it was found that 
renal clearance decreased with increasing  MW. However, hepatic clearance of 
dextrans showed a maximum for the 70 kDa species: a further increase in MW 
resulted in a decrease of liver uptake.  
 Whether IgG accumulates in infections in a specific or nonspecific way has 
been a matter of debate for a long time. Accumulation has been ascribed to a process 
of increased vascular permeability (nonspecific) (7;8), the chemical nature of the 
radiolabel (nonspecific) (22;23), binding to bacteria (24) and specific trapping of IgG 
by Fc-receptors on inflammatory cells (25). However, assignment of a major role for 
Fc-receptor binding was rejected later (10;16;23). The results reported in this study 
indicate that the superior characteristics of IgG for infection imaging are most likely 
due to a long circulatory half-life of the radiolabel and increased vascular permeability 
at the site of infection. The present results are in line with the hypothesis that 
accumulation of radiolabeled IgG is nonspecific due to nonspecific leakage through 
the leaky capillaries near infectious foci. The data in the present study suggest that no 
mechanisms including specific interactions are required to explain focal accumulation. 
The effect of blood retention time on abscess uptake of nonspecific agents was noticed 
already in studies with radiolabeled liposomes (26) and supposed to play a role in the 
accumulation of immunoglobulins at the site of infection (12). 
 In conclusion, molecular weight of a nonspecific tracer protein is not the 
principal determinant in targeting infections. Blood residence time has a more 
profound effect on abscess uptake of nonspecific tracers. The ideal nonspecific 
infection imaging agent is a protein with a long circulatory half-life. From the proteins 
tested here IgG and serum albumin showed the best characteristics for an infection 
imaging agent.  
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ABSTRACT 
 
Interleukin-8 (IL-8) is a chemotactic cytokine involved in activation and recruitment of 
neutrophils to areas of infection. In our previous studies in rabbits we tested 123I-labeled 
IL-8 for its potential to image infections and showed that IL-8 rapidly and efficiently 
accumulated in infectious foci. However, labeling of IL-8 with 123I is costly, laborious 
and the specific activity of the preparation was low. In the present study IL-8 was labeled  
with 99mTc via the hydrazinonicotinamide (HYNIC) chelator.  
Methods: The leukocyte receptor binding capacity of the preparation was determined in 
vitro. Rabbits with E. coli abscesses were i.v. injected with 7 MBq  99mTc-HYNIC-IL-8. 
Biodistribution of the radiolabel was determined by γ-camera imaging and tissue 
counting at 8 h p.i.  99mTc-HYNIC-Lysozyme was used as a size-matched control. 
Results: The leukocyte receptor binding capacity of the 99mTc-HYNIC-IL-8 preparation 
was preserved as determined in vitro, but labeling efficiency was modest with a specific 
activity of 3 MBq/µg.   99mTc-HYNIC-IL-8 accumulated rapidly in the abscess up to 0.33 
± 0.06 %ID/g at 8 h p.i (versus 0.025  ± 0.003 %ID/g for 99mTc-HYNIC-Lysozyme). 
Total uptake in the abscess was 4.9 ± 0.7 %ID (versus 0.44 ± 0.05 %ID for 99mTc-
HYNIC-Lysozyme). Abscess-to-contralateral muscle ratios increased up to 127 ± 23 
(compared to 6.7 ± 1.1 for 99mTc-HYNIC-Lysozyme) and abscess-blood ratios to 11.9  ± 
2.2 (0.24 ± 0.03 for 99mTc-HYNIC-Lysozyme). The radiolabel was excreted renally, with 
a retention in the kidneys of 28 %ID. Gamma camera imaging rapidly visualized the 
abscess from 1 h p.i. onwards, with abscess-to-background ratios improving with time up 
to 22 at 8 h  p.i. (vs 2.7 for 99mTc-HYNIC-Lysozyme), as determined by quantitative 
analysis of the images. Most importantly, only a transient (30 min) moderate drop of 
leukocyte counts and no leukocytosis was observed after injection of an imaging dose of  
99mTc-HYNIC-IL-8. 
Conclusion: IL-8 can be labeled with 99mTc using HYNIC as a chelator. By this method 
the leukocyte receptor binding capacity is preserved. The preparation allows rapid 
visualization of infection in a rabbit model with high target-to-background ratios. The 
mild transient drop of leukocyte counts and the absence of leukocytosis suggest that 
99mTc-HYNIC-IL-8 may be used as an imaging agent with only mild and  transient side-
effects.  
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INTRODUCTION 
 
A wide range of radiopharmaceuticals has been proposed to visualize infections and 
inflammations scintigraphically. Autologous leukocytes, labeled with 111 In or  99mTc, is 
still considered the ‘gold standard’ nuclear medicine technique to image infection and 
inflammation. With regard to diagnostic accuracy there is no need for a better imaging 
agent than labeled autologous leukocytes. However, the labeling procedure is time-
consuming, complex and could be hazardous. Therefore, there is a need for a 
radiopharmaceutical with at least similar clinical performance, that can be prepared 
rapidly and easily. In the search for new agents to image infections and inflammations, 
the development of new radiopharmaceuticals has gradually shifted during the past 
decades: from large proteins with aspecific uptake mechanisms (e.g. IgG (1-3)) via 
receptor-specific proteins of large size (e.g. anti-granulocyte (4;5) and anti-E-selectin 
antibodies (6)) and moderate size (antibody fragments (7)) to small receptor-binding 
proteins and peptides (e.g. cytokines).  
 Labeled cytokines such as interleukin-1, interleukin-2 and interleukin-8 are a 
promising class of protein radiopharmaceuticals of small molecular weight (<20 kDa). 
Cytokines act through an interaction with specific cell-surface receptors expressed on 
known cell populations. Binding affinities are usually high (nanomolar range).  
 Interleukin-1 (IL-1) binds receptors as expressed mainly on granulocytes, 
monocytes and lymphocytes, with high affinity. Studies in mice with focal 
Staphylococcus aureus infections showed specific uptake of radioiodinated IL-1 at the 
site of infection (infection-to-background ratios exceeded 40, 48 h p.i.) (8). 
Unfortunately, the biologic effects (e.g., hypotension, headache) of IL-1 even at very low 
doses (10 ng/kg) precluded clinical application of radiolabeled IL-1.  
 Chronic inflammation is characterized by infiltration of the target tissue by 
lymphocytes. It was successfully targeted with radiolabeled Interleukin-2 (IL-2) via 
specific binding to IL-2 receptors, expressed on activated T-lymphocytes. A method was 
developed that allowed the preparation of a 99mTc-IL-2 preparation with a high specific 
activity (9). Studies in patients with insulin-dependent diabetes, Hashimoto thyroiditis, 
Graves’ disease, Crohn’s disease or coeliac disease demonstrated localization of 123I- or 
99mTc-labeled IL-2 at the site of lymphocytic infiltration (10).  
 Interleukin-8 (IL-8) is a member of the CXC subfamily of the chemokines, or 
chemotactic cytokines, in which the first two cysteine residues are separated by one 
aminoacid residue. IL-8 binds the CXC type I (=IL-8 type A) and CXC type II (= IL-8 
type B) receptors expressed on neutrophils and monocytes with high affinity (0.3 – 4 
nM) (11;12). Hay and collegues (13) studied the in vivo behaviour of  radioiodinated 
IL-8 in a rat model with carrageenan-induced sterile inflammations. The uptake 
  
60     Chapter 4 
peaked at 1-3 hours after injection and declined thereafter. Target-to-background ratios 
did not exceed 2.5. In a pilot study in 8 patients these investigators showed that a 123I-
IL-8 could visualize inflammatory foci (14). We investigated the behaviour and 
kinetics of radioiodonated IL-8 in various models of  infection and sterile 
inflammation in rabbits (15;16). These studies showed that particularly IL-8 labeled 
according to the Bolton-Hunter method showed  superior imaging characteristics. In 
rabbits with focal E. coli infection, accumulation of 123I-labeled IL-8 in the abscess 
was rapid and high (0.85 ± 0.1 %ID, 8 h p.i.).  Abscess-to-contralateral muscle ratios 
exceeded 100 in this model within 8 h postinjection. The specific activity of this IL-8 
preparations was relatively low; the imaging dose of  123I-IL-8 (25 µg/kg) caused a 
transient drop of peripheral leukocyte counts to 45%, followed by a leukocytosis (170 
% of preinjection level) during several hours.   
For clinical imaging 123I is not a very suitable radionuclide: it is expensive and 
the Bolton-Hunter labeling method is rather laborious. For clinical application, a 
simple and rapid labeling procedure of  IL-8, using the radionuclide 99mTc, would be 
preferable. In the present study we investigated the potential of  99mTc-labeled IL-8 to 
image infections in a rabbit model. We aimed to develop a labeling technique that 
would result in a radiopharmaceutical with a high specific activity in order to reduce 
the IL-8 dose, thus reducing biologic activity. At the same time the leukocyte receptor 
binding capacity ought to be conserved. In order to accomplish this we used the 
bifunctional chelator hydrazino-nicotinamide (HYNIC). 99mTc-labeled Lysozyme 
(MW 14.3 kDa),  with no specific receptor interaction, was used  as a size-matched 
control in this study.  
 
 
MATERIALS AND METHODS 
 
Preparation of HYNIC-conjugates with IL-8 
Human recombinant IL-8 was kindly provided by Dr I. Lindley (Novartis, Vienna, 
Austria). Lysozyme was purchased from Sigma (St. Louis, MO). IL-8 was conjugated 
to hydrazino-nicotinamide (HYNIC) essentially as described  by Abrams et al. (17). 
Briefly,  in a 1.5 ml vial 1.5 µl  1 M NaHCO3,  pH 8.2 was added to 15 µl of IL-8 (5.7 
mg/ml). Subsequently succinimidyl-hydrazinonicotinamide (S-HYNIC) in 5 µl dry 
DMSO  was added dropwise to the mixture. A series of conjugates was prepared by 
using different molar conjugation ratios IL-8 : S-HYNIC (1:1 - 1:10) and different 
reaction times (3 - 60 min.). After incubation at room temperature, the reaction was 
stopped by adding an excess of 1.0 M glycine. Subsequently,  precooled PBS was 
added to a total volume of 170 µl. To remove excess unbound S-HYNIC the mixture 
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was extensively dialyzed against PBS (0.1-0.5 ml dialysis cell 3.5 MWCO, Pierce, 
Rockford, IL). Dialyzed samples of circa 7 µg  IL-8-HYNIC were stored at –20 0C. 
The preparation of  the Lysozyme-HYNIC-conjugate was similar; a three-fold molar 
excess of S-HYNIC was used and the reaction was stopped after 3, 10 or 30 minutes. 
 
99mTc-labeling of HYNIC conjugated IL-8  
Tricine-SnSO4-kits (0.2 ml) were prepared containing  20 mg tricine (N-
[Tris(hydroxymethyl)-methyl]glycine, Fluka, Buchs, Switzerland) and 0.01 mg SnSO4 
(Merck, Darmstadt, Germany) in 0.2 ml PBS pH 7.0. To prevent precipitation of 
stannous, SnSO4 dissolved in 2 M HCl was added to a solution of tricine in PBS and  
the pH was subsequently adjusted to 7.0 with 1.0 M NaOH.  
For receptor binding assays the HYNIC-conjugated IL-8 preparations with 
different molar conjugation ratios and different conjugation reaction times were 
labeled and tested. For animal studies the HYNIC-IL-8 preparation which showed the 
best leukocyte receptor binding capacity was selected for labeling and i.v. 
administration. As control a HYNIC-Lysozyme preparation with the same reaction 
conditions was chosen. For receptor binding assays a 0.2 ml tricine-SnSO4-kit  and 0.1 
- 0.3  ml 20 - 30 MBq 99mTcO4-  in saline were added to 5 µg thawed HYNIC-IL-8 and 
incubated at room temperature for 30 minutes. For animal studies a 0.2 ml tricine-
SnSO4-kit  and  0.5  ml 500 MBq 99mTcO4-  in saline were added to 20 µg thawed 
HYNIC-IL-8 or HYNIC-Lysozyme and incubated at room temperature for 30 minutes. 
The radiochemical purity was determined by instant thin-layer chromatography  
(ITLC) on ITLC-SG strips (Gelman Laboratories, Ann Arbor, MI) with 0.1 M citrate, 
pH 6.0, as the mobile phase.  
 Following the labeling reaction the reaction mixture was applied to a Sephadex G-
25 column (PD-10; Pharmacia, Uppsala, Sweden) and eluted with 0.5 % BSA in PBS to 
purify the radiolabeled IL-8 or Lysozyme conjugate.  
 
Receptor binding assay 
Human neutrophils were isolated from heparinized whole blood obtained from healthy 
donors. Receptor binding assays were performed essentially as described previously (16), 
using  99mTc-labeled IL-8 instead of radioiodinated IL-8. 
 
Animal studies 
Animal studies were performed essentially as described previously (16). The experiments 
were carried out in accordance with the guidelines of the local animal welfare committee. 
Abscesses were induced in the left thigh muscle of ten female New Zealand rabbits (2.4-
2.7 kg) with 4 x 1010 colony forming units (cfu) of Escherichia coli in 0.5 ml. During the 
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procedure, the rabbits were sedated with a subcutaneous injection of a 0.6 ml mixture of 
fentanyl 0.315 mg/ml and fluanisone 10 mg/ml (Hypnorm, Janssens Pharmaceutical, 
Buckinghamshire, UK). After 24 hours, when swelling of the muscle was apparent, six 
rabbits were  injected with 7 MBq 99mTc-HYNIC-IL-8 (protein dose 2.5 µg) via the ear 
vein. Three of them were used for gamma camera imaging (0, 1, 2, 4 and 8 h p.i.), while 
the other three were used to determine the pharmacokinetics and monitor white blood 
cell counts. A control group of five rabbits was injected with 18 MBq 99mTc-
HYNIC-Lysozyme (protein dose 2.5 µg). Two of these animals were imaged with a 
gamma camera (0, 1, 2, 4 and 8 h p.i.).  
 For imaging, rabbits were  immobilized, placed prone on the gamma camera and 
injected with either 99mTc-HYNIC-IL-8 or 99mTc-HYNIC-Lysozyme  in the lateral ear 
vein. Images were recorded at 1 min, 1, 2, 4 and 8 hr p.i. with a single-head gamma 
camera (Orbiter, Siemens Medical Systems Inc., Hoffman Estates, IL) equipped with a 
parallel-hole low-energy all purpose collimator. Images (100,000-200,000 counts per 
image) were obtained and digitally stored in a 256 x 256 matrix. 
 The scintigraphic results were analyzed quantitatively by drawing regions of 
interest (ROI) over the abscess and  the uninfected contralateral thigh muscle 
(background). Abscess-to-background ratios were calculated. 
 Pharmacokinetics and white blood cell counts were determined in a  group of  three 
rabbits injected with  7 MBq  2.5 µg  99mTc-HYNIC-IL-8. Blood samples were collected 
at –1, 1, 3, 5, 10, 30, 60, 120, 240 and 480 minutes after injection. Blood samples were 
weighed, their activity was measured and their uptake expressed as %ID/g and as %ID in 
the blood pool based on an estimated total blood volume of 6% of the total body weight 
of the rabbit (18). White blood cell counts were measured in the same blood samples and 
expressed as percentage of the pre-injection value. 
 After completion of the final imaging and blood sampling (8 h p.i.), the rabbits 
were killed with a lethal dose of sodium phenobarbital. Samples of blood, infected thigh 
muscle, uninfected contralateral thigh muscle, lung, spleen, liver, kidneys and intestines 
were collected. The dissected tissues were weighed and counted in a gamma counter. 
Injection standards were counted simultaneously to correct for radioactive decay. The 
measured activity in samples was expressed as percentage of injected dose per gram 
tissue (%ID/g). Additionally, total uptake of the radiopharmaceutical (%ID) was 
measured for  kidneys and abscesses. Abscess-to-contralateral muscle ratios and abscess-
to-blood ratios were calculated. 
 
Statistical analysis 
All mean values are given as %ID/g or ratios ± one standard error of the mean (s.e.m.). 
The data were analyzed statistically using the one-way analysis of variance (ANOVA). 
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RESULTS 
 
Radiolabeling and characterization of 99mTc-HYNIC-IL-8  
The labeling efficiencies (%) and receptor binding fractions RBF (%) of various 99mTc-
HYNIC-IL-8 and 99mTc-HYNIC-Lysozyme preparations are shown in Table 1.  There is 
an inverse relationship between labeling efficiency and leukocyte receptor binding 
capacity (RBF). For animal studies the most mildly modified HYNIC-IL-8-preparation 
with the highest receptor binding capacity was chosen, i.e. the preparation with molar 
conjugation protein:S-HYNIC of 1:3 and a conjugation reaction time of 3 min. The 
conventional binding plot for this preparation is presented in figure 1. As control the 
HYNIC-Lysozyme preparation with the same molar conjugation ratio 1:3 and 
conjugation time 3 minutes was chosen. The specific activity was 2.8 MBq/µg for the 
99mTc-HYNIC-IL-8 preparation and 7.2 MBq/µg for the 99mTc-HYNIC-Lysozyme 
preparation. The radiochemical purity of all radiopharmaceuticals was higher than 95% 
after gel filtration as determined by ITLC. In other experiments we used a more 
rigorously conjugated IL-8 preparation (molar conjugation ratio protein:S-HYNIC 1:10; 
conjugation reaction time 60 min.) (19). This preparation showed a labeling efficiency of 
97% with specific activities as high as 75 MBq/µg. However, the leukocyte receptor 
binding capacity was greatly reduced (RBF=16%), indicating that the conjugation 
conditions were too aggresive and modifications occurred in regions of the protein that 
are critical for receptor binding. 
 
Table 1. Labeling efficiencies (%) and receptor binding fractions RBF (%) of various 99mTc-
HYNIC-IL-8  and 99mTc-HYNIC-Lysozyme preparations.*  
 
Protein Molar conjugation ratio 
Protein : S-HYNIC 
Reaction time 
(min) 
Labeling 
Efficiency (%) 
RBF 
(%) 
IL-8 1 : 1 3 15 65 
IL-8 1 : 1 60 87 31 
IL-8 1 : 2 60 94 24 
IL-8 1 : 3 3 20 65 
IL-8 1 : 3 10 71 37 
IL-8 1 : 3 30 83 30 
IL-8 1 : 3 60 95 21 
IL-8 1 : 10 60 97 16 
Lysozyme 1 : 3 3 69 n.d. 
Lysozyme 1 : 3 10 90 n.d. 
Lysozyme 1 : 3 30 95 n.d. 
*For determination of labeling efficiencies, 5 µg of HYNIC-conjugated protein was used with 20 
- 30 MBq 99mTc. (n.d. = not determined) 
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Figure 1.  The conventional binding plot of  99mTc-HYNIC-IL-8 as determined on isolated human 
granulocytes. The specific binding over total applied radioactivity is plotted as a function of 
increasing cell concentration. 
 
 
99mTc-HYNIC-IL-8 in rabbits with E. coli infection  
Immediately after injection of  99mTc-HYNIC-IL-8 (1 µg/kg body weight), a transient 
reduction of peripheral leukocyte levels to 54% was observed (Fig. 2). The white blood 
cell count returned to base levels within 30 minutes. No subsequent leukocytosis was 
observed.  The blood clearance pattern fitted a two-phase model with a half-life (t½α) of  
4.2 min during the distribution phase and  a half-life (t½β) of 5.1 h during the elimination 
phase (Fig. 3). 
 The abscesses were clearly delineated on the images recorded from 1 h onwards 
(Fig. 4). 99mTc-HYNIC-IL-8 rapidly accumulated at the site of infection. Quantitative 
analysis of the images indicated that the abscess-to-background ratios improved with 
time up to 21.8 ± 1.0 at 8 h p.i. (Fig. 5). Immediately after injection high kidney uptake 
was observed; kidney uptake remained high during the 8 h p.i. In addition, activity was 
found in bladder, liver and lungs. The control agent  99mTc-HYNIC-Lysozyme showed a 
similar kidney uptake pattern, but failed to accumulate significantly at the site of 
infection. Abscess-to-background ratios did not exceed 2.7 (Fig. 5).  
 Tissue biodistribution of the radiolabel determined at 8 h p.i. is summarized in table 
2. Except for the kidneys and the spleen, the highest uptake of  99mTc-HYNIC-IL-8 was 
found in the abscess: 0.33 ± 0.06 %ID/g, versus 0.025 ± 0.003 %ID/g for 99mTc-HYNIC-
Lysozyme (p=0.0001). Total uptake in the infected tissue was 4.9 ± 0.7 %ID versus 0.44 
± 0.05 %ID for 99mTc-HYNIC-Lysozyme (p=0.0001), indicating preferential retention of 
IL-8 in infected tissue.  Abscess-to-contralateral muscle ratios reached a value as high as 
127 ± 23 at 8 h p.i. versus 6.7 ± 1.1 for 99mTc-HYNIC-Lysozyme (p<0.001). The 
abscess-to-blood ratio was 11.9 ± 2.2 at 8 h p.i. compared to 0.24 ± 0.03 for 99mTc-
HYNIC-Lysozyme (p=0.0001). Kidney retention was high: at 8 h p.i. 28  ± 1 %ID was 
found in the kidneys (35 ± 1 %ID for 99mTc-HYNIC-Lysozyme).  
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Figure 2 (left). White blood cell counts in blood of  E. coli infected New Zealand rabbits after 
intravenous injection of 2.5 µg 99mTc-HYNIC-IL-8, expressed as percentage of the pre-injection 
value. The error bars indicate s.e.m 
 
 
Figure 3 (right). Blood clearance of  99mTc-HYNIC-IL-8  determined in rabbits with E. coli 
infection. Data are expressed as percentage of the injected dose in the blood pool. The error 
bars indicate s.e.m. 
 
Interleukin-8 
 
 
 
 
 
                   1 min                1 h                   2 h                4 h               8 h p.i. 
 
Lysozyme 
 
 
 
 
 
 
                    1 min                1 h                    2 h                  4 h               8 h p.i. 
 
Figure 4. Images of rabbits with an E. coli abscess in the left thigh muscle at 1 min, 1, 2, 4 and 8 
hr after injection of 99mTc-HYNIC-IL-8 (upper panel) or 99mTc-HYNIC-Lysozyme (lower panel). 
All photographs were produced with the same image contrast. 
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Figure 5. The abscess-to-background ratios as determined by quantitative analysis of the images 
of rabbits with E. coli infection injected with 99mTc-HYNIC-IL-8 or 99mTc-HYNIC-Lysozyme. The 
error bars indicate s.e.m.  
 
 
 
 
 
Table 2. Biodistribution of 99mTc-HYNIC-IL-8  and 99mTc-HYNIC-Lysozyme in rabbits with E. 
coli infections at 8 h p.i. (%ID/g, mean values ± s.e.m.)  
 
 
Organ 99mTc-IL-8 
n=6 
99mTc-Lysozyme 
n=5 
Blood      0.028   ±  0.001  0.105    ±  0.006 
Abscess      0.33     ±  0.06  0.025    ±  0.003 
Muscle      0.0026 ± 0.0001  0.0041  ±  0.0008 
Lung      0.19     ±  0.04  0.077    ±  0.011 
Spleen      0.64     ±  0.06  0.119    ±  0.005 
Kidney      1.47     ±  0.06  1.77      ±  0.06 
Liver      0.14     ±  0.01  0.124    ±  0.006 
Intestine      0.025   ±  0.002  0.028    ±  0.001 
   
Abscess/muscle         127   ±  23     6.7     ±  1.1 
Abscess/blood         11.9  ±  2.2     0.24   ±  0.03 
 
Total uptake infected  tissue (%ID) 
          
         4.9   ±  0.7  
     
    0.44   ±  0.05 
Total uptake in kidneys (%ID)          28    ±  1      35     ±  1 
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DISCUSSION 
 
Based on results with radioiodinated IL-8 previously obtained in our laboratory, we  
explored here the potential of 99mTc-labeled IL-8 to image infection and inflammation  in 
rabbits with E. coli infection. The present study showed that IL-8 can be labeled with 
99mTc using HYNIC as a chelator with preservation of its leukocyte receptor binding 
capacity. The preparation allows rapid visualization of infection within a few hours after 
injection and high target-to-background ratios. The mild transient drop of leukocyte 
counts and the absence of leukocytosis suggest that 99mTc-HYNIC-IL-8 may be applied 
as a clinically useful imaging agent.  
 The labeling efficiency and leukocyte receptor binding capacity of various 99mTc-
HYNIC-IL-8 preparations was tested. Mildly modified 99mTc-HYNIC-IL-8 preparations 
showed  good receptor binding but modest 99mTc binding, with a relatively low specific 
activity of nearly 3 MBq/µg. On the other hand, higher substitution of the protein with S-
HYNIC resulted in 99mTc-HYNIC-IL-8 preparations with high specific activities (as high 
as 75 MBq/µg), but with a severe loss of receptor binding capacity. The best infection 
imaging characteristics were obtained with the mildly modified 99mTc-HYNIC-IL-8 
preparation presented in this study. This was demonstrated for instance by an abscess-
muscle ratio at 8 h p.i. of 127 as compared to 36 for a more rigorously conjugated IL-8 
preparation formerly used (19). 
 The observation that infection uptake of 99mTc-HYNIC-IL-8  was more than ten 
times higher than the uptake of 99mTc-HYNIC-Lysozyme suggested that abscess uptake 
was a result of the interaction of IL-8 with its receptors in the infectious foci. Specific 
uptake was shown also by an abscess-muscle ratio of 127 as compared to 6.7 for the 
control peptide. Uptake in the kidneys was high for both peptides which is a common 
phenomenom for radiolabeled peptides  (20-24). The mechanism of renal uptake and 
retention of proteins is believed to involve glomerular filtration and subsequent 
reabsorption and catabolism in the proximal tubular cells (25;26). This process is 
dependent on molecular weight and charge of the proteins. Proteins exceeding a 
molecular weight of approximately 60 kDa are too large to pass the glomerular basement 
membrane and are thus not retained in the kidneys. Cationic proteins, as compared to 
anionic ones, are preferably retained in the kidneys. Several investigators have lowered 
renal uptake by infusing basic amino acids such as lysine and arginine (for a Review see 
26). Other strategies involve chemical modification of the protein. A substantial 
reduction of renal uptake has been achieved by glycolation of free amino groups (lysine 
side chains) (27-28). 
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 In previous studies IL-8 has been investigated for scintigraphic detection of 
infection and inflammation by Hay et al. (13) and in our laboratory by Van der Laken et 
al. (15;16). In these studies IL-8 was radioiodonated according to the chloramine-T, the 
iodogen or the Bolton-Hunter method. The last method was found to be superior. With  
preparations of iodonated IL-8 via the Bolton-Hunter method (123I-BH-IL-8) abscess-
muscle and abscess-blood ratios of 115 and 12 respectively (8 h p.i.) were obtained in a 
rabbit model, similar to the ratios obtained in the present study. With both preparations, 
abscesses were visualized as early as 1 h p.i. Uptake of activity in the kidneys was high 
with both preparations, although it was less pronounced for 123I-BH-IL-8. The difference 
is caused by clearance of the radioiodonated label from the tubular cells after degradation 
in the lysosomes, whereas radiometal chelates remain trapped within lysosomes (21,26-
28). Labeling IL-8 with 99mTc via HYNIC offers great advantages over the Bolton-
Hunter iodonation method.  In the first place, the preparation of  99mTc-HYNIC-IL-8 as 
compared to 123I-BH-IL-8 is easy, fast and suitable for instant kit formulations for routine 
use. Secondly, a formulation with 99mTc is inexpensive and always available, compared 
to 123I. Most importantly,  a preparation with much higher specific activity could be 
obtained. In this way the amount of biologically active material injected is reduced  25-
fold: 1 µg/kg 99mTc-HYNIC-IL-8 versus 25 µg/kg 123I-BH-IL-8. Using a dose of 25 
µg/kg, IL-8 induced transient leukopenia followed by a leukocytosis lasting for several 
hours (15), while at a dose level of 1 µg/kg only a mild transient drop of leukocyte counts 
without subsequent leukocytosis was observed. This suggests that 99mTc-HYNIC-IL-8 
can be used as an imaging agent potentially without clinically significant side-effects.  
 Besides IL-8 several small  99mTc-labeled peptides capable of binding to leukocytes 
in vivo have been developed and tested for their imaging qualities. 99mTc labeled N-
formyl-methionyl-leucyl-phenylalanyl-lysine (fMLFK) (29) and Platelet Factor 4 derived 
peptide P483H (30) are effective infection-seeking agents. However, in the same animal 
model abscess-muscle ratios obtained with these agents were only a quarter of those 
obtained with IL-8. In addition, fMLFK showed relatively high activity in bowel and 
liver resulting in high background activity, making this imaging agent less suitable for 
detection of infections in the abdomen.  
 Future experiments with 99mTc labeled IL-8 will focus on improvement of the 
labeling efficiency without compromising the receptor binding activity and infection 
localizing capacity of the agent. Site specific attachment of a bifunctional chelating group 
in a region of IL-8 not critical for receptor binding will be the proper solution. 
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CONCLUSION     
 
The present study showed that 99mTc-labeled IL-8 has excellent characteristics as an 
infection imaging agent: it rapidly accumulated in infectious foci, while it rapidly cleared 
from nontarget tissues. The technetium chemistry allowed labeling of IL-8 with 
preservation of its leukocyte receptor binding capacity. The mild transient drop of 
leukocyte counts without subsequent leukocytosis suggest that 99mTc-HYNIC-IL-8 may 
be used as a clinically useful imaging agent without significant side-effects. These results 
warrant further development of an IL-8 based radiopharmaceutical for infection imaging. 
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ABSTRACT 
 
In our previous studies interleukin-8 (IL-8) was labeled with 99mTc using  hydrazino-
nicotinamide (HYNIC) as bifunctional coupling agent and tricine as coligand. This 
preparation showed excellent characteristics for imaging of infection in a rabbit model of 
soft-tissue infection. In the present study the propylaldehyde hydrazone formulation of 
HYNIC was introduced to stabilize HYNIC-IL-8. 99mTc-HYNIC-IL-8 was prepared 
using 5 different coligand formulations. The effect of these coligand formulations on the 
in vitro characteristics and in vivo behavior of 99mTc-HYNIC-IL-8 was investigated.  
Methods: HYNIC-conjugated IL-8 was labeled with 99mTc in the presence of either (A) 
Tricine, (B) ethylenediaminediacetic acid (EDDA), (C) Tricine and trisodium 
triphenylphosphinetrisulfonate (TPPTS), (D) Tricine and nicotinic acid (NIC) or (E) 
Tricine and isonicotinic acid (ISONIC). These preparations were characterized in vitro 
by RP-HPLC, determination of the octanol/water partition coefficient, stability studies 
and by receptor binding assays. The in vivo biodistribution of the radiolabel in rabbits 
with E.coli induced soft-tissue infection was determined both by γ-camera imaging as 
well as by tissue counting at 6 h p.i. 
Results: Specific activity (MBq/µg) was highest for (ISO)NIC (up to 80) > TPPTS (40) 
> Tricine (15) > EDDA (7). RP-HPLC and octanol/water partition coefficients showed a 
shift toward higher lipophilicity for the TPPTS preparation. The leukocyte receptor 
binding fractions were around 40-55% for all preparations except for TPPTS, which 
showed predominantly nonspecific binding. All preparations were stabilized in serum, 
but the stability in PBS was highest for NIC and TPPTS > EDDA > ISONIC > Tricine. 
The in vivo biodistribution showed highest abscess/muscle for NIC and ISONIC (>200) 
> EDDA and Tricine (∼100) > TPPTS (<40). Gamma camera imaging rapidly visualized 
the abscess from 2 h p.i. onwards for all formulations. The abscess/background (A/B) at 
6 h p.i. for ISONIC was significantly higher (P<0.05) than that of Tricine and the A/B of 
TPPTS was significantly lower (P<0.05). 
Conclusion: IL-8 can be rapidly and easily labeled with 99mTc using HYNIC as a 
chelator in combination with various coligands. The most optimal infection imaging 
characteristics were found for formulations using Nicotinic acid/tricine as coligand 
system combining a high specific activity and high in vitro stability with high 
abscess/muscle ratios (>200) and high abscess/background ratios (>20). Protein doses to 
be administered were as low as 70 ng/kg bodyweight. At these low protein doses side 
effects are not to be expected in the human system. This paves the way for infection 
imaging studies in patients. 
 
Effects of coligand on in-vivo characteristics     73 
INTRODUCTION 
 
Scintigraphic imaging of infectious and noninfectious inflammation is a powerful 
diagnostic tool in the management of patients with inflammatory disorders. Most 
inflammatory foci can be visualized accurately with ex vivo radiolabeled autologous 
leukocytes. However, preparation of this radiopharmaceutical is laborious and requires 
the handling of potentially contaminated blood with inherent risks for both personnel 
and patients. 
 There is an ongoing search for radiolabeling small molecules that bind to 
circulating leukocytes (in vivo labeling of leukocytes) after the relatively poor results 
obtained with large size monoclonal antibodies directed against leukocytes. These 
small molecules include chemotactic peptides (analogues of formyl-Met-Leu-Phe) and 
cytokines (e.g., the interleukins, platelet factor 4 derivatives) [for a review: (1)]. We 
have actively pursued a research program to explore the potential of radiolabeled 
formyl-Met-Leu-Phe-Lys, interleukin-1, interleukin-8 and other cytokines for imaging 
inflammation. 
 Radiolabeled interleukin-8 (IL-8) proved to be the most promising candidate so 
far. IL-8 is a member of the CXC subfamily of chemokines, or chemotactic cytokines, in 
which the first two cysteine residues are separated by one aminoacid residue. This 
cytokine  binds the CXC type l (= IL-8 type A) and CXC type ll (= IL-8 type B) 
receptors expressed on neutrophils and monocytes with high affinity (0.3-4 nM) (2,3). 
Hay and colleagues (4) studied the in vivo behavior of  radioiodinated IL-8 in a rat model 
with carrageenan-induced sterile inflammations and found only modest target-to-
background ratios of 2.5. In a pilot study in eight patients these investigators showed that 
a 123I-IL-8 could visualize inflammatory foci (5).  
 We investigated the in vivo behavior of radiolabeled IL-8 in various models of  
infection and sterile inflammation in rabbits (6-10). Studies with 123I-labeled IL-8 in 
rabbits with focal E. coli infection showed rapid accumulation of the 
radiopharmaceutical in the abscess (6,7).  Abscess-to-contralateral muscle ratios 
exceeded 100 in this model within 8 h postinjection. A drawback of this preparation was 
its relatively low specific activity; the imaging dose of 123I-IL-8 (25 µg/kg) caused a 
transient drop of peripheral leukocyte counts to 45%, followed by a leukocytosis (170% 
of preinjection level) during several hours. Moreover, 123I is not a very suitable 
radionuclide for clinical imaging: it is expensive and the Bolton-Hunter labeling method 
used for preparing 123I-labeled IL-8 is rather laborious.  
 For clinical application, a simple and rapid labeling procedure of  IL-8, using the 
radionuclide 99mTc, is preferable. 99mTc combines highly favorable physical 
characteristics (t½ = 6 h, Emax = 140 keV) with easy availability and low cost. In a 
  
74     Chapter 5 
subsequent study IL-8 was labeled with 99mTc using hydrazinonicotinamide (HYNIC) as 
bifunctional coupling agent (8). HYNIC has been introduced by Abrams and co-workers 
(11) for labeling polyclonal IgG with 99mTc to image infections. Since the HYNIC group 
can only occupy one or two coordination sites in the technetium coordination sphere, an 
additional coligand is required. For labeling HYNIC conjugated IL-8 with 99mTc tricine 
was chosen as coligand, because specific activities obtained with this coligand are much 
higher than with e.g. glucoheptonate (12). The specific activity of the 99mTc-labeled IL-8 
preparation was found to be 25x higher than the specific activity of the 123I-labeled IL-8 
preparation. In rabbits with E.coli induced softtissue infection abscess to contralateral 
muscle ratios and abscess to blood ratios obtained with the 99mTc- and the 123I-labeled 
preparation were similar. Preparing 99mTc-labeled IL-8 is easy and fast, offering a major 
advantage over the radioiodination procedure. 
 The aim of the present study was to improve the characteristics for imaging 
infection of a 99mTc-labeled IL-8 preparation together with a further increase in specific 
activity of the preparation, thus reducing the required IL-8 protein dose. Two aspects 
of the labeling procedure were further optimized. 
 First, a modified form of HYNIC was synthesized. To improve long term 
stability Schwartz and coworkers introduced the use of a propylaldehyde hydrazone 
formulation to stabilize HYNIC modified proteins (13,14). This protection of the 
hydrazine moiety of HYNIC ensures greater stability in aqueous solutions and the 
hydrazone retains the capacity to produce enough free hydrazine for successful labeling 
with 99mTc.  
 Second, different coligand formulations were adopted in labeling HYNIC 
conjugated IL-8 with 99mTc. Babich and Fischman (15) were the first to show that the 
nature of the coligand has a distinctive influence on the biologic properties of the 
radioconjugate. Liu and Edwards et al. have performed systematic studies on labeling 
a HYNIC-conjugated platelet glycoprotein receptor antagonist with 99mTc using 
various coligand formulations: tricine; ethylenediaminediacetic acid (EDDA) (16); 
tricine in combination with water soluble phosphines (17); tricine in combination with 
imine-N-containing heterocycles  (18).  
 In the present study HYNIC conjugated IL-8 was labeled with  99mTc using five 
different coligand systems: i) tricine; ii) EDDA; iii) tricine in combination with trisodium 
triphenyl-phosphine-3,3’,3’’-trisulfonate (TPPTS); iv) tricine in combination with 
nicotinic acid; and v) tricine in combination with isonicotinic acid (see Fig. 1). The 
proposed structures (16-18) of the resulting binary technetium complexes [99mTc(IL-8-
HYNIC)(tricine)2]  and  [99mTc(IL-8-HYNIC)(EDDA)] and ternary technetium 
complexes [99mTc(IL-8-HYNIC)(tricine)(L)] (L = TPPTS or nicotinic acid or isonicotinic 
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acid) are depicted in Fig. 2. The effect of the coligand on the in vivo behavior of  99mTc-
labeled IL-8 was investigated in a rabbit model of E.coli induced soft tissue infection. 
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Figure 1. Structures of coligands used in this study. 
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Figure 2. Binary technetium complexes [99mTc(IL-8-HYNIC)(tricine)2] [Fig. 2A] and [99mTc(IL-
8-HYNIC)(EDDA)] [Fig. 2B]. The exact nature of the bonding between the IL-8-HYNIC-99mTc 
core and EDDA is unclear. X is a supposed additional monodentate ligand, such as Cl- (16). 
Ternary technetium complexes [99mTc(IL-8-HYNIC)(tricine)(L)] (L = TPPTS or nicotinic acid or 
isonicotinic acid) [Fig 2C]. 
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MATERIALS AND METHODS 
 
Human recombinant IL-8 was kindly provided by Dr I. Lindley (Novartis, Vienna, 
Austria). Tricine (N-[Tris(hydroxymethyl)-methyl]glycine was purchased from Fluka, 
Buchs, Switzerland. EDDA (ethylenediaminediacetic acid), TPPTS (trisodium triphenyl-
phosphine-3,3’,3’’-trisulfonate), nicotinic acid and isonicotinic acid were obtained from 
Sigma-Aldrich (St. Louis, MO).  
 
Conjugation of HYNIC to IL-8   
The propylaldehyde hydrazone of succinimidyl-hydrazinonicotinamide (HYNIC) was 
synthesized essentially as described by Abrams, Schwartz et al. (11,13). The IL-8-
HYNIC conjugate was prepared as described previously (8). Briefly, in a 1.5 ml vial 4 µl  
1 M NaHCO3,  pH 8.2 was added to 35 µl of IL-8 (4.8 mg/ml). Subsequently, a three-fold 
molar excess of HYNIC in 5 µl dry DMSO  was added dropwise to the mixture. After 
incubation for  five minutes at room temperature, the reaction was stopped by adding an 
excess of 200 µl 1 M glycine in PBS. To remove excess unbound HYNIC the mixture 
was extensively dialyzed against PBS (0.1-0.5 ml dialysis cell 3.5 MWCO, Pierce, 
Rockford, IL). Dialyzed samples of circa 5 µg IL-8-HYNIC were stored at –20 0C.  
 
99mTc-labeling of HYNIC conjugated IL-8  
i)Tricine as coligand 
Tricine-SnSO4-kits (0.2 ml) were prepared containing  20 mg tricine and 0.01 mg SnSO4 
in 0.2 ml PBS, pH 7.0. To prevent precipitation of stannous, SnSO4 dissolved in 2 M HCl 
was added to a solution of tricine in PBS and  the pH was adjusted to 7.0 with 1.0 M 
NaOH. A 0.2 ml tricine-SnSO4-kit and 100 - 350 MBq 99mTcO4-  in saline were added to 
5 µg thawed HYNIC-IL-8 and incubated at room temperature for 30 minutes.  
ii) EDDA as coligand 
10 µg thawed HYNIC-IL-8 was incubated with 0.5 ml of solution of EDDA (10 mg/ml 
in PBS), 100 - 350 MBq 99mTcO4-  in saline, and 10 µl of tin(II)solution (1.0 mg/ml 
SnSO4 in nitrogen purged 0.1 N HCl) for 30 minutes at 70 0C. 
iii) TPPTS/tricine as coligands 
5 µg thawed HYNIC-IL-8 was incubated with 0.1 ml of solution of TPPTS (10 mg/ml in 
25 mM benzoate buffer, pH 5.0), 0.3 ml of a tricine solution (100 mg/ml in 25 mM 
benzoate buffer, pH 5.0), 100 - 350 MBq 99mTcO4-  in saline, and 25 µl of tin(II)solution 
(1.0 mg/ml SnSO4 in nitrogen purged 0.1 N HCl) for 30 minutes at 70 0C. 
iv) Nicotinic acid/tricine as coligands 
5 µg thawed HYNIC-IL-8 was incubated with 0.1 ml of solution of nicotinic acid (20 
mg/ml in 25 mM benzoate buffer, pH 5.0), 0.4 ml of a tricine solution (100 mg/ml in 25 
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mM benzoate buffer, pH 5.0), 100 - 350 MBq 99mTcO4-  in saline, and 25 µl of 
tin(II)solution (1.0 mg/ml SnSO4 in nitrogen purged 0.1 N HCl) for 30 minutes at 70 0C. 
v) Isonicotinic acid/tricine as coligands 
The labeling procedure was identical to the one above, using isonicotinic acid instead of 
nicotinic acid. 
 
Chemical characterization of 99mTc-labeled IL-8 preparations 
i) Radiochemical purity by ITLC 
The radiochemical purity was determined by instant thin-layer chromatography  (ITLC) 
on ITLC-SG strips (Gelman Laboratories, Ann Arbor, MI) with 0.1 M citrate, pH 6.0, as 
the mobile phase.  
ii) Purification 
Following the labeling reaction the reaction mixture was applied to a Sephadex G-25 
column (PD-10; Pharmacia, Uppsala, Sweden) and eluted with PBS, 0.5% BSA to 
purify the radiolabeled IL-8 conjugate.  
iii) Octanol/water partition coefficient as a measure of lipophilicity 
In order to determine the lipophilicity of the various 99mTc-HYNIC-IL-8 preparations, 
approximately 100,000 cpm of a purified preparation was diluted with PBS to a total 
volume of three mL. An equal volume of octanol was added and the resulting biphasic 
system was mixed vigorously for one minute and gently for another ten minutes. The two 
phases were separated by centrifugation (10 min 2000 g) and 0.2 mL aliquots were taken 
from each layer. The partition coefficient was expressed as the ratio of cpm in the octanol 
phase to the cpm in the PBS phase. 
iv) Stability in PBS and in serum 
Following the labeling reactions, the five 99mTc-labeled IL-8 preparations were 
purified on a Sephadex G-25 column eluted with PBS without BSA. The stability of 
the purified preparations was monitored in PBS  at room temperature and in human 
serum (1:5) at 37 0C for six hours. At several time points post incubation (0, 2, 4 and 6 
h), samples were analyzed for the amount of free radiolabel using ITLC. Samples of 
the serum incubated preparations were diluted 1:5 in PBS with 0.5% BSA before 
applying to the ITLC-strip in order to prevent protein overload of the strips by serum 
proteins. 
v) Analytical RP-HPLC 
The radiochemical purity was determined by reversed phase high-performance liquid 
chromatography (RP-HPLC) (HP 1100 series, Hewlett Packard, Palo Alto, CA) using 
an Agilent Zorbax Stable Bond Analytical 4.6x250mm column (300SB-C8) at a flow 
rate of 1 mL/min. The radioactivity of the eluate was monitored using an in-line 
radiodetector (Flo-one Beta series A-100, Radiomatic, Meriden, CT). 
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Method 1: Solvents used: A) 0.01% TFA in water; B) 90% acetonitrile (ACN), 10% 
solution A. Gradient: from 70% A and 30% B to 45% A and 55% B in 30 minutes.  
Method 2:  Solvents used: A) 10 mM phosphate buffer pH 6.0; B) 100% ACN. Gradient: 
0-3 min 0% B, 3-18 min 0%-30% B, 18-23 min 30% B, 23-33 min 30%-75% B, 33-34 
min 70%-0% B.   
 
Receptor binding assays 
The receptor binding fraction (RBF) of the various 99mTc-HYNIC-IL-8 preparations was 
determined in receptor binding assays essentially as described by Lindmo et al. (19). The 
in vitro receptor binding assays were performed using Jurkat cells transfected with either 
IL-8 receptor 1 (CXCR1) or IL-8 receptor 2 (CXCR2), a kind gift of Drs. Loetscher and 
Baggiolini (Theodor Kocher Institute, University of Bern, Bern, Switzerland). The two 
cell lines were cultured at 37 oC in a humidified atmosphere of air/CO2 (95:5) in RPMI 
1640 medium (GIBCO, Gaithersburg, MD) containing 10% fetal calf serum and 1% 
glutamine, amino acids and pyruvate. The medium also contained Pen/Strep, 5 x 10-5 M 
of β-mercaptoethanol and 1.5 µg/ml puromycin for selection. Live Jurkat cells were 
centrifuged (5 min, 2000xg) and washed once with assay buffer (RPMI 1640, 0.5% BSA, 
0.05% NaN3). A series of serially diluted cell suspensions (0.125-2 x 108 cells/ml) of 
cells bearing CXCR1 and a second series bearing CXCR2 were incubated with 10,000 
cpm of a 99mTc-labeled IL-8 preparation in assay buffer. For each series, a duplicate of 
the lowest cell concentration was incubated in the presence of at least a 100-fold molar 
excess of unlabeled IL-8 to correct for nonspecific binding. After 30 minutes incubation 
at 37 oC, cells were centrifuged (5 min, 2000xg) and the radioactivity in the pellet (total 
bound radioactivity) was measured in a shielded well-type gamma counter (Wizard; 
Pharmacia, Uppsala, Sweden). The data were graphically analyzed in a modified 
Lineweaver-Burk plot: a double inverse plot of the conventional binding plot 
(specifically bound fraction versus cell concentration). The receptor-binding fraction at 
infinite cell excess was calculated by linear extrapolation to the ordinate. 
 
Animal studies 
Abscesses were induced in the left thigh muscle of 25 female New Zealand rabbits (2.4-
2.7 kg) with 1-2 x 1011 colony forming units (cfu) of Escherichia coli in 0.5 ml. During 
the procedure, rabbits were anaesthetized with a subcutaneous injection of a 0.6 ml 
mixture of fentanyl 0.315 mg/ml and fluanisone 10 mg/ml (Hypnorm, Janssens 
Pharmaceutical, Buckinghamshire, UK). The rabbits were divided into five groups of 
five animals (five animals per 99mTc-HYNIC-IL-8 coligand formulation). After 24 hours, 
when swelling of the muscle was apparent, the rabbits were injected with 10-40 MBq 
99mTc-HYNIC-IL-8 (protein dose 0.2-2 µg) via the ear vein. Three rabbits out of each 
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group were used for gamma camera imaging. These rabbits were  immobilized, placed 
prone on the gamma camera and images were recorded at 0, 2, 4 and 6 h p.i. with a 
single-head gamma camera (Orbiter, Siemens Medical Systems Inc., Hoffman Estates, 
IL) equipped with a parallel-hole low-energy all purpose collimator. Images were 
obtained with a 15% symmetrical window over the 140 keV energy peak of 99mTc. After 
acquisition of 100,000-300,000 counts, the images were digitally stored in a 256 x 256 
matrix. 
 Scintigraphic images were analyzed quantitatively by drawing regions of interest 
(ROI) over the abscess and  the uninfected contralateral thigh muscle (background). 
Abscess-to-background ratios were calculated. 
 After completion of the final imaging (6 h p.i.), all rabbits were killed with a lethal 
dose of sodium phenobarbital. Samples of blood, infected thigh muscle, uninfected 
contralateral thigh muscle, lung, spleen, liver, kidneys and intestines were collected. The 
dissected tissues were weighed and counted in a gamma counter. To correct for 
radioactive decay injection standards were counted simultaneously. The measured 
activity in samples was expressed as percentage of injected dose per gram tissue 
(%ID/g). Additionally, total uptake of the radiopharmaceutical (%ID) was determined for 
kidneys and abscesses. Abscess-to-contralateral muscle ratios and abscess-to-blood ratios 
were calculated. 
 
Statistical analysis 
All mean values are given as %ID/g, %ID or ratios ± 1 standard error of the mean 
(s.e.m.). The data were analyzed statistically using the one-way ANOVA with Dunnett’s 
posttest (GraphPad Instat 3.00 Win 95, San Diego, CA, USA) comparing data for the 
EDDA, the TPPTS, the nicotinic and the isonicotinic preparation with data for the tricine 
preparation.  
 
 
RESULTS 
 
Radiolabeling and characterization of 99mTc-labeled IL-8 preparations 
Table 1 shows the specific activities (MBq/µg), the octanol/water partition 
coefficients, the receptor binding fractions RBF for CXCR1 and CXCR2 receptors and 
the stability of the preparations in PBS and in serum. The five preparations will be 
denoted here by their main discriminating component: tricine, EDDA, TPPTS, nicotinic 
acid and isonicotinic acid.  
 Radiolabeling of each of the five HYNIC-IL-8 coligand formulations was rapid 
and straightforward, resulting in high specific activities of four out of five formulations. 
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With EDDA only a modest specific activity could be obtained (7 MBq/µg) as compared 
to tricine (15 MBq/µg), TPPTS (40 MBq/µg), nicotinic acid and isonicotinic acid (up 
to 80 MBq/µg). In our experience, the protection of the hydrazine moiety with 
propylaldehyde resulted in a HYNIC-conjugated IL-8 product with increased stability 
(at –20 0C): it could be labeled with high labeling efficiency over longer time periods 
(several months). Using the same tricine coligand formulation, the specific activity of 
99mTc-labeled hydrazine protected HYNIC-IL-8 was found to be 15 MBq/µg as 
compared to 3 MBq/µg for 99mTc-labeled free hydrazine HYNIC-IL-8 previously 
reported (8). Both products started at similar labeling efficiencies but the free 
hydrazine HYNIC-IL-8 product showed a gradual decrease in labeling efficiency over 
3 months even when stored at –20 0C. 
 The lipophilicity as reflected in the octanol/water partition coefficient was highest 
for the TPPTS preparation. This is in line with the HPLC-analyses (Fig. 3) and a 
significantly higher liver uptake of the TPPTS preparation as found in the biodistribution 
(Table 2) (see below).  
 All the formulations with the exception of TPPTS showed similar RBF-values 
for both receptors: between 45% and 55% for CXCR1 and between 36% and 45% for 
CXCR2. The TPPTS preparation showed predominantly nonspecific binding to the cells.  
 All radiolabeled IL-8 preparations were stable in human serum: after six hours of 
incubation at 37 0C the amount of free radiolabel was less than 10% as determined by 
ITLC. However, the same preparations diluted in PBS showed a large variation in 
stability: after six hours of incubation at room temperature the amount of free radiolabel 
was less than 10% for TPPTS and nicotinic acid only. For EDDA between 35 and 45% 
of the radiolabel was released, for isonicotinic acid between 55 and 60% and for 
tricine around 80%.   
  
Table 1. In vitro characteristics of five different 99mTc-labeled IL-8 coligand preparations. 
_____________________________________________________________________________                                   
Coligand system                     Specific           Octanol/water               RBF:                             Stability:        
                                                 activity               partition         CXCR1      CXCR2            PBS       serum 
______________________________________________________________________________________ 
         Tricine        15 MBq/µg         0.017 50-55%       40-45%          15-20%     >90% 
         EDDA                       7 MBq/µg        0.0053         45-50%       36-42%          55-65%     >90%  
TPPTS / tricine               40 MBq/µg         0.033               n.s.          n.s.       >90%      >90%  
Nicotinic acid / tricine       80 MBq/µg        0.0046         46-50%       42-45%            >90%     >90% 
Isonicotinic acid / tricine        80 MBq/µg        0.0049         50-54%       40-45%          40-45%    >90%  
______________________________________________________________________________________ 
Specific activities (MBq/µg), octanol/water partition coefficients, receptor binding fractions RBF (%) to Jurkat cells 
transfected with either IL-8 receptor 1 (CXCR1) or IL-8 receptor 2 (CXCR2) and stabilities in PBS and in serum 
(labeling efficiencies after six hours of incubation).  n.s. = predominantly non-specific cellbinding. 
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Figure 3.  Radio-HPLC chromatograms of 99mTc-labeled IL-8 with coligand tricine (Fig. 3A) 
and coligand TPPTS/tricine (Fig. 3B) using HPLC method 1. Radio-HPLC chromatograms of 
99mTc-labeled IL-8 with coligand nicotinic acid/tricine (Fig. 3C) and coligand TPPTS/tricine 
(Fig. 3D) using HPLC method 2.   
 
 
The radio-HPLC chromatograms (method 1) of  tricine and of TPPTS are presented in 
Figure 3A and 3B. The tricine chromatogram shows a pertechnetate peak with retention 
time of 3.5 minutes (<1.5%) and a doublet peak of [99mTc(IL-8-HYNIC)(tricine)2] with 
retention times of 10.3 and 10.9 minutes. The radiochromatograms of the EDDA, the 
nicotinic acid and isonicotinic acid preparations showed essentially the same profile. 
Retention times of the doublet peak were found at 10.3 and 10.9 minutes for EDDA, at 
10.3 and 11.0 minutes for nicotinic and at 10.4 and 11.1 minutes for isonicotic. The 
radiochromatogram of TPPTS turned out to be completely different: the major peak 
eluted much later (16.3 min) indicating the higher lipophilicity of the preparation. It 
might be the case that TPPTS interacts with the protein outside the protein-HYNIC-core. 
For instance, triaryl phosphines like TPPTS can reduce disulfide linkages, whereas 
maintenance of the disulfide structure is critical for IL-8 activity. The possibility of 
interaction of TPPTS with IL-8 outside the protein-HYNIC-core was investigated in an 
additional experiment. The radiochromatograms of a iodinated IL-8 preparation and the 
same preparation incubated at 70 0C for 30 minutes in the presence of an excess of 
TPPTS  were compared (not shown). The 125I-IL-8 radiochromatogram showed a profile 
similar to that of  [99mTc(IL-8-HYNIC)(tricine)2] with a doublet at 11.2 and 11.9 minutes. 
The radiochromatogram of 125I-IL-8 incubated with TPPTS was similar, indicating that 
(chemical) interaction of TPPTS with IL-8 is not the principal determinant for the 
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aberrant in vitro behavior of [99mTc(IL-8-HYNIC)(tricine)(TPPTS)]. The characteristics 
of the mobile phase itself may explain the chromatographic behavior of TPPTS. The 
acidic sulfonate groups of TPPTS are partly protonated/deprotonated using the acidic 
TFA/ACN mobile phase of method 1. A mix of protonation states might be responsible 
for the broad and multispecies chromatogram of TPPTS. To investigate this, the acidic 
mobile phase of HPLC method 1 (diluted TFA/ACN) was replaced by a more pH neutral 
mobile phase in HPLC method 2 (phosphate buffer pH 6.0/ACN) in an additional 
experiment. The radio-HPLC chromatograms (method 2) of nicotinic acid (representative 
for tricine, EDDA and isonicotinic acid) and of TPPTS are presented in Figure 3C and 
3D. The nicotinic acid chromatogram showed a pertechnetate peak with a retention time 
of 3.7 minutes and a single peak of [99mTc(IL-8-HYNIC)(tricine)(nicotinic acid)] with a 
retention time of 19.4 minutes. The chromatogram of TPPTS showed a pertechnetate 
peak with a retention time of 3.7 minutes and, again, a multispecies pattern with peaks at 
19.0, 21.8 and 27.8 minutes, indicating a higher lipophilicity of the TPPTS preparation.  
 
 
 
Table 2. Biodistribution of five different 99mTc-labeled IL-8 coligand preparations in rabbits 
with E. coli infections at 6 h p.i. (% ID/g, % ID or ratios, mean values ± s.e.m.). 
_____________________________________________________________________________ 
 
%ID/g                         tricine                     EDDA              TPPTS/tricine      nicotinic/tricine    isonicotinic/tricine  
_____________________________________________________________________________________________   
           
blood 0.045± 0.005  0.024± 0.005  0.010± 0.001  0.030± 0.007  0.032± 0.003  
muscle 0.0044± 0.0007  0.0037± 0.0001  0.0022± 0.0002  0.0024± 0.0003  0.0027± 0.0003  
abscess 0.39± 0.02  0.42± 0.04  0.075± 0.004  0.55± 0.13  0.53± 0.07  
lung 0.36± 0.03  0.39± 0.03  0.17± 0.04  0.31± 0.07  0.33± 0.02  
spleen 0.86± 0.10  1.00± 0.15  1.01± 0.04  0.83± 0.20  0.98± 0.13  
kidney   2.59± 0.14  2.86± 0.17  2.69± 0.11  1.75± 0.14  1.91± 0.13  
liver 0.10± 0.01  0.12± 0.01  0.28± 0.01  0.10± 0.02  0.10± 0.02  
intestine 0.030± 0.003  0.030± 0.001  0.019± 0.002  0.017± 0.002  0.019± 0.002  
            
abscess/muscle 94± 12  116± 14  36± 5  248± 69  204± 24  
abscess/blood 9.6± 2.0  22.3± 5.6  7.6± 0.8  18.6± 3.5  17.0± 2.3  
       
%ID abscess   5.6± 0.2  6.0± 0.3  1.1± 0.1  6.5± 1.3  7.8± 0.5  
%ID kidneys   43± 2  44± 1  48± 1  29± 2  34± 1  
_______________________________________________________________________ 
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Animal studies 
The coligand system clearly affected the biodistribution of  99mTc-labeled IL-8-HYNIC 
as showed in Table 2. Figure 4 summarizes the main in vivo characteristics: 
abscesss/muscle and abscess/blood ratios and  the principal routes of clearance (renally 
and/or hepatobiliary) of the five preparations. As compared to tricine,  the EDDA 
preparation cleared faster from the blood, resulting in a significantly lower percentage of 
residual activity in the blood (P<0.05) and (in combination with a similar muscle uptake) 
in a significantly higher abscess/blood ratio (P<0.05) (Fig. 4b). The biodistribution 
pattern of TPPTS was very different from the other ones. This preparation had a 
significantly reduced uptake in the abscess as well as in muscles, lungs and intestines 
(P<0.05). Blood clearance was much faster (P<0.001), presumably due to a more than 
twofold higher uptake by the liver (P<0.001). Lower lung uptake might suggest that there 
was less interaction of this preparation with leukocytes. The nicotinic acid and 
isonicotinic acid preparation had almost identical in vivo characteristics. In comparison to 
the tricine preparation a significantly lower percentage residual activity in the muscles 
(P<0.001 and P<0.05 resp.) and intestines (P<0.001) was found. Abscess/muscle ratio of 
the nicotinic acid preparation was significantly higher (P<0.05) (Fig. 4a). At 6 h p.i. 
kidney uptake was significantly lower for nicotinic and isonicotinic acid (P<0.001) (Fig. 
4c). All preparations were excreted renally except for the TPPTS preparation which 
partly cleared via the hepatobiliary route (Fig. 4c and 4d). 
 The abscesses were clearly delineated on the images recorded from 2 h onwards 
for all preparations with the exception of TPPTS (Fig. 5). Quantitative analysis of the 
images indicated that the abscess/background ratios (A/B) improved with time for all 
preparations (Fig. 6). The A/B at 6 h p.i. of isonicotinic acid was significantly higher 
(P<0.05) than that of tricine and the A/B of TPPTS was significantly lower (P<0.05). 
Immediately after injection high kidney uptake was observed for all preparations, 
remaining prominent during the 6 h p.i. In addition to this, high liver uptake was seen on 
all the TPPTS images. 
Fig. 4A
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Figure 4.  Biodistribution ratios: Abscess/muscle (4A) and abscess/blood (4B). Principal routes 
of clearance: Renal (4C) and hepatobiliar (4D). The five different 99mTc-labeled IL-8 coligand 
preparations are named by their discriminating component (Nicotinic = nicotinic acid; Isonico. 
= isonicotinic acid). Data are taken from Table 2. The error bars indicate s.e.m. 
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Figure 5.  Images of rabbits with an E.coli abscess in the left thigh muscle at 1 min, 2, 4 and 6 hr 
after injection of five different 99mTc-HYNIC-IL-8 coligand preparations. 
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Figure 6. The abscess/background ratios as determined by quantitative analysis of the images of 
rabbits with E.coli infection injected with five different 99mTc-HYNIC-IL-8 coligand 
preparations. The coligand preparations are named by their discriminating component 
(Nicotinic = nicotinic acid; Isonico. = isonicotinic acid). The error bars indicate s.e.m. 
 
Effects of coligand on in-vivo characteristics     85 
DISCUSSION 
 
In our previous study IL-8 was conjugated with HYNIC and subsequently labeled with 
99mTc using tricine as coligand (8). This preparation showed excellent characteristics 
as an infection imaging agent, approaching the characteristics of the ideal 
radiopharmaceutical for infection imaging: rapid and high accumulation in infectious 
foci together with rapid clearance from the blood and the nontarget tissues. The 
leukocyte receptor binding capacity was still largely preserved.  
The primary concern in using IL-8 in vivo is that it is a highly potent activator 
of neutrophils. Administration doses of micrograms of IL-8 per kg of body-weight in 
healthy rabbits caused a serious but transient neutropenia followed by a leukocytosis 
lasting several hours (6). These side-effects are undesirable for a diagnostic utility in 
routine clinical practice. Our research program focussed on increasing the specific 
activity of a radiolabeled IL-8 preparation in combination with preservation of the 
leukocyte receptor binding capacity. A first and most important reduction of the 
amount of biologically active material to be injected was achieved with 99mTc-HYNIC-
IL-8 (with coligand tricine) as compared to radioiodinated IL-8: 1 µg/kg 99mTc-
HYNIC-IL-8 versus 25 µg/kg 123I-IL-8 (8). 
 In the present study the bifunctional coupling agent HYNIC was adopted again 
for labeling IL-8 with technetium. A decisive improvement was obtained with a 
slightly modified HYNIC formulation: the propylaldehyde hydrazone formulation 
instead of the free hydrazine formulation (13).  Protection of the hydrazine group of 
HYNIC in HYNIC-conjugated IL-8 resulted in a product with improved long-term 
stability resulting in an increased labeling efficiency using the same coligand tricine as 
in previous studies.  
 Further improvement was sought in the exploration of various coligands. Liu 
and Edwards et al. have performed systematic studies on labeling a HYNIC-
conjugated platelet glycoprotein receptor antagonist with 99mTc using various 
alternative coligand systems. The formulation with tricine was found to be unstable in 
solution, particularly under dilute conditions, and to exist in many isomeric forms (16). 
Increased stability of the complex and reduction of the number of isomers could be 
achieved by replacing tricine by other coligand systems like EDDA (16), 
tricine/TPPTS (17), tricine/(iso)nicotinic acid (18). High specific activities were 
obtained with all these preparations, though the labeling efficiency using EDDA as 
coligand was not as high as that using the other coligand systems. Decristoforo and 
Mather described the preclinical evaluation of  99mTc-labeled HYNIC-conjugated 
somatostatin analogues using tricine, EDDA and tricine in combination with nicotinic 
acid as coligands (20-22). These preparations showed preserved binding affinity for 
the somatostatin receptor. Again, reduced in vitro stability was found for the complex 
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using tricine only as coligand, resulting in higher blood levels. The preparation using 
tricine/nicotinic acid produced significant levels of activity in the gastrointestinal tract. 
The preparation using EDDA showed the most promising overall biodistribution 
profile, though labeling efficiency was considerably lower. Consequently, a first 
clinical study was performed with this EDDA formulation (23).  
Our findings concerning stability of the coligand complexes are in line with the 
above reported results. The tricine formulation was found to be unstable in vitro under 
diluted conditions (PBS). Alternative coligand systems offered a solution towards 
more stable in vitro complexes, especially the TPPTS and the nicotinic acid 
preparations. In contrast, in serum all preparations proved to be equally stable. In a 
recent study Ono and coworkers have demonstrated that plasma proteins can stabilize 
99mTc-labeled HYNIC conjugated Fab-fragments when tricine is used as coligand (24). 
The authors proposed that one of the tricine coligands is replaced by a plasma protein 
to generate higher molecular weight species that exhibit a slower blood clearance. This 
could explain not only the stability of the [99mTc(IL-8-HYNIC)(tricine)2] complex in 
serum, but also the relatively slow blood clearance of the [99mTc(IL-8-HYNIC)(tricine)2] 
complex. In addition, Ono et al. found that replacement of one tricine molecule by a 
nicotinic acid molecule in the reported complexes resulted in a stabilized ternary 
ligand system which demonstrated a significantly faster blood clearance. We arrived at 
similar conclusions for [99mTc(IL-8-HYNIC)(tricine)(nicotinic)]. 
 It is rather surprising that the in vitro and in vivo properties of a 72 aminoacid 
protein as IL-8 could be greatly affected by a coligand. Introduction of the bulky 
coligand TPPTS resulted in a severe reduction of in vitro receptor binding affinity, a 
shift in lipophilicity of the total complex, significant lower abscess uptake and lower 
blood levels, and a much higher liver uptake. Quality of the images was poor as 
compared to the other coligand systems. Several explanations can be given for the 
marked change in biodistribution pattern of TPPTS. First, TPPTS is considerably 
larger than the other coligands (Fig. 1). TPPTS equals the size of approximately four 
aminoacid residues, whereas the other coligands have the size of just one aminoacid 
residue. Steric hindrance of the relatively bulky TPPTS group might, at least in part, 
explain the major impact on binding affinity towards the IL-8 receptors. Second, the 
charge of the complex is affected by the three TPPTS sulfonato groups. These 
sulfonato groups are expected to be deprotonated under physiologic conditions (17), 
which has a definite impact on the (local) electron distribution. We investigated the 
possibility of interaction of TPPTS with IL-8 outside the protein-HYNIC-core and 
compared the radiochromatograms of a iodinated IL-8 preparation with the same 
preparation incubated at 70 0C for 30 minutes in the presence of an excess of TPPTS. In 
this experiment the dramatic changes in RP-HPLC patterns were not seen as with the 
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99mTc-labeled IL-8 TPPTS preparation. Apparently, interaction of TPPTS with IL-8 
outside the protein-HYNIC-core does not play a major role in explaining the aberrant in 
vitro and in vivo behavior of the TPPTS preparation.  
 The 99mTc-HYNIC-IL-8 EDDA preparation showed highly favorable 
characteristics for infection imaging. The preparation cleared relatively rapidly from 
the blood. EDDA is, however, not the coligand of choice for IL-8 for two reasons. 
First, the formulations using (iso)nicotinic acid generated higher abscess/muscle (and 
A/B) ratios. Second, the EDDA preparation had a relatively low specific activity. The 
specific activity of the tricine formulation was twice as high as that of EDDA, and 
with (iso)nicotinic acid specific activities were up to ten times higher (Table 1). 
 The most optimal characteristics for infection imaging were obtained with 
formulations using nicotinic acid or isonicotinic acid as coligands. With these 
coligands specific activities 20-fold higher than those previously reported with the 
unprotected hydrazine and with tricine as coligand could be achieved, without 
compromising the receptor binding capacity. Administration of doses as low as 70 
ng/kg 99mTc-HYNIC-IL-8 (versus 1 µg/kg previously reported) will suffice for 
imaging procedures. Moreover, (iso)nicotinic acid showed the most favorable in vivo 
characteristics with abscess/muscle, abscess/blood and ROI derived abscess 
/background ratios being twice as high as those obtained with tricine. Its higher in 
vitro stability makes nicotinic acid the preferred coligand. Future experiments with 
99mTc-HYNIC-IL-8 will exploit the advantages of the nicotinic acid/tricine coligand 
formulations. At low IL-8 protein doses of 70 ng/kg side effects are not to be expected in 
the human system. This opens the way to infection imaging studies in patients. 
 In conclusion, IL-8 can be rapidly, easily and efficiently labeled with 99mTc 
using (hydrazine protected) HYNIC as chelator and using various coligands. The most 
optimal infection imaging characteristics were found for formulations using nicotinic 
acid/tricine as coligands combining a high specific activity (up to 80 MBq/µg) and high 
in vitro stability with high abscess/muscle ratios (>200) and high abscess/background 
ratios (>20) in vivo. High quality images with clear delineation of infectious foci could be 
obtained within two hours after injection of the radiopharmaceutical. The low 
administration doses of 70 ng/kg 99mTc-HYNIC-IL-8 paves the way for infection 
imaging studies in patients. 
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We read with interest the paper by Gross et al. entitled “Imaging of human infection with 
131I-labeled recombinant human Interleukin-8” (1). The authors conducted a pilot study 
with 131I-labeled IL-8 for detection of infection in patients. The data nicely showed that 
this IL-8 preparation could visualize infectious foci in patients with osteomyelitis and 
cellulitis. Furthermore, the agent appeared to be safe, since no significant side effects 
were observed upon i.v. administration. Apparently, the study was performed years prior 
to the present publication (2). In the meantime we studied several aspects related to 
labeling IL-8 for detection of infection. 
 We have shown that the labeling method used in this study is rather suboptimal 
for IL-8 and that substantial improvements can be obtained by using alternative 
labeling strategies. IL-8 was radioiodinated according to the chloramine-T method (3). 
This method results in iodination of the tyrosine residues similar to the iodogen 
method. We pointed out that the radioiodination method clearly affected the in vivo 
biodistribution of IL-8 (4). IL-8 radioiodinated via the Bolton-Hunter method, showed 
superior characteristics for infection imaging as compared to IL-8 radioiodinated via 
the iodogen method. In a rabbit model of E.coli induced soft tissue infection, abscess-
to-background ratios as determined by ROI analysis of the images were 3 for 123I-IL-8 
(iodogen method) versus 13 for 123I-IL-8 (Bolton-Hunter method) at 8 h p.i.. As 
pointed out by the authors themselves, labeling IL-8 with 123I would have been a better 
choice instead of labeling with 131I. The physical properties of 131I limit spatial 
resolution.  
The authors made the suggestion that IL-8 labeled with a radiometal instead of 
iodine may be preferable as infection imaging agent. Indeed, preclinical studies in our 
laboratory with 99mTc-labeled IL-8 showed excellent imaging characteristics for this 
preparation with abscess-to-background ratios up to 22 at 8 h p.i. (5). Studies in 
patients using 99mTc-labeled IL-8 are planned to evaluate the efficacy of this particular 
preparation to visualize inflammatory foci in humans. 
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ABSTRACT 
 
Radiolabeled autologous leukocytes (WBC) are the gold standard for imaging 
inflammatory bowel disease (IBD). For the rapid and adequate management of 
patients with IBD, there is need for a new agent, which is at least as good as 
radiolabeled WBC, but easier to prepare and without its inherent risks. In the present 
study, the potential of Interleukin-8 labeled  with 99mTc via hydrazinonicotinamide 
(HYNIC) to image IBD was investigated in a rabbit model of acute colitis and compared 
to that of 99mTc-HMPAO-labeled granulocytes.  
Methods: In rabbits with chemically-induced acute colitis, inflammatory lesions were 
scintigraphically visualized following injection of either IL-8 or purified granulocytes 
both labeled with 99mTc. Gamma camera images were acquired at 2 min, 1, 2 and 4 hrs 
p.i.. At  4 h p.i. the rabbits were killed, and the uptake of the radiolabel in the dissected 
tissues was determined. Furthermore, the dissected colon was imaged and the 
inflammatory lesions were scored macroscopically. For each affected colon segment, 
the colitis index (CI, affected colon-to-normal colon uptake ratio) was calculated and 
correlated to the macroscopically scored severity of inflammation.  
Results: 99mTc-HYNIC-IL-8 visualized the colitis within 1 h p.i.. 99mTc-HYNIC-IL-8 
images of the colonic abnormalities were more accurate, the intensity of uptake in the 
affected colon continously increased until 4 h p.i., whereas no further increase after 1 h 
p.i. was noticed scintigraphically for 99mTc-HMPAO-granulocytes. The uptake in the 
affected colon was much higher for IL-8 than for the radiolabeled granulocytes with 
the percentage injected dose per gram (%ID/g) 0.41 ± 0.04 and 0.09 ± 0.05 at 4 h p.i., 
respectively. With increasing severity, the CI at 4 h p.i. for 99mTc-HYNIC-IL-8 was 
4.4 ± 0.6, 13.5 ± 0.5 and 25.8 ± 1.0; for granulocytes, the CI at 4 h p.i. was 1.5 ± 0.1, 
3.4 ± 0.2 and 6.4 ± 0.5, respectively. The CI correlated with the severity of the 
inflammation (r=0.95, p<0.0001 for IL-8 and r=0.95, p<0.0001 for granulocytes).  
Conclusion: Already within 1 h p.i. visualization of the extent of colonic 
inflammation in vivo was possible with 99mTc-HYNIC-IL-8. Within 2 h p.i. 99mTc-IL-8 
allowed a good and at 4 h p.i. a meticulous evaluation of the severity of IBD. 99mTc-
HMPAO-granulocytes were able to delineate the extent of IBD within 2 h p.i., 
whereas an accurate estimation of severity of inflammation was not possible. 99mTc-
HYNIC-IL-8 is an inflammation imaging agent that showed promising results in this 
study. 99mTc-IL-8 can be prepared off-the-shelf and yields excellent imaging with high 
target / background ratios.  
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INTRODUCTION 
 
The degree of activity of inflammatory bowel disease (IBD) may be difficult to 
evaluate because of the fluctuating episodes of relapses and remissions of acute colitis. 
A noninvasive method for monitoring the disease is needed to allow accurate 
therapeutic management of the patients during exacerbations of IBD. Various nuclear 
medicine diagnostic procedures have become available for evaluating the status of the 
diseased colon. The advantage of nuclear medicine procedures over conventional 
diagnostic modalities, such as planar radiography with barium is their ability to 
provide functional information and to allow an estimation of the degree of 
inflammatory activity in affected areas in the intestine, rather than to give more 
morphologically orientated information. The radiopharmaceutical of choice for 
imaging IBD at present is radiolabeled leukocytes. Unfortunately, the preparation has 
several disadvantages limiting its application (laborious, handling of possibly 
contaminated blood). Therefore, search for an agent, that is at least as good as 
radiolabeled-WBC, but easier to prepare, is needed.   
 IBDs with chronic character such as Crohn’s disease are characterized by a high 
intestinal mononuclear cell infiltration (1). More acute IBDs, such as ulcerative colitis, 
are characterized by a strong neutrophil infiltration to the extracellular matrix of the 
colonic wall. Proinflammatory cytokines play an important role in the neutrophil 
recruitement of neutrophils into the colonic mucosa. Levels of these cytokines (IL-1β, 
IL-6, IL-8, and TNF-α) as well as neutrophils expressing receptors for these cytokines 
are markedly increased in active ulcerative colitis as compared to the normal 
noninflamed bowel tissue (2). In acute IBD, chemotactic factors generated in the 
mucosa attract neutrophils from the circulation into the inflammatory site and induce 
infiltration of neutrophils in the interstitial tissue, thus contributing to accumulation 
and activation of neutrophils in the infected mucosa (3). Since neutrophils express 
high affinity IL–8 receptors (0.3-4 nM) (4-7), radiolabeled IL-8 might prove useful for 
the imaging of acute IBD. 
The scintigraphic imaging characteristics of radiolabeled IL-8 strongly depend 
on the procedure of labeling. Van der Laken et al. showed that 123I-IL-8  labeled via 
the Bolton-Hunter method was clearly superior to 123I-IL-8 labeled via the iodogen 
method, despite similar in vitro cell binding characteristics (8). Recently, we described 
the development of a 99mTc-labeled IL-8 preparation using HYNIC as a chelator (9). In 
rabbits with E. coli infection, absolute uptake of  99mTc-HYNIC-IL-8 in the soft tissue 
abscess was more rapid and higher than that obtained with the radioiodinated preparation, 
while abscess-to-muscle ratios reached values over 100 at 8 h  p.i.(9). Furthermore, 
99mTc-HYNIC-IL-8 showed a remarkably fast clearance from nontarget tissues. 
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We studied the performance of 99mTc-HYNIC-IL-8 in a well established animal 
model of acute inflammatory bowel disease (10, 11). 99mTc-HMPAO-labeled purified 
granulocytes were used as a reference agent in this study. The in vivo characteristics of 
99mTc-HYNIC-IL-8 were compared in rabbits with chemically-induced colitis (11) to 
those obtained after administration of 99mTc-HMPAO-labeled purified granulocytes. 
The aim of this study was twofold: a.) to determine the potential of 99mTc-HYNIC-
IL-8 to visualize acute colitis in rabbits, and b.) to find the earliest imaging time point, 
that allows accurate diagnosis of acute colitis using this agent. 
 
 
MATERIAL AND METHODS 
 
Animal Model  
In 10 female New Zealand white rabbits (weight 2.5 - 3 kg), acute colitis was induced 
as described previously with minor modifications (12-14). Briefly, animals were 
anesthetized with an intramuscular injection of a 0.7-ml mixture of fentanyl 0.315 
mg/ml and fluanisone 10 mg/ml (Hypnorm, Janssen Pharmaceutical, Oxford, UK). 
After retrograde insertion of a flexible silicone tube, first 1 ml 50% ethanol followed 
by 1 ml 25 mg trinitrobenzene sulfonic acid (TNBS; Sigma Chemicals, St. Louis, MO) 
in 50% ethanol, and 3 ml 50% ethanol flush, was instilled in the colon at a 25 cm 
proximally of the anal sphincter. Forty-eight hours after induction of the colitis, the 
respective radiopharmaceuticals were injected via the ear vein. Experiments were 
performed in accordance with the guidelines of the local animal welfare committee. 
During the experiment, the rabbits were fasted. Water was provided ad libitum. 
 
Radiopharmaceuticals 
  Preparation of HYNIC-conjugated IL-8: Human recombinant IL-8 was kindly provided 
by Dr I. Lindley (Novartis, Vienna, Austria). IL-8 was conjugated to hydrazino-
nicotinamide (HYNIC) essentially as described  by Abrams et al. (15). Briefly,  in a 1.5 
ml vial 1.5 µl  1 M NaHCO3,  pH 8.2 was added to 15 µl of IL-8 (5.7 mg/ml). 
Subsequently a three-fold excess of succinimidyl-hydrazinonicotinamide (S-HYNIC) in 5 
µl dry DMSO  was added dropwise to the IL-8 solution. After incubation at room 
temperature for 10 minutes, the reaction was stopped by adding 115 µl of 1.0 M glycine 
solution in PBS. Subsequently,  30 µl precooled PBS was added to a total volume of 170 
µl. To remove excess unconjugated S-HYNIC, the mixture was extensively dialyzed 
against PBS (0.1-0.5 ml dialysis cell 3.5 MWCO, Pierce, Rockford, IL). Dialyzed 
samples of circa 7 µg  IL-8-HYNIC were stored at –20 0C.  
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  99mTc-labeling of HYNIC conjugated IL-8: Tricine-SnSO4-kits (0.2 ml) were prepared 
containing 20 mg tricine (N-[Tris(hydroxymethyl)-methyl]glycine, Fluka, Buchs, 
Switzerland) and 0.01 mg SnSO4 (Merck, Darmstadt, Germany) in 0.2 ml PBS pH 7.0. 
To prevent precipitation of stannous, SnSO4 dissolved in 2 M HCl was added to a 
solution of tricine in PBS pH was subsequently adjusted with 1.0 M NaOH to 7.0.  
For animal studies a 0.2 ml tricine-SnSO4-kit  and  0.5  ml 400 MBq 99mTcO4-  in saline 
were added to 7 µg thawed HYNIC-IL-8 and incubated at room temperature for 30 
minutes. Following the labeling reaction the reaction mixture was applied on a 
Sephadex G-25 column (PD-10; Pharmacia, Uppsala, Sweden) and eluted with 0.5 % 
BSA in PBS to purify the radiolabeled IL-8. The radiochemical purity was determined 
by instant thin-layer chromatography  (ITLC) on ITLC-SG strips (Gelman Laboratories, 
Ann Arbor, MI) with 0.1 M citrate, pH 6.0, as the mobile phase. Each animal was 
injected with 18.5 MBq 99mTc labeled to 0.5 ml IL-8 solution.  
 
Receptor binding assay 
As previously described by Rennen et al. (9) the leukocyte receptor binding fraction of 
the 99mTc-IL-8 preparation was determined in an in vitro receptor binding assay. For 
this assay heparinized human whole blood (10 ml) was mixed with 2.5 ml 5% Dextran 
(Sigma, St. Louis, MO). After sedimentation of the red blood cell bulk during 1 h at room 
temperature, the remainder of the blood sample was washed in incubation buffer (1 mM 
NaH2PO4, 5 mM Na2HPO4, 140 mM NaCL, 0.5 mM MgCL2, 0.15 mM CaCl2, 0.5% 
HSA, pH 7.4) and centrifuged at 500xg for 20 min. The cell pellet was then resuspended 
in 7 ml incubation buffer and layered on 5 ml Ficoll-Hypaque (Pharmacia, Uppsala, 
Sweden), followed by centrifugation at 500xg for 20 min. The pellet was washed once 
and subsequently resuspended in incubation buffer. Afterwards, a series of serially diluted 
PMN suspensions (0.5 - 8 x 106 PMN/0.5ml) was incubated with 10,000 cpm of  99mTc-
labeled IL-8 during 2 h at 370 C. A duplicate of the lowest cell concentration was 
incubated in the presence of a 100-fold molar excess of unlabeled IL-8 to determine the 
nonspecific binding. The radioactivity in the cell pellet (total bound activity) was 
measured in a shielded well-type gamma counter (Wizard, Pharmacia-LKB, Sweden).  
The specific activity of 99mTc-IL-8 was 20 MBq/µg. The radiochemical purity of 
the  radiopharmaceutical was higher than 95% after gel filtration as determined by ITLC. 
The receptor binding fraction of the 99mTc-IL-8 preparation was 65%. 
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99mTc-HMPAO-granulocytes 
Carotid artery canulation was performed in one anesthetized donor rabbit. A total amount 
of 100 ml blood was carefully drawn into acid citrate dextrose-tubes (containing 7 ml acid 
citrate dextrose per 35 ml blood). The total leukocyte count of the donor rabbits was  7.1 
x 109/L with approximately 50% granulocytes. Purification of granulocytes was 
performed according to the method described by Lillevang et al. (16) with minor 
modifications (17). Briefly, the blood was mixed with 0.1 volume of 6% dextran (Dextran 
500, Pharmacia, Uppsala, Sweden) solution in 0.9% NaCl and allowed to settle for 1 h at 
room temperature. The leukocyte-rich supernatant was layered carefully on 1/3 volume of 
Nycoprep density medium (14.1% Nycodenz, 0.3% NaCl, 5 mM Tricine / NaOH  pH 7.2, 
density = 1.077 g/ml, osmolality = 265 mOsm: Nycomed, Oslo, Norway) and centrifuged 
for 15 min at 600x g. The plasma above the mononuclear cells, the mononuclear band 
and the density medium above the granulocyte pellet were carefully removed. The pellet 
was washed with 5 ml of Hank’s balanced salt solution (HBSS) with 10% autologous 
plasma and centrifuged for 10 min at 50xg. The cell pellet was resuspended in 1.5 ml 
HBSS, 10% rabbit plasma. Following this purification procedure the granulocyte purity 
was > 90% (11).  0.5 GBq freshly prepared 99mTc-HMPAO was added to the cell 
suspension. The cells were incubated at room temperature for 30 min and centrifuged for 
10 min at 50xg. The pellet was resuspended in 5 ml of cell free autologous plasma. 
Labeling efficiency (Cell associated activity / total activity added) exceeded 80%. 
Functional integrity of labeled granulocytes  was evaluated by their in vivo performance, 
including transit through the lungs, hepatic- and splenic uptake. A dose of 18.5 MBq 
99mTc-labeled granulocytes was administered intravenously in each rabbit.    
 
Gamma camera image acquisition and data analysis   
Fourty-eight hours after induction of the colitis, five rabbits were intravenously 
injected through the ear vein with 99mTc-HYNIC-IL-8. Another group of five rabbits 
was injected with 99mTc-HMPAO-WBC. The rabbits were immobilized in a mold and 
placed prone on a gamma camera equipped with a parrallel-hole, low-energy all 
purpose collimator (Orbiter; Siemens Inc., Hoffman Estate, IL). Each rabbit was 
imaged at 2 min, 1 h, 2 h, and 4 h after injection. Images with 300,000 counts were 
acquired and stored in a 256 x 256 matrix.  
After acquiring the final images, the rabbits were killed with an overdose of 
sodium phenobarbital and biodistribution of the radiolabeled radiopharmaceuticals 
was determined. After dissection, an image of the entire dissected colon was acquired 
(100,000 counts per image) using the same collimator and matrix. Blood was obtained 
by cardiac puncture. Tissues [lung, liver, spleen, kidney, small intestine, normal 
(ascending) colon and affected (transverse and descending) colon] were obtained. The 
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affected colon was divided in seven consecutive colonic segments of 5 cm each. The 
degree of inflammation of the colonic segments was scored macroscopically on an 
arbitrary scale  (0= no visible abnormalities, 1= redness and wall thickening, 2= 
ulcers). The tissue samples were weighed and the radioactivity was measured in a 
shielded well-type scintillation gamma counter (Wizard, Pharmacia-LKB, Sweden). 
The stool and the intestinal wall of the inflamed and the noninflamed colon were 
separately analyzed and their average uptake was assessed. To correct for decay and to 
permit calculation of the uptake of the radiolabeled radiopharmaceuticals  in each 
organ as a fraction of the injected dose, aliquots of 1% of the injected dose were 
counted simultaneously. The results were expressed as percent injected dose per gram 
(%ID/g). From these results, the colitis index (CI, affected-to-normal colon ratio) for 
each of the radiopharmaceuticals was calculated for each segment. 
 
Statistical Analysis 
All mean uptake values are given as %ID/g ± 1 s.e.m.  For statistical analysis the 
Mann-Whitney test was performed and correlations were calculated by linear 
regression analysis: Spearman Rank correlation (GraphPad InStat 3.00 Win 95, 
GraphPad Software, San Diego, CA., USA). The level of significance was set at p < 
0.05. 
 
 
RESULTS 
 
Two days after the retrograde installation of TNBS in all 10 rabbits severe mucosal 
alterations in the colon transversum and colon descendens were observed.  
The scintigraphic images of the two radiotracers at 1, 2 and 4 h p.i. as well as the 
respective image of the dissected colon 4 h p.i. are shown in Figure 1. Both 
radiotracers showed focally increased uptake in the inflamed colon. Quantitative 
analysis of the scintigrams of 99mTc-HMPAO-granulocytes showed that the lung 
uptake decreased from 39 %ID to 17 %ID between 5 min and 1 h p.i.and that the 
hepatic uptake did not exceed 17 %ID at 2 h p.i., indicating that the 99mTc-labeling  
procedure had not compromised granulocyte function.  
 99mTc-HYNIC-IL-8 nicely delineated the inflamed colon as early as 1 h p.i. 
With 99mTc-HYNIC-IL-8 the extent of the inflammation in the colon was clearly 
visualized at 2 h p.i., while a further increase of uptake in the inflamed colon was 
observed until 4 h p.i. Whole-body images of the rabbit and images of the dissected 
colon clearly showed the focal ulcerations and the extent of the colonic inflammation . 
  
98     Chapter 6 
 
   
 
 
                    1 h                      2 h                     4 h                                               
                          99mTc-HYNIC-IL-8  
 
 
 
                     1 h                      2 h                     4 h                                               
                          99mTc-HMPAO-granulocytes 
 
 
Figure 1: Scintigraphic images of rabbits with experimental colitis, imaged at 1, 2, and 4 h 
after injection of 99mTc-HYNIC-IL-8 (upper panel) or 99mTc-HMPAO-granulocytes (lower 
panel) together with  separate images of the dissected colons.  
99mTc-IL-8 in colitis     99 
Using 99mTc-HMPAO-granulocytes, images were less precise since uptake in the 
inflammatory foci was much lower at 2 h and 4 h p.i.. No nonspecific bowel uptake 
was apparent with either of the radiotracers until 4 h p.i.  
        The biodistribution data of 99mTc-HYNIC-IL-8 and 99mTc-HMPAO-granulocytes 
at 4 h p.i. are shown in Table 1. The uptake of 99mTc-HYNIC-IL-8 in the affected 
colon exceeded that of 99mTc-HMPAO-WBC by a factor of 4.5 (%ID/g 0.41 ± 0.04 for 
99mTc-IL-8 and 0.091 ± 0.05 for 99mTc-HMPAO-WBC respectively) (p < 0.01).  99mTc-
HYNIC-IL-8 showed higher CIs at 4 h p.i. compared to 99mTc-HMPAO-granulocytes 
(p<0.008 each grade) (Figure 2). The uptake of both radiotracers in the nonaffected 
colon was similarly low. Consequently, the affected colon / nonaffected colon uptake 
was much higher for 99mTc-HYNIC-IL-8 with 18.5±4.1 compared to 4.1±1.4 for 
99mTc-HMPAO-granulocytes (p<0.01). With both radiotracers the CIs increased with 
the severity of inflammation. When evaluating the relative uptake in the affected 
segments for both radiopharmaceuticals, a positive correlation was observed between 
CIs and the severity of the macroscopic abnormalities (Figure 3). For 99mTc-HYNIC-
IL-8 the correlation (r2 = 0.95, p< 0.0001) was as strong as for 99mTc-HMPAO-WBC 
(r2 = 0.95, p< 0.0001). 
99mTc-IL-8 and 99mTc-HMPAO-granulocytes showed similar low uptake in the 
stool of the affected colon and the nonaffected colon as well as in the nonaffected 
colonic wall. The total uptake in the stool of the inflamed colon and the total uptake in 
the inflamed colonic wall and the ratios of the uptake in the inflamed colon and the 
nonaffected colon are shown in Table 1. The 4.5 fold higher %ID/g uptake of 99mTc-
IL-8 compared with 99mTc-HMPAO in the affected colonic wall led to a affected 
colonic wall / affected stool ratio of 31:1 for 99mTc-IL-8 compared with a ratio of 4:1 
for 99mTc-HMPAO-WBC, respectively. 
Regarding the uptake at 4 h p.i. 99mTc-HYNIC-IL-8  showed significantly 
higher uptake for the different grades of inflammation (p<0.008) compared to those 
after injection of 99mTc-HMPAO-granulocytes. Focal uptake in the inflamed colon 4 h 
p.i. allowed a point-by-point comparison with macroscopic ulcerations at 
inflammatory sites. Furthermore, 99mTc-HYNIC-IL-8 had significantly lower blood 
levels than 99mTc-HMPAO-WBC (p<0.01) resulting in a lower uptake in background 
tissues (muscle, small intestine). In the kidneys, the uptake of the 99mTc-IL-8 was 
higher, probably due to tubular reabsorption of the peptide (18, 19). The uptake of 
both radiotracers in most other tissue samples was remarkably similar. Hepatic uptake 
of 99mTc-HYNIC-IL-8 was relatively low, reflecting the predominantly renal excretion 
of the tracer. 
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Table 1. Biodistribution at 4 h p.i. of 99mTc-HYNIC-IL-8 and 99mTc-HMPAO-granulocytes in 
two groups of 5 rabbits with experimental colitis (%ID/g or %ID or ratios; mean ± s.e.m.) 
_________________________________________________________________________________________ 
          99mTc-HYNIC-IL-8                 99mTc-HMPAO-granulocytes  
_________________________________________________________________________________________ 
   %ID/g     p∗   %ID/g 
   Blood    0.044±0.001   <0.01  0.30±0.03 
   Lung    0.27 ±0.09      0.18 ±0.01 
   Spleen    0.67 ±0.22      0.83 ±0.12 
   Kidney   1.86 ±0.28    <0.01  0.20 ±0.01 
   Liver     0.091±0.005   <0.01  0.21 ±0.03 
   Small Intestine   0.032±0.003      0.024±0.003 
Nonaffected colon tissue  0.025±0.004      0.023±0.008 
Affected colon  tissue  0.41 ±0.04    <0.01  0.091±0.055 
Feces nonaffected colon  0.005±0.001   <0.05  0.015±0.003 
Feces affected colon  0.013±0.002      0.022±0.007 
 
     Ratio      p∗        Ratio 
Affected/Nonaffected colon tissue      18.5±4.1           <0.01                 4.1±1.4    
      
    %ID    (as % of total uptake       %ID    (as % of total uptake 
                 in stool + colonic wall)     in stool + colonic wall) 
Total uptake inflamed colonic wall      5.18           (87.3%)                           1.70          (80.1%) 
Total uptake stool in inflamed colon     1.07          (12.6%)                            0.38          (19.8%) 
Total uptake in stool + colonic wall      6.25           (100%)                            2.08           (100%) 
                                                                                                                                                                                     
∗Mann-Whitney test =99mTc-HYNIC-IL-8 versus 99mTc-HMPAO-granulocytes. Biodistribution of 2 groups of 5 
rabbits is shown at 4 h after injection. The level of significance was set at p < 0.05.  
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               Figure 2.                                                                    Figure 3. 
  
Figure 2 (left): Colitis Indices (affected-to-normal-colon-uptake ratio) of both radiotracers at 
4 h p.i., compared with the severity of macroscopic inflammation (grade 0 = normal, grade 1 
= inflammation, grade 2 = ulceration). Error bars represent s.e.m. 
 
 
Figure 3 (right): Macroscopic aspect of colonic mucosa in trinitrobenzene sulfonic acid 
induced  acute colitis. Scoring of inflammation is shown: 0 = normal (colon descending), 1 = 
inflammation (sigmoide colon), 2 = ulceration (rectum). 
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DISCUSSION 
             
For nuclear medicine imaging of IBD, the use of radiolabeled leukocytes still is the 
“gold standard”, because an accurate diagnosis of the extent and severity of IBD is 
possible. Several reports documented superior performance of 99mTc-HMPAO labeled 
white blood cells (WBC) compared with 111In-labeled-WBC for the evaluation of 
colitis (20-22). When 99mTc-HMPAO-WBC are used, only early 2 h p.i. images (23) 
will allow specific imaging of IBD, because at later images nonspecific bowel uptake 
occurs. However, preparation of  labeled autologous leukocytes is rather laborious and 
time consuming. Furthermore, there is a small but definite risk of personnel 
contamination or even inadvertent cross-contamination between patients (24). 
Therefore, there is an urgent need for a sensitive and specific imaging agent which can 
be prepared relatively easy. 
Recently, we introduced 99mTc-HYNIC-IL-8 as such a new agent for 
scintigraphy. In a rabbit animal model with E. coli infection, 99mTc-HYNIC-IL-8 
allowed rapid visualization of the abscess as early as 1 h p.i. with high  and rapid 
accretion of the radiolabel in the abscess. 
The present study was designed to test this new 99mTc-HYNIC-IL-8 agent for 
its potential to visualize inflammatory lesions in a more clinically relevant animal 
model and to determine the earliest time point for diagnosis of IBD.  Diagnostic 
imaging was done until 4 h p.i., since no further increase of uptake in the affected 
colon can be expected with 99mTc-HMPAO-granulocytes (11). In the present study we 
demonstrated, that the 99mTc-HYNIC-IL-8 preparation already at 1 h p.i. visualized the 
affected colon. The images of 99mTc-HYNIC-IL-8 were superior to those of 99mTc-
HMPAO-granulocytes at all time points. Uptake in the affected colon increased to a 
level of 4.5-fold higher than with 99mTc-HMPAO-granulocytes at 4 h p.i.. 99mTc-
HYNIC-IL-8 scintigraphically allowed a visual differentiation between mild (grade 1 
= inflammation) and severe (grade2 = ulceration) inflammation within 2 h 
postinjection. In addition, image quality improved even further from 2 h to 4 h p.i. 
(Figure 1). Such a differentiation between mild and severe inflammation was not 
possible with 99mTc-HMPAO-granulocytes. Ex vivo, very mild nonspecific uptake in 
the nonaffected colon was observed with 99mTc-HMPAO-granulocytes after dissection, 
whereas this was not seen with 99mTc-HYNIC-IL-8, apparently due to specific binding. 
The higher uptake in the affected colon for 99mTc-HYNIC-IL-8 was mainly due to an 
increased uptake of 99mTc-IL-8 in the inflamed colonic wall. This led to a more 
accurate visual differentiation between inflamed colon and noninflamed colon for 
99mTc-HYNIC-IL-8 compared with 99mTc-HMPAO-granulocytes. Furthermore, in 
favor of the excellent performance of 99mTc-HYNIC-IL-8 was its low uptake in the cell 
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wall of the nonaffected colon and the low uptake in the stool of the affected colon.  
Apparently this seems to be an important reason for the dramatically better 
performance of 99mTc-HYNIC-IL-8 compared with 99mTc-HMPAO-granulocytes in 
scintigraphic imaging of chemically induced colitis. The CI index of 99mTc-HYNIC-
IL-8 was fourfold higher than that of 99mTc-HMPAO-granulocytes, almost allowing a 
point-by-point comparison between whole-body images and macroscopical 
observations. In addition, as compared to labeled-granulocytes, labeled HYNIC-IL-8 
has the important advantage of an easier preparation without the need for blood 
manipulation.  
The moderate performance of 99mTc-HMPAO-granulocytes compared with 
99mTc-HYNIC-IL-8  is remarkable (23, 8). This could be due to the longer circulating 
time and slower background clearance of labeled white blood cells or, more probable, 
to additional specific uptake of IL-8 in inflammatory cells. Since quantitative analysis 
of the scintigrams of 99mTc-HMPAO-labeled granulocytes demonstrated rapid initial 
lung transit and low hepatic uptake, there was no indication of deterioration of 
granulocyte function due to the labeling procedure. 
 Previous studies showed that 99mTc-HYNIC-IL-8 induced a transient neutropenia 
in rabbits (8,9). Actually, we aim to further increase the specific activity of the 99mTc-
HYNIC-IL-8 preparation and to decrease the biological activity of the agent. Until now, 
going from 123I to 99mTc as radiolabel, a 25-fold reduction of protein dose was achieved 
(9).  
 
 
CONCLUSION  
 
In this rabbit model the imaging performance of 99mTc-HYNIC-IL-8 appeared superior 
to that of 99mTc-HMPAO-labeled white blood cells in the evaluation of experimental 
colitis at all time points after injection of the respective radiotracers. Due to its high 
uptake in inflammatory foci in combination with minimal nonspecific bowel uptake, 
99mTc-HYNIC-IL-8 allowed a point-by-point correlation with the macroscopical 
observation at 4 h p.i.. These results suggest that 99mTc-HYNIC-IL-8 potentially is an 
ideal imaging agent for accurate diagnosis of IBD, provided that the problem related to 
the biologic activity can be circumvented. 
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ABSTRACT 
 
Interleukin-8 (IL-8) is a chemotactic cytokine that binds with high affinity to receptors 
on neutrophils. Previously we showed that 99mTc-labeled IL-8 is highly suitable for 
scintigraphic imaging in rabbit models of intramuscular infection and of colitis. Here, 
99mTc-labeled IL-8 was tested for its potential to image pulmonary infection in three 
experimental rabbit models: aspergillosis in immunocompromized rabbits, 
pneumococcal (gram-positive) pneumonia and E.coli-induced (gram-negative) 
pneumonia in immunocompetent rabbits.  
Methods: A derivative of hydrazinonicotinamide (HYNIC) was used as bifunctional 
coupling agent to label IL-8 with 99mTc. Biodistribution of 99mTc-IL-8 was determined 
both by γ-camera imaging and by counting dissected tissues at 6 h after injection. 
Results: 99mTc-IL-8 enabled early (within 2h after injection) and excellent 
visualization of localization and extent of pulmonary infection in each of the three 
experimental models of pulmonary infection. Uptake of 99mTc-IL-8 in the infected lung 
and the contralateral lung was (in percentage of the injected dose per gram of tissue ± 
SEM) at 6h after injection 0.63±0.12 and 0.12±0.02 (aspergillosis), 0.89±0.04 and 
0.44±0.04 (pneumococcal pneumonia) 1.53±0.12 and 0.36±0.06 (E.coli pneumonia), 
respectively. In the E.coli model, uptake of 99mTc-IL-8 in the focus of infection even 
exceeded uptake in the kidneys, the main clearing organs.  
Discussion: 99mTc-IL-8 offers many advantages over the conventionally used 
radiopharmaceuticals to image pulmonary infection, 67Ga-citrate and radiolabeled 
leukocytes, i.e.: rapid and easy preparation, short time span between injection and 
imaging, low radiation burden and most importantly: clear delineation of the infectious 
foci. 
 
 
INTRODUCTION 
 
Adequate diagnosis of infection presents a major challenge to the clinician. Early and 
accurate detection of infection is crucial to enable adequate treatment. In cases 
suspected of pulmonary infection, chest X-ray and computed tomograpy (CT) provide 
high-quality anatomic information. However, early stages of pulmonary infection, in 
the absence of structural changes in the lungs, are difficult to diagnose by these 
methods. Moreover, scar tissue formation may complicate the interpretation of the 
images. Also, in immunosuppressed patients with pneumonia, chest X-ray findings are 
often minimal or even absent. An alternative approach for detection of pulmonary 
infection is radionuclide imaging. Scintigraphic imaging does not depend on structural 
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changes in the lung induced by the presence of the invaded microorganisms, but on 
physiologic changes in the lung as induced by these microorganisms. Therefore, 
radionuclide imaging can be complementary to the conventional anatomic imaging 
modalities.  
In the United States, 67Ga-citrate, 111In- and 99mTc-labeled leukocytes are the 
only approved radiopharmaceuticals for imaging of infection. 67Ga-citrate binds, once 
injected intravenously, to circulating transferrin. This complex extravasates at the site 
of infection due to the locally enhanced vascular permeability (1). There are several 
shortcomings in the use of 67Ga-citrate that limit its clinical application. For instance, this 
radiopharmaceutical has unfavorable imaging characteristics (long physical half-life and 
high energy gamma photons), causing poor image quality and high radiation absorbed 
doses (2). Moreover, the interval between injection and imaging is relatively long 
(several days). 
Techniques using isolated leukocytes, labeled either with 111In or 99mTc, have 
been introduced in the seventies and eighties of the past century (3-6) and are generally 
adopted in nuclear medicine as techniques for infection imaging. Ex vivo labeling 
requires the withdrawal of blood from the patient, purification of leukocytes, labeling 
and reinjection of the radiolabeled cells. Radiolabeled leukocytes can be used to image 
infection due to the fact that leukocytes, even after ex-vivo labeling, have the capacity 
to migrate to the inflamed area. Disadvantages of this approach are, among others, a 
laborious preparation (3 hours) and handling of potentially contaminated blood (7). 
These have stimulated investigators to search for alternative methods that would allow 
labeling of leukocytes in the circulation. Instead of isolating the white blood cells from 
a patient and labeling the cells ex vivo, new methods now aim to label white blood 
cells in vivo.  
Radiolabeled Interleukin-8 (IL-8) is an interesting candidate to replace 
radiolabeled leukocytes by in vivo labeling of neutrophils. Neutrophilic granulocytes 
are known to express two types of Interleukin-8 (IL-8) receptors, CXCR1 and CXCR2, 
abundantly (8). IL-8 binds these receptors with high affinity (0.3-4 nM) (9-12). 
Recently, we described the development of a 99mTc-labeled IL-8 preparation using 
hydrazino-nicotinamide (HYNIC) as a bifunctional coupling agent (13). This 
preparation showed good characteristics for imaging of infection and inflammation 
(13-15).  
In the present study, 99mTc-labeled IL-8 was tested for its potential to image 
pulmonary infection. Three different experimental rabbit models were introduced in 
order to simulate a broad range of clinically relevant applications: aspergillosis in 
immunocompromized rabbits, Pneumococcal pneumonia and E.coli-induced 
pneumonia in immunocompetent rabbits. Invasive pulmonary aspergillosis is an 
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important cause of infectious morbidity and mortality in patients with 
granulocytopenia following chemotherapy. Streptococcus pneumoniae is a 
representative of the group of gram-positive bacteria and is the leading cause of 
community-acquired pneumonia. E.coli-induced pneumonia is an example of a 
pneumonia caused by gram-negative bacteria and is frequently encountered as a 
nosocomial infection. Severe S.pneumoniae and E.coli pneumonia infections have 
significant morbidity and mortality rates. 
 
 
METHODS 
 
Human recombinant IL-8 was kindly provided by Dr I. Lindley (Novartis, Vienna, 
Austria). Tricine (N-(Tris(hydroxymethyl)-methyl)glycine was purchased from Fluka 
(Buchs, Switzerland), nicotinic acid from Sigma-Aldrich (St. Louis, MO).  
 
Conjugation of HYNIC to IL-8  
The propylaldehyde hydrazone of succinimidyl-hydrazinonicotinamide (HYNIC) was 
synthesized essentially as described previously (16,17). The IL-8-HYNIC conjugate was 
prepared as described previously (13,18). Briefly, in a 1.5 ml vial 5 µl  1 M NaHCO3,  pH 
8.2 was added to 35 µl of IL-8 (5 mg/ml). Subsequently, a three-fold molar excess of 
HYNIC in 5 µl dry DMSO  was added dropwise to the mixture. After incubation for  five 
minutes at room temperature, the reaction was stopped by adding an excess of glycine 
(200 µl, 1 M in PBS). To remove excess unbound HYNIC the mixture was extensively 
dialyzed against PBS (0.1-0.5 ml dialysis cell 3,500 molecular weight cut-off, Pierce, 
Rockford, IL). Dialyzed samples of circa 8 µg  IL-8-HYNIC were stored at –0020 0C.  
 
Technetium-99m labeling of HYNIC conjugated IL-8  
To a thawed sample of 8 µg IL-8-HYNIC was added 0.2 ml of a solution of tricine and 
nicotinic acid (125 mg/ml and 12.5 mg/ml respectively, in PBS, adjusted to pH 7.0 
with 2M NaOH), 20 µL of a freshly prepared tin (II) solution (10 mg SnSO4 in 10 ml 
nitrogen-purged 0.1 N HCl) and 400 MBq 99mTcO4-  in saline. The mixture was 
incubated at 70 0C for 30 minutes. The radiochemical purity was determined by instant 
thin-layer chromatography  (ITLC) on ITLC-SG strips (Gelman Laboratories, Ann 
Arbor, MI) with 0.1 M citrate, pH 6.0, as the mobile phase. Following the labeling 
reaction the reaction mixture was diluted with PBS, 0.5% BSA to a concentration of 
40 MBq/ml, ready for i.v. administration in the rabbits. A description of an extensive 
in vitro characterization (HPLC, stability, receptor binding assays) has been given 
elsewhere (18). 
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Animal studies 
All animal experiments were carried out in accordance with the guidelines of the local 
animal welfare committee. Female New Zealand White rabbits weighing 2.3-2.8 kg 
were used in these experiments. Animals were housed individually and fed standard 
laboratory chow and water ad libitum. 
 
Pulmonary infection models 
  Pulmonary aspergillosis.  
Induction of aspergillosis was based on the animal model described by Groll et al. 
with a few modifications (19). Four female New Zealand White rabbits received 
injections of Cytarabine (Onco-Tain, Faulding Pharmaceuticals, Brussels, Belgium) 
to reduce their neutrophil counts. Cytarabine was administered daily intravenously (25 
mg/kg ~ 525 mg/m2) on day –4 through –1 prior to the injection of 99mTc-IL-8. At day 
–3, after the second dose of cytarabine, the inoculation of Aspergillus fumigatus was 
performed. A. fumigatus was isolated from an immunocompromized patient positively 
diagnosed with aspergillosis. Before inoculation animals were sedated with a 
subcutaneous injection of 0.7 ml Hypnorm (Fentanyl 0.315 mg/ml + Fluanisone 10 
mg/ml) (Janssen Pharmaceutical, Buckinghamshire, UK). The rabbits were 
anesthetized with a mixture of isoflurane, nitrous oxide and oxygen and placed on the 
surgical table. The inoculum of 1x108 conidia in 250 µL of phosphate buffered saline 
(PBS) was given intra-tracheally into the left lung, together with 50 µL of 5% Evans 
blue dye (Sigma-Aldrich, Zwijndrecht, Netherlands) via a syringe attached to a 
polyethyleen 0.76*1.22 mm catheter (Maxxim Medical, Oss, Netherlands). 
  Pneumococcal pneumonia and E.coli induced pneumonia.  
Pneumonia was installed in female New Zealand White rabbits one day before 
injection of  99mTc-IL-8. The animals were sedated and anesthetized as described 
above. Four rabbits were inoculated intra-tracheally with 1x109 CFU of Streptococcus 
pneumoniae and four rabbits with 1x109 E.coli together with 50 µL of 5% Evans blue 
dye as described above. 
 
Scintigraphic imaging of rabbits with pulmonary infection 
20 MBq 99mTc-labeled IL-8 (0.4 µg protein, 0.5 ml) was injected via the ear vein in 
rabbits with aspergillosis two days after installation of pulmonary aspergillosis and in 
rabbits with S.pneumoniae and E.coli pulmonary infection one day after induction of 
pulmonary infection (four rabbits in each group). Three rabbits out of each group were 
randomly selected and used for gamma camera imaging. These rabbits were  
immobilized in a mold, placed prone on the gamma camera and images were acquired at 
1-5 min, 2, 4 and 6 h p.i. with a single-head gamma camera (Orbiter, Siemens Medical 
 
110     Chapter 7 
Systems Inc., Hoffman Estates, IL) equipped with a parallel-hole low-energy all purpose 
collimator. Images were obtained with a 15% symmetrical window over the 140 keV 
energy peak of 99mTc. After acquisition of 200,000-300,000 counts, the images were 
digitally stored in a 256 x 256 matrix. Scintigraphic images were analyzed quantitatively 
by drawing regions of interest (ROI) over the affected region of the left lung (=target, T) 
and a similar region over the contralateral unaffected right lung (=background, BGr). 
Target-to-background ratios (T/BGr) were calculated. 
 After completion of the final imaging session (6 h p.i.), all rabbits were killed with 
a lethal dose of pentobarbital (Euthesate, Ceva Sante Animale, Naaldwijk, The 
Netherlands). Samples of blood, muscle, affected lung, unaffected contralateral lung, 
spleen, liver, kidneys and intestines were collected. The dissected tissues were weighed 
and the activity in the samples was measured in a gamma counter. To correct for 
radioactive decay injection standards were counted simultaneously. The measured 
activity in samples was expressed as percentage of injected dose per gram tissue 
(%ID/g). Affected-lung-to-control-lung ratios and affected-lung-to-blood ratios were 
calculated.  
 For comparison, two rabbits with pneumococcal pneumonia were imaged with 
67Ga-citrate (Mallinckrodt, Petten, Netherlands), using the same gamma camera as above 
equipped with a parallel-hole medium energy collimator. Images were acquired at 1-5 
min, 2, 4, 6 and, additionally, 24 h after injection of 18 MBq of 67Ga-citrate.   
 For histological examination, samples of affected and unaffected lung were fixed in 
formalin and embedded in paraffin. 5 µm sections were cut and stained with 
hematoxylin-eosin (HE) and/or Grocott’s methenamine silver (aspergillosis only) for 
light microscopic examination.  
 
 
Statistical analysis 
All mean values are expressed as %ID/g, %ID or ratios ± 1 standard error of the mean 
(SEM). Data were analyzed statistically using the one-way ANOVA test with Tukey-
Kramer multiple comparisons posttest (GraphPad Instat 3.00 Win 95, San Diego, CA, 
USA).   
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RESULTS 
 
99mTc-labeling of IL-8 
The radiochemical purity of the 99mTc-IL-8 preparation exceeded 98%, as determined 
by instant thin-layer chromatography, excluding the need for further purification, in 
line with our previous findings (18). The specific activity of the 99mTc-IL-8 
preparations used in these studies was  high, approximately 50 MBq per microgram 
IL-8.  
 
Animal studies 
  Pulmonary infection models.  
Cytarabine treatment of rabbits in the aspergillosis group resulted in an average 
reduction of total white blood cell counts of 61% ± 7%. Histological examination 
revealed the presence of abundant A.fumigatus conidia in lung tissue and a moderate 
leukocyte infiltration similar to what was found in our rat aspergillosis model (20). 
Massive leukocyte infiltration in infected lung tissue in both pneumococcal pneumonia 
and E.coli induced pneumonia was observed. 
  Scintigraphic imaging of pulmonary infection in rabbits.  
Figure 1 shows the scintigrams acquired between 0 and 6 h after injection of 99mTc-IL-
8. The pulmonary infections were clearly delineated in all three models. Images 
acquired immediately after injection occasionally showed the affected lung area as a 
photopenic area: High uptake of 99mTc-IL-8 in the contralateral unaffected lung and 
relatively low uptake in the affected part of the lung, resulting in a photopenic area 
(see arrow, figure 1), suggesting that the affected area is less well perfused and 
accumulation of  99mTc-IL-8 in the focus of infection occurs in the first hours after 
injection.  
Quantitative analysis of the images as shown in Figure 2 showed that the 
Target-to-Background (T/Bgr: affected lung to nonaffected lung) ratios improved with 
time in all models of pulmonary infection up to 3.4 ± 0.3 in the aspergillosis model, 
3.2 ± 0.5 in the S.pneumoniae model and 4.5 ± 0.25 in the E.coli model. These values 
were not significantly different.  
The biodistribution of 99mTc-IL-8 in the three rabbit models of pulmonary 
infection is presented in Table 1. 99mTc-IL-8 cleared faster from the blood in rabbits 
with aspergillosis as compared to rabbits with S.pneumoniae or E.coli infection, 
resulting in a significantly lower percentage of residual activity in the blood at 6 h p.i. 
(P<0.01). Uptake of 99mTc-IL-8 in the contralateral healthy lung lobe was lowest in the 
aspergillosis model (P<0.01). Uptake of the radiolabel in the infected lung was similar 
in the aspergillosis and the S.pneumoniae model. The uptake in the infected lung in the  
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Figure 1. Images of rabbits with pulmonary infection in the left lung at 1-5 min, 2, 4 and 6 h 
after injection of 99mTc-IL-8. Typical example of aspergillosis (upper row), pneumococcal 
pneumonia (second row) and E.coli induced pneumonia (third row). An arrow in the 1-5 min 
E.coli infection image indicates a remarkable photopenic area in the affected part of the lung. 
 
 
 
E.coli model surpassed the uptake in the other models in this area (P<0.01). In the 
aspergillosis model the uptake in the spleen was significantly lower than in the 
S.pneumoniae model (P<0.05). Kidneys were the main clearing organs in all three 
models and kidney uptake was highest in the aspergillosis model (P<0.05). In the 
E.coli model, the uptake in the infected lung was even higher than uptake in the 
kidneys. Figure 3 summarizes uptake of 99mTc-IL-8 in (affected and nonaffected) lungs 
and spleen. Physiologic uptake of 99mTc-IL-8 in nonaffected lungs was threefold lower 
in immunocompromized rabbits with aspergillosis than in immunocompetent rabbits 
with S.pneumoniae or E.coli infection. Spleen uptake was twofold higher in 
immunocompetent rabbits.  
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analysis of the images of rabbits with pulmonary infection at 1-5 min, 2, 4 and 6 h after 
injection of 99mTc-IL-8. 
 
 
 
 
T
rabbits per model) at six hours after injection. Values are expressed as percentages of the 
injected dose per gram tissue (%ID/g) ± one standard error of the mean or as ratios thereof.  
___________________________________________________________________________ 
 Aspergillosis S.pneumoniae E.coli 
    
lood 0.0069 0022  0.041 .008  0.035 .007  
 0 0  
   
0  0 0  
ne 
ng abscess/control 5.5 6  2.1 .2  4.4 .4  
________ _______ _________ ___________ 
      
b ± 0. ± 0 ± 0
muscle 0.0010 ± 0.0002  .0032 ± 0.0009  .0020 ± 0.0001 
lung abscess 0.63 ± 0.12  0.89 ± 0.04  1.53 ± 0.12  
lung control 0.12 ± 0.02  0.44 ± 0.04  0.36 ± 0.06  
spleen 0.56 ± 0.18  1.31 ± 0.18  1.16 ± 0.20  
kidney  1.56 ± 0.08  1.09 ± 0.09  1.25 ± 0.04  
liver .059 ± 0.006 .069 ± 0.013  .083 ± 0.012 
intesti 0.010 ± 0.001  0.013 ± 0.001  0.015 ± 0.001  
        
lu  ± 1. ± 0 ± 0
lung abscess/blood 66 ± 11  26 ± 8  50 ± 10  
_____________ _______ _______ _______
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Figure 3. Uptake of 99mTc-IL-8 at six hours after injection in tissues with a high natural 
abundancy of neutrophils lung (infected and control non-infected) and spleen in three 
different rabbit models of pulmonary infection. Values are expressed as percentages of the 
injected dose per gram tissue (%ID/g) ± one standard error of the mean. 
 
 
 
Figure 4 shows for comparison scintigraphic images of a rabbit with pneumococcal 
pneumonia after injection of 67Ga-citrate, illustrating the rather suboptimal 
characteristics of this radiopharmaceutical. 
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Figure 4. Scintigraphic images of a rabbit with pneumococcal pneumonia in the left lung at 
1-5 min, 2, 4, 6 and 24 h after injection of 67Ga-citrate.  
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DISCUSSION 
 
99mTc-IL-8 has favorable characteristics as an infection imaging agent: rapid 
accumulation in target tissue and rapid clearance from blood and non-target tissues. 
The activity is mainly cleared via the kidneys, which is an advantage over 
hepatobiliary clearance: high activity in liver and bowel would have made this agent 
less suitable for imaging of the abdominal region. This study in particular showed the 
suitability of 99mTc-IL-8 to delineate infectious foci in rabbits with pulmonary 
infection. 
 In previous studies with 99mTc-IL-8 (13,18) and with radioiodinated IL-8 (21), a 
diffuse and initially high physiologic uptake of radiolabeled IL-8 was seen in the 
lungs. Therefore there was concern about the suitability of 99mTc-IL-8 to image foci of 
infection in the chest. High uptake in the lungs, immediately after i.v. administration 
of 99mTc-IL-8, has been ascribed to the biologic, agonistic effects of IL-8 on 
neutrophils (22-25). Circulating neutrophils pass through the narrow pulmonary 
capillary bed. Under nonstimulating conditions, there is already a delay in the 
pulmonary microvascular transit of neutrophils, relative to erythrocyte transit (26,27). 
Cell deformability plays a crucial role in transit time. IL-8 treated neutrophils showed 
a transient increase in F-actin, which reduces cell deformability. A marked and rapid 
reduction of cell deformability could result in immediate retention of the neutrophils in 
the microvasculature of the lungs. It has been shown that cell deformability recovers 
within minutes following exposure to IL-8.   
 The initially high physiologic uptake of 99mTc-IL-8 in the lungs did not hamper 
the visualization of infectious foci in the lungs, for two reasons. In the first place, 
clearance of radioactivity from the lungs was relatively fast. Secondly, 99mTc-IL-8 
accumulated in the infected lung to a relatively high degree. The uptake in the lungs 
changed dramatically in the first hours after injection of 99mTc-IL-8. Immediately after 
injection of 99mTc-IL-8, uptake in the noninfected lung was often higher than in the 
infected lung, resulting in a relatively photopenic area in the affected part of the lung 
on the scintigrams. In contrast, images acquired at 2 h after injection showed a 
reversal: a clearly positive image of the affected area and a strongly reduced uptake in 
noninfected lung tissue. Although the activity in the background was higher in the 
pulmonary infection models than in our previous studies in the muscular infection 
model, this is compensated by a stronger signal from the target. Residual activity (as 
expressed in percentage of the injected dose per gram of tissue) in infected tissue 
ranged from 0.63 ± 0.12 to 1.53 ± 0.12 in pulmonary infection, as compared to 0.55 ± 
0.13 in intramuscular infection (18). In the aspergillosis model, the relatively modest 
uptake in the affected lung was balanced by low uptake of the radiolabel in the 
unaffected lung, being about one third of the lung background activity in the other 
pulmonary infection models and the models of intramuscular infection as well.  
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 We have selected three different experimental models of pulmonary infection in 
order to cover a broad range of (clinical) applications of 99mTc-IL-8 in detection of 
pulmonary infection. First, we studied a rabbit model of invasive pulmonary 
aspergillosis that would reflect conditions encountered in patients with profound 
granulocytopenia after e.g. chemotherapeutic treatment. Even if the underlying 
disorder (e.g., tumor) has resolved completely, the aspergillosis may persist. Despite 
aggressive antifungal therapy, the mortality from pulmonary aspergillosis in these 
patients remains high, illustrating the need for early and accurate diagnosis. In this 
study, 99mTc-IL-8 proved to be a useful diagnostic tool for pulmonary aspergillosis. As 
99mTc-IL-8 binds to receptors expressed on neutrophils, the use of this 
radiopharmaceutical might encounter its limitations in diagnosing pulmonary 
aspergillosis in deeply neutropenic conditions. We found in our aspergillosis model 
lower physiologic uptake of 99mTc-IL-8 in neutrophil abundant organs such as lung and 
spleen as compared to infection models with normal neutrophil counts. A significant 
reduction of background signal in unaffected lung tissue resulted in a good 
visualization of the infectious foci in the affected lung. However, in persistent, deeply 
neutropenic conditions, i.e., in a severe paucity of target cells for 99mTc-IL-8, this new 
tool may meet its limitations as an infection imaging agent. Clinical trials with this 
new radiopharmaceutical are planned and will reveal whether 99mTc-IL-8 can be used 
to image patients with deep neutropenia.  
 Two more experimental models of pulmonary infection were included in this 
study. Pneumococcal and also E.coli-induced pneumonia in previously healthy 
individuals is in most cases easily detected by chest X-ray. Diagnosing these infections 
in patients with pre-existent lung disease is more difficult. Conventional techniques 
such as chest X-ray and CT have difficulty in distinguishing residual anatomic changes 
due to cured processes from active infection. Since IL-8 scintigraphy shows 
physiologic changes only, it should be able to differentiate scar tissue from active 
infection in such patients. Early diagnosis and prompt treatment of active infection, 
especially in patients with pre-existent lung disease, will result in earlier recovery and 
may reduce mortality in these patients. 99mTc-IL-8 showed to be very efficacious in 
visualizing foci of pulmonary infection in experimental models of Pneumococcal and 
E.coli induced pneumonia. Uptake of 99mTc-IL-8 in affected and nonaffected lungs and 
in the spleen was higher in immunocompetent rabbits in these two models than in 
immunocompromized rabbits in the aspergillosis model. These results strongly suggest 
a relationship between numbers of neutrophils in spleen and lung tissue and uptake of 
99mTc-IL-8. IL-8-receptors are preferentially expressed on neutrophils and high uptake 
of 99mTc-IL-8 is seen in neutrophil abundant organs as lung and spleen. As a result, in 
immunocompromized rabbits, with lower levels of IL-8-receptor expressing cells, 
physiologic uptake of 99mTc-IL-8 in these organs is lower. Higher uptake of 99mTc-IL-8 
by the kidneys and a lower level of residual activity in the blood might be explained by 
the fact that a larger percentage of 99mTc-IL-8 in immunocompromized rabbits is not 
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bound to target cells (neutrophils) and unbound 99mTc-IL-8 is fastly cleared by the 
kidneys.  
 99mTc-IL-8 offers several advantages over the most commonly used 
radiopharmaceuticals for infection imaging, 67Ga-citrate and radiolabeled leukocytes 
(28). The radionuclide 99mTc is preferred over 67Ga because of its virtually ideal 
physical characteristics (short half life, ideal energy, low radiation burden), its cost-
effectiveness and general availability (2). 67Ga has a longer physical half-life and high 
energy gamma radiations, causing high radiation absorbed doses and generating 
images of lower resolution. Generally, 67Ga-citrate shows relatively slow 
pharmacokinetics. As a consequence, a long interval between injection of the 
radiopharmaceutical and imaging is required. Typically, 67Ga-imaging is performed 
between 48 and 72 h p.i. In imaging rabbits using 99mTc-IL-8, a 2 h interval between 
injection and imaging was sufficient. In humans, slower pharmacokinetics can be 
expected, but diagnostic images within 4 h after injection in patients should be 
possible.  
 99mTc-IL-8 offers many advantages over radiolabeled leukocytes. Preparation of 
99mTc-IL-8 is easy and rapid, ready within 30 minutes and with no need for further 
purification, whereas preparation of labeled leukocytes, be it with either 111In or 99mTc, 
is cumbersome, time-consuming and not possible in granulocytopenic patients (2). The 
procedure of taking blood from a patient, purification of the leukocytes and labeling of 
these cells takes a trained technician approximately 3 hours. Cells should be handled 
cautiously in order to preserve their capacity to migrate to the inflamed area upon 
reinjection. In addition, the need to handle potentially contaminated blood could lead 
to transmission of blood-born pathogens such as HIV (7) and presents serious risks to 
both personnel and patient. The convenient method of labeling leukocytes in vivo with 
99mTc-IL-8 reflects the traditional method of labeling leukocytes ex vivo, with all the 
advantages of the new method mentioned above.  
  
 
CONCLUSION 
 
Imaging of a variety of pulmonary infections with 99mTc-IL-8 proved to be feasible 
and offers many advantages over the conventionally used tools in nuclear medicine, 
67Ga-citrate and radiolabeled leukocytes. 99mTc-IL-8 allowed excellent visualization of 
localization and extent of pulmonary infection in three experimental models simulating 
immunocompromized conditions (aspergillosis) as well as  models simulating 
immunocompetent conditions with gram-positive (S.pneumoniae) as well as gram-
negative (E.coli) bacterial infections.  
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ABSTRACT 
 
The cytokine interleukin-8 (IL-8) binds with high affinity to the CXCR1 and CXCR2 
receptors on neutrophils. In previous studies we showed that 99mTc-IL-8 could rapidly 
and effectively delineate foci of infection and inflammation in rabbit models of 
intramuscular infection, colitis and osteomyelitis. Here, the in vivo kinetics and 
pharmacodynamics of 99mTc-IL-8 are studied in detail. A derivative of 
hydrazinonicotinamide (HYNIC) was used as bifunctional coupling agent to label the 
protein with 99mTc. 
Methods: i) To address specificity of uptake of 99mTc-IL-8 in the abscess, uptake in 
turpentine-induced abscesses in neutropenic rabbits was compared to uptake in 
turpentine-induced abscesses in normal rabbits. ii) The pharmacokinetics of 99mTc-IL-8 
were studied in neutropenic rabbits and compared to those in normal rabbits. To 
investigate the interaction of 99mTc-IL-8 with blood cells in circulation in normal 
rabbits, the distribution of the radiolabel over circulating white and red blood cells and 
plasma was determined. iii) The in vivo kinetics of 99mTc-IL-8 were studied by 
quantitative analysis of whole body images acquired between 0 and 6 h p.i. The results 
of this analysis (in vivo biodistribution) were validated by ex vivo counting of 
radioactivity in dissected tissues.  
Results: i) Abscess uptake (%ID/g ± s.e.m.) in immunocompetent rabbits (0.41 ± 
0.05) was ten times higher than  in neutropenic rabbits (0.038 ± 0.014), demonstrating 
specificity of the target uptake of 99mTc-IL-8. Abscess-to-muscle ratios (± s.e.m.) were 
also ten times higher (110 ± 10 vs 10 ± 5). Lung and spleen uptake in normal rabbits 
was three times higher than in neutropenic rabbits. ii) The blood clearance of the 
radiolabel in neutropenic rabbits was similar to that in normal rabbits. In circulation, 
most of 99mTc-IL-8 (70%) was found in the plasma fraction. Less than one third was 
associated with red blood cells, and only a very low percentage (<2.5%) with white 
blood cells. iii) Image analysis revealed a gradually increasing abscess uptake over 
time up to over 15% ID, which was confirmed by ex vivo gamma counting of the 
infected muscle. Highest increase in uptake in the abscess was observed after 2 h p.i., 
when most of 99mTc-IL-8 was cleared from the blood, suggesting specific neutrophil-
mediated accumulation of 99mTc-IL-8 in the abscess. Furthermore, region-of-interest 
analysis revealed that gradual accumulation of 99mTc-IL-8 in the abscess was 
accompanied by a simultaneous clearance of activity from the lungs, suggesting that 
neutrophil associated 99mTc-IL-8 that was initially trapped in the lungs migrates to the 
abscess at later time-points, favoring neutrophil-bound transportation from the lungs to 
the abscess.  
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Conclusion: Substantial support is given for the hypothesis that 99mTc-IL-8 localizes 
in the abscess mainly as bound to peripheral neutrophils. Accumulation in the abscess 
is a highly specific, neutrophil-driven process. As assessed by in vivo and ex vivo 
analysis, the total fraction that accumulates in the inflamed tissue is extremely high (up 
to over 15% ID), compared to other agents used for imaging infection and 
inflammation.    
 
 
INTRODUCTION 
 
Neutrophils are known to express two types of interleukin-8 (IL-8) receptors, CXCR1 
and CXCR2, abundantly (1). IL-8 binds these receptors with high affinity (0.3-4 
nmol/L) (2-5). The in vivo behavior of radioiodinated IL-8 has been studied in rat (6) 
and rabbit (7,8) models of infection. Gross et al. showed in a pilot study that 131I-
labeled IL-8 could visualize osteomyelitic lesions in patients (9). We have pointed out 
that the radioiodination method clearly affected the in vivo biodistribution of IL-8 (10). 
For clinical applications, a labeling procedure using the radiometal 99mTc is to be 
preferred over iodine (10). Recently, we described the development of a 99mTc-labeled 
IL-8 preparation using hydrazinonicotinamide (HYNIC) as a bifunctional coupling 
agent (11). This preparation showed excellent characteristics for imaging infection in 
three different models of infection and inflammation in rabbits (11-13). In rabbits with 
intramuscular infection induced by E.coli, uptake of 99mTc-IL-8 in the abscess was 
rapid and high (11). Moreover, 99mTc-IL-8 showed a remarkably fast clearance from 
nontarget tissues. Abscess-to-muscle ratios exceeded 100 at 8 h after injection.  
In rabbits with chemically induced acute colitis, inflammatory lesions were 
scintigraphically visualized after injection of either IL-8 or purified granulocytes, both 
labeled with 99mTc (13). Within a few hours after injection, 99mTc-IL-8 allowed an 
adequate evaluation of the inflamed colon. Absolute uptake in the inflamed foci in the 
colon was much higher for 99mTc-IL-8 than for 99mTc-labeled granulocytes.  
In a third study, the performance of 99mTc-IL-8 was evaluated in an 
experimental model of acute osteomyelitis in rabbits (12). The results were compared 
with those obtained using the conventional and well-established agents 111In-
granulocytes, 67Ga-citrate and 99mTc-MDP. In this rabbit model of osteomyelitis, 
99mTc-IL-8 clearly delineated the osteomyelitic lesions. Although absolute uptake in 
the osteomyelitic area was lower than that obtained with 67Ga-citrate and 99mTc-MDP, 
the target-to-background ratios were significantly higher for 99mTc-IL-8.  
IL-8 is a proinflammatory chemotactic cytokine. For scintigraphic purposes 
protein doses to be administered should be below levels that generate side-effects. We 
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showed that a preparation with a high specific activity (80 MBq/µg) and high in vitro 
stability could be prepared when nicotinic acid was used as a coligand (14). Imaging 
doses as low as 70 ng/kg 99mTc-IL-8 open the way to infection imaging studies in 
patients.  
In the present study three fundamental aspects of the in vivo behavior of 99mTc-
IL-8 were investigated: a) Specificity of uptake of 99mTc-IL-8 in the abscess; b) 
Mechanism of migration of 99mTc-IL-8 from the circulation to the inflammatory focus; 
c) Kinetics of 99mTc-IL-8 in vivo.  
 
 
MATERIALS AND METHODS 
 
Human recombinant IL-8 was kindly provided by Dr I. Lindley (Novartis, Vienna, 
Austria). Tricine (N-[Tris(hydroxymethyl)-methyl]glycine was purchased from Fluka 
(Buchs, Switzerland), nicotinic acid from Sigma-Aldrich (St. Louis, MO).  
 
Conjugation of HYNIC to IL-8   
The propylaldehyde hydrazone of succinimidyl-hydrazinonicotinamide (HYNIC) was 
synthesized essentially as described previously (15,16). The IL-8-HYNIC conjugate was 
prepared as described previously (8). Briefly, in a 1.5 ml vial 4 µl  1 M NaHCO3,  pH 8.2 
was added to 35 µl of IL-8 (4.8 mg/ml). Subsequently, a three-fold molar excess of 
HYNIC in 5 µl dry DMSO  was added dropwise to the mixture. After incubation for  five 
minutes at room temperature, the reaction was stopped by adding an excess of glycine 
(200 µl, 1 M in PBS). To remove excess unbound HYNIC the mixture was extensively 
dialyzed against PBS (0.1-0.5 ml dialysis cell 3.5 MWCO, Pierce, Rockford, IL). 
Dialyzed samples of circa 5 µg  IL-8-HYNIC were stored at –20 0C.  
 
Technetium-99m Labeling of HYNIC Conjugated IL-8  
5 micrograms IL-8-HYNIC were incubated with 0.2 ml of tricine solution (100 mg/ml 
in PBS), 25 µL of a freshly prepared tin (II) solution (10 mg SnSO4 in 10 ml nitrogen-
purged 0.1 N HCl) and 150 - 350 MBq 99mTcO4-  in saline at room temperature for 30 
minutes. The radiochemical purity was determined by instant thin-layer 
chromatography  (ITLC) on ITLC-SG strips (Gelman Laboratories, Ann Arbor, MI) 
with 0.1 M citrate, pH 6.0, as the mobile phase. Following the labeling reaction the 
reaction mixture was applied to a Sephadex G-25 column (PD-10; Pharmacia, 
Uppsala, Sweden) and eluted with PBS, 0.5% BSA to purify radiolabeled IL-8. A 
description of an extensive in vitro characterization (HPLC, stability, receptor binding 
assays) has been given elsewhere (14). 
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Animal Studies 
All animal experiments were carried out in accordance with the guidelines of the local 
animal welfare committee.  
     Specificity of Uptake of 99mTc-IL-8 in the Abscess. Neutropenia was induced in five 
female New Zealand rabbits (2.4-2.7 kg) by i.v. administration of cytarabine (David Bull 
Laboratories, Mulgrave, Victoria, Australia)  (50 mg per rabbit per day during 7 days). 
Routinely a rabbit model of intramuscular infection induced by Escherichia coli is used, 
because it generates a strong leukocytic response and it is a good reflection of a common 
bacterial infection. In neutropenic rabbits the immune system is seriously troubled and an 
infection induced by Escherichia coli could have a fatal effect on these animals. For that 
reason a sterile turpentine inflammation rather than a bacterial infection was installed. On 
day 8, a sterile inflammation was induced in the left thigh muscle of these five 
neutropenic rabbits and in a control group of four immunocompetent rabbits (0.5 ml of 
turpentine i.m.). During the procedure, rabbits were anaesthetized with a subcutaneous 
injection of a 0.6 ml mixture of fentanyl 0.315 mg/ml and fluanisone 10 mg/ml 
(Hypnorm, Janssens Pharmaceutical, Buckinghamshire, UK). On day 9, blood samples 
of 1 ml were taken from the rabbits and a manual differential leukocyte count of these 
samples was performed. Then, both groups of rabbits received 20 MBq 99mTc-IL-8 
(protein dose 0.5 µg) via the ear vein. Three rabbits out of each group were used for 
gamma camera imaging. These rabbits were  immobilized in a mold, placed prone on the 
gamma camera and images were acquired at 0, 1, 2 and 4 h p.i. with a single-head 
gamma camera (Orbiter, Siemens Medical Systems Inc., Hoffman Estates, IL) equipped 
with a parallel-hole low-energy all purpose collimator. Images were obtained with a 15% 
symmetrical window over the 140 keV energy peak of 99mTc. After acquisition of 
100,000-300,000 counts, the images were digitally stored in a 256 x 256 matrix. 
Scintigraphic images were analyzed quantitatively by drawing regions of interest (ROI) 
over the abscess and  the contralateral thigh muscle (background). Abscess-to-
background ratios were calculated. 
 After completion of the final imaging session (4 h p.i.), all rabbits were killed with 
a lethal dose of sodium phenobarbital. Samples of blood, infected thigh muscle, 
uninfected contralateral thigh muscle, lung, spleen, liver, kidneys and intestines were 
collected. The dissected tissues were weighed and the activity in the samples was 
measured in a gamma counter. To correct for radioactive decay injection standards were 
counted simultaneously. The measured activity in samples was expressed as percentage 
of injected dose per gram tissue (%ID/g). Abscess-to-contralateral muscle ratios and 
abscess-to-blood ratios were calculated.  
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 For histological examination, samples of infected thigh muscle of neutropenic as 
well as normal rabbits were fixed in formalin and embedded in paraffin. 5 µm sections 
were cut and stained with hematoxylin-eosin for lightmicroscopic examination. 
 Mechanism of Migration of 99mTc-IL-8 from the Circulation to the Inflammatory 
Focus. Pharmacokinetics of 99mTc-IL-8 were determined in neutropenic as well as 
normal rabbits with turpentine-induced abscesses (three rabbits per group). Multiple 
blood samples were collected between one minute and four hours after injection. Blood 
samples were weighed, their activity was measured and their uptake expressed as %ID/g 
and as %ID in the blood pool based on an estimated total blood volume of 6% of the total 
body weight of the rabbit (17).  
 The association of  99mTc-IL-8 with blood cells in circulation was studied 
following intravenous injection of radiolabeled IL-8. Blood samples of 3 ml (in 
heparinized tubes) of three normal rabbits with turpentine induced inflammation were 
taken at five minutes, two hours and four hours  after injection of the radiolabel. The 
blood was mixed with 1/4 dextran (dextran 500, Pharmacia, Uppsala, Sweden) 6% 
solution in 0.9% NaCl, and allowed to sediment for one hour at room temperature. The 
leukocyte-rich supernatant was carefully removed. The leukocyte-rich layer and the 
erythrocyte-rich layer were centrifuged for 15 minutes at 500xg. The supernatants of both 
layers were removed and retained. The leukocyte pellet and the erythrocyte pellet were 
washed three times with 5 ml of Hank’s balanced salt solution (HBSS) and centrifuged 
for 10 minutes at 500xg. The supernatants of all washing steps were retained. 
Radioactivity of the leukocyte pellet, the erythrocyte pellet, the plasma layer and the 
supernatants of the washing steps was counted in a gamma-counter. All radioactivity in 
plasma layer and supernatants of the washing steps were taken together and designated as 
“plasma”.  
 Kinetics of 99mTc-IL-8 In Vivo. Soft-tissue infections were induced in the left thigh 
muscle of four female New Zealand rabbits (2.5-3.0 kg) with 1-2 x 1011 colony forming 
units (cfu) of Escherichia coli in 0.5 ml. After 24 hours the rabbits were injected i.v. with 
99mTc-labeled IL-8. Scintigraphic images were obtained with a dual head Siemens 
MultiSpect 2 gamma-camera connected to a Scintiview image processor and ICON 
computersystem (Siemens Inc., Hoffman Estates, IL). All images were collected in 
digital format in a 256x256 matrix. Low-energy parallel-hole collimators were used (140 
keV photopeak, 15% symmetric window). Three rabbits were imaged alternately at a 
preset time of 10 minutes per image, one set of three images taking approximately 35-40 
minutes. In this way, 10 sets of whole-body images were generated between 0 and 6 h 
p.i. The animals were killed after completion of the last image and tissue samples were 
collected, weighed and counted in a gamma counter. Scintigraphic images were analyzed 
quantitatively by drawing regions of interest (ROI) over the abscess, the contralateral 
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thigh muscle, kidneys, bladder, liver, spleen, lungs and heart, spine. In addition, regions 
were drawn near the organs for background correction.  
 Results of quantitative analysis of the images (in vivo biodistribution) were 
compared to results of counting radioactivity in dissected tissues (ex vivo biodistribution) 
in an additional experiment. To ascertain whether in vivo biodistribution data are in 
accordance with ex vivo biodistribution data, one rabbit with intramuscular infection was 
imaged on the dual headed Siemens MultiSpect 2 gamma-camera as described above. 
After finishing the last image at 6 h p.i., the animal was killed and dissected. 
Radioactivity was counted in whole organs on a NaI-crystal connected to a multichannel 
analyzer. Appropriate standards of injected dose (1%, 3%, 6%, 10%, 20% and 30% ID) 
were counted as well. Special attention was paid to the analysis of radioactivity uptake in 
the infected hindleg. After counting radioactivity in the whole infected leg (similarly to 
drawing a ROI over the total high-uptake region), the leg was dissected stepwise in the 
direction of the central part of the abscess. The various dissected parts were weighed and 
counted. In this way, total percentages of the injected dose (%ID) and %ID per gram of 
tissue could be determined (ex vivo data). Similarly, abscess uptake was analyzed on the 
whole body image, by drawing concentric regions around the central focus of the abscess 
(in vivo data). Ex vivo data were compared to in vivo data.  
 
Statistical Analysis 
All mean values are expressed as %ID/g, %ID or ratios ± 1 standard error of the mean 
(s.e.m.). Data were analyzed statistically using the unpaired t-test (GraphPad Instat 3.00 
Win 95, San Diego, CA, USA). 
 
 
RESULTS 
 
Specificity of Uptake of 99mTc-IL-8 in the Abscess  
Hematoxylin-eosin stained 5-µm sections of the abscess of a normal, immunocompetent 
rabbit and a neutropenic rabbit are shown in Figure 1. Microscopic examination revealed 
a massive influx of predominantly polymorphonuclear cells (neutrophils) in the abscesses 
of normal rabbits (Figure 1a). Remarkably, in neutropenic rabbits the abscesses were also 
characterized by high numbers of infiltrating cells. However, in these animals the 
invading leukocytes were predominantly mononuclear, i.e. lymphocytes and/or 
monocytes (Figure 1b).  
 The reduction of neutrophil counts markedly affected the biodistribution of 99mTc-
IL-8 in these rabbits as shown in Table 1 and Figure 2. Two cytarabine-treated rabbits 
were designated as “semineutropenic rabbits” because of higher neutrophil levels as 
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compared to three deeply neutropenic rabbits (8% and 19% versus 4%, 0% and 1% 
respectively). These “semineutropenic” rabbits showed higher abscess uptakes than the 
deeply neutropenic rabbits. Abscess uptake correlated well with neutrophil counts in the 
cytarabine-treated and non-treated animals (r=0.90, data not shown).   
 
 
A B
 
Figure 1. Hematoxylin-eosin stained tissues of turpentine induced abscesses in a normal, 
immunocompetent rabbit (A) and a neutropenic rabbit (B). Note the massive infiltration of 
polymorphonuclear cells (neutrophils) in A and mononuclear cells in B. Magnification 400x 
and 1000x (inset).  
 
 
 
Table 1. Biodistribution of 99mTc-IL-8 in neutropenic and normal rabbits with turpentine-
induced abscesses. Uptake is given as %ID/g. Values are expressed as mean ± 1 SEM. 
                                           
 Neutropenic Normal 
 rabbit (n=3) rabbits (n=4)  
   
Blood 0.073 ± 0.004 0.069 ± 0.004 
Muscle 0.005 ± 0.001 0.004 ± 0.001 
Abscess   0.038 ± 0.014 0.41 ± 0.05 
Lung 0.10 ± 0.02  0.34 ± 0.04 
Spleen 0.38 ± 0.04 0.90 ± 0.08 
Kidney 2.32 ± 0.30 2.13 ± 0.22 
Liver 0.110 ± 0.024 0.080 ± 0.006 
Intestine 0.044 ± 0.008 0.025 ± 0.002 
   
 Ratios   
    
Abscess/Blood 0.5 ± 0.2          5.9 ± 0.7 
Abscess/Muscle        10 ± 5         110 ± 10 
   
Target/Background 1.2 ± 0.1           15 ± 1 
                                         _______________________________ 
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Figure 2 illustrates the dramatic impact of neutrophil reduction on uptake of 99mTc-IL-8 
in the abscess: Low abscess uptake in a neutropenic rabbit, moderate uptake in a 
“semineutropenic” rabbit and high uptake in a normal rabbit. Association of 99mTc-IL-8 
with neutrophils is demonstrated in Table 1: (i) abscess uptake is significantly higher 
(P<0.01) in normal rabbits as compared to neutropenic rabbits; (ii) lung uptake is 
significantly higher (P<0.01) in normal rabbits (0.34 ± 0.04 %ID/g vs 0.10 ± 0.02 
%ID/g); (iii) uptake in spleen is also significantly higher (P<0.01) in normal rabbits 
(0.90 ± 0.08 %ID/g vs 0.38 ± 0.04 %ID/g). These organs are known for accommodating 
high concentrations of neutrophils. Remarkably, uptake in intestinal tissue was 
significantly higher (P<0.05) in neutropenic rabbits (0.044 ± 0.008 %ID/g vs 0.025 ± 
0.002 %ID/g). The ratios Abscess/Blood, Abscess/Muscle and Target/Background from 
analysis of the images were significantly higher (P<0.01, P<0.001, P=0.0001 
respectively) for normal rabbits as compared to the neutropenic ones. 
 
 
Neutropenic rabbit  
 
 
 
 
 Semineutropenic rabbit 
 
 
 
 
 
 Normal rabbit 
 
 
 
 
 
 
      0 h                   1 h                      2 h                    4 h 
 
 
Figure 2. Images of rabbits with turpentine induced abscesses in the left thigh muscle at 5 
minutes, 1, 2 and 4 hour after injection of 99mTc-IL-8. Neutrophil counts varied from very low 
levels (Neutropenic rabbit) via low levels (Semineutropenic rabbit) to normal levels (Normal 
rabbit). 
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Mechanism of Migration of 99mTc-IL-8 from the Circulation to the Inflammatory 
Focus 
The blood clearance patterns of 99mTc-IL-8 in normal versus neutropenic rabbits with 
turpentine-induced soft-tissue abscesses were essentially congruent (Figure 3), 
demonstrating that there is no major effect of the reduction of the number of 
neutrophils in circulation on the blood clearance of 99mTc-IL-8. The association of 
99mTc-IL-8 with blood cells in samples of normal rabbits with turpentine-induced 
abscesses is shown in Table 2. The major fraction of the radiolabel was found in the 
plasma fraction, ranging from 68% immediately after injection, to 76% at the last time 
point. Less than one third of the radiolabel was associated with red blood cells, and 
only a very low percentage (<2.5%) with white blood cells.  
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Figure 3. Blood clearance of 99mTc-IL-8 in immunocompetent, normal rabbits and in 
neutropenic rabbits with turpentine induced inflammation. Data are expressed as percentage 
of the injected dose (%ID) in the blood pool.  
 
 
 
 
 
Table 2. Distribution of 99mTc-IL-8 over red blood cells, white blood cells, and plasma in 
normal rabbits with turpentine-induced abscesses. 
                                                                                                          
                      ________________________________________________________ 
 %plasma %RBC %WBC 
T=5' 68 ± 2 31 ± 2 0.3 ± 0.02 
T=2h 68 ± 4 30 ± 4 2.3 ± 0.2 
T=5h 76 ± 4 23 ± 4 0.8 ± 0.2 
RBC = red blood cells; WBC = white blood cells. From plasma blood samples at 3 different 
time points. Values are expressed as mean ± 1 SEM. 
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Kinetics of 99mTc-IL-8 In Vivo 
The kinetics of the in vivo distribution of 99mTc-IL-8 in rabbits with E.coli-induced 
infection are summarized in Figure 4. The whole body activity (corrected for physical 
decay) did not decrease. Ergo, during the experiment radioactivity was not excreted 
from the body. An example of a posterior image with regions of interest (ROI) drawn 
is given in Figure 5. Analysis of the images showed a gradual increase in abscess 
uptake up to 15 ± 1 % of whole body activity (WBA) at 5.5 h p.i. At that time 
maximum uptake was not reached yet. Kidney uptake reached high levels immediately 
after injection of the radiolabel and remained stable from one hour onwards at a level 
of approximately 30 %WBA. Uptake in the lungs showed a gradual decrease from a 
high level of uptake immediately after injection (23 ± 0.5 %WBA) towards a moderate 
level at 5.5 h p.i. (13 ± 1 %WBA). Liver uptake was nearly stable over time at 
approximately 10 %WBA. Spleen uptake appeared to be marginal in this experiment; 
<1 %WBA at all time points. Activity in the bladder was low and did not exceed 3 ± 1 
%WBA at 5.5 h p.i. In addition, ROI’s of spine and corresponding background areas 
were drawn, revealing only marginal uptake in the spine area (data not shown). A 
substantial amount of uptake was observed in the head and forelegs region, declining 
from 15  ± 1 %WBA at the start to 9 ± 1 %WBA at the end (not shown in Figure 4). 
The major shifts in radioactivity distribution over time involved a clearance from the 
lungs (-10 %WBA), the head/forelegs (-6 %WBA) and the trunk (minus organs) in 
favor of kidney (+9 %WBA) and the abscess (+12 %WBA). 
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Figure 4. Kinetics of the in vivo distribution of 99mTc-IL-8 in rabbits with E.coli induced 
infection as determined by quantitative analysis of the images. Uptake is quantified as 
percentage of whole body activity. The error bars indicate ± SEM. 
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21.9 g = 0.17 %ID/g
34.5 g = 0.10 %ID/g  
Abscess core: 3.8%
Muscle part: 11% 57 g = 0.13 %ID/g200 g  = 0.055 %ID/g
Bone part: 2.3%
55 g = 0.042 %ID/g
Hip part: 1%
Muscle "infected": 7.2%
Peripheral: 3.5%
Muscle "normal": 3.8%Upper hind leg
Upper hind leg: 17.6%
without skin: 14.5%
Hind leg total: 18.4%
Skin: 3.1%
Lower hind leg: <0.5%
140 g = 0.027 %ID/g
 
Figure 5. Detailed ex vivo analysis of uptake of 99mTc-IL-8 in the E.coli infected hind leg of a 
New Zealand white rabbit at 6 h after injection. Uptake is given as percentage of the injected 
dose (%ID) and as %ID per gram for the central parts of the affected muscle (see also in vivo 
analysis data of Table 3).  
 
 
Table 3. Detailed analysis of uptake of 99mTc-IL-8 in E. coli-infected hindleg of a New Zealand 
white rabbit. Comparison of radioactivity uptake in whole unfragmented organs and abscess 
parts (ex vivo analysis; Fig. 5) with uptake as determined by quantitative analysis of images 
at 6 h after injection. Ex vivo data are expressed as %ID; in vivo data are expressed as 
percentage of whole body activity (WBA). 
 
dissected parts 
ex vivo data 
% injected dose 
 
regions of interest 
in vivo data 
% whole body
abscess  core 3.8% abscess core 4.5% 
muscle part 11% abscess peripheral 12.2% 
upper hindleg 17.6% abscess total 18.5% 
kidney left 14.4% kidney left 13.2% 
kidney right 15.4% kidney right 15.1% 
liver  8.6% liver  9.7% 
spleen 0.75% spleen 0.60% 
lungs 4.4% lungs 3.9% 
                    __________________________________________ 
 
The results of a detailed analysis (both ex vivo and in vivo) of uptake of 99mTc-
IL-8 in one rabbit are presented in Table 3 and Figure 5. Regions of interest were 
drawn as in Figure 6. Data of ex vivo and in vivo analysis showed a fair congruency. 
Ex vivo analysis displayed a gradual increase in radioactivity concentration (%ID/g) 
towards the core of the abscess. Taking into account considerably large uptakes in 
concentric areas around this abscess core, a total uptake in the affected leg of 17.6% 
ID was determined. Similarly, in vivo analysis displayed a gradual increase in Target-
to-Background ratios towards the center of inflammation, from 8.1 (abscess total), 
14.2 (abscess periphery) up to 20.0 (abscess core). Total uptake in the affected leg 
(designated as abscess total) amounted to 18.5 %WBA, based on ROI analysis, as 
compared to 17.6 %ID from the ex vivo analysis.  
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Figure 6. Typical example of regions of interest (ROI) in an image of a rabbit with an E.coli 
induced intramuscular infection injected with 99mTc-IL-8. 
 
 
DISCUSSION 
 
Specific uptake of 99mTc-IL-8 in inflamed tissue is assumed to be based on high-
affinity binding to IL-8 receptors on neutrophils. Neutrophil-driven specificity can be 
demonstrated in various ways. Firstly, by studying the behavior of a control protein 
with similar size and charge but with no specific interaction with receptors on 
neutrophils. The observation in a previous study that abscess uptake of 99mTc-IL-8 was 
more than ten times higher than abscess uptake of 99mTc-Lysozyme suggested that 
abscess uptake was a result of the interaction of IL-8 with its receptors in 
inflammatory foci (11). An alternative way to demonstrate specific uptake is in vivo 
receptor blocking using an excess of unlabeled IL-8 or an excess of receptor blocking 
monoclonal antibodies. However, saturation of receptors before injection of 99mTc-IL-
8 is not feasible because excessive amounts of unlabeled IL-8 will generate 
unacceptable biological effects or would require excessive amounts of costly 
monoclonal antibodies. In the present study an alternative approach was chosen: 
Comparing abscess uptake of 99mTc-IL-8 in neutropenic rabbits with that in rabbits 
with normal numbers of neutrophils. Microscopic examination of inflamed muscular 
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tissue samples showed a shift in infiltrating leukocyte populations from predominantly 
polymorphonuclear cells (i.e., neutrophils) in normal rabbits to mononuclear cells 
(lymphocytes, monocytes) in cytarabine-pretreated rabbits. Patel et al. demonstrated 
that activated neutrophils express high numbers of CXCR1 and CXCR2 receptors 
(104/cell), whereas activated mononuclear cells express low numbers of these 
receptors (<102/cell)(1). As a consequence, the number of available receptors for 
99mTc-IL-8 is greatly reduced in neutrophil-depleted rabbits. Accordingly, the uptake 
of 99mTc-IL-8 in the abscess was dramatically reduced in neutrophil-depleted rabbits. 
More precisely, a good correlation between neutrophil counts and abscess uptake was 
found (r=0.90). Specific involvement of 99mTc-IL-8 with neutrophils was also reflected 
in high uptake in neutrophil abundant organs such as lungs and spleen. Low uptake in 
neutrophil-depleted animals in these organs and in the abscess strongly suggests that 
accumulation of 99mTc-IL-8 is a neutrophil-driven process. Only a minor fraction of 
99mTc-IL-8 localizes in the abscess nonspecifically. In neutropenic rabbits, uptake of 
99mTc-IL-8 in the abscess is only 10% as compared to abscess uptake in normal rabbits 
(Table 1), but is still ten times as high as uptake in contralateral muscle. A similar 
uptake pattern was seen for 99mTc-Lysozyme in a previous study (11), suggesting again 
that some 10% of uptake of the radiolabel in the abscess could be ascribed to 
nonspecific uptake.  
 The mechanism of migration of 99mTc-IL-8 from the circulation to the focus of 
inflammation was the second issue of investigation. Several mechanisms of 
transportation can be conceived, grossly divided into neutrophil-bound transportation 
and non-neutrophil-bound transportation. Neutrophil-bound transportation involves 
high affinity binding of 99mTc-IL-8 to receptors on peripheral neutrophils, followed by 
migration of the labeled cells to the inflamed tissue and passage through the 
endothelium. Non-neutrophil-bound transportation involves freely circulating 99mTc-
IL-8 which extravasates and is subsequently trapped by receptors on infiltrated 
neutrophils. In addition, it has been shown that 99mTc-IL-8 can bind to some degree to 
receptors on red blood cells with low affinity (18). The present study pointed out that 
some 30% of the injected 99mTc-IL-8 was bound to red blood cells. The binding to red 
blood cells is rapidly reversible and dissociation of 99mTc-IL-8 from the binding site on 
red blood cells is supposed to take place at the site of inflammation where 99mTc-IL-8 
is exposed to massive numbers of high affinity binding sites on neutrophils (8,18).  
 Only a very low percentage of 99mTc-IL-8 in blood samples was associated with 
white blood cells. This observation is in favor of a non-neutrophil-bound 
transportation mechanism. On the other hand, several observations do support the 
concept of neutrophil-bound transportation. Blood clearance of 99mTc-IL-8 in rabbits 
with turpentine-induced soft-tissue abscess showed a fast initial clearance (Fig. 3) 
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within the first hour after injection, whereas the time period of highest increase in 
uptake of 99mTc-IL-8 in the abscess was between 2 and 5 h p.i. (Fig. 4). Uptake during 
that time period increased from some 7 to approximately 15 percent of the injected 
dose. This observation, that the major part of 99mTc-IL-8 accumulates in the abscess in 
the time period that 99mTc-IL-8 has cleared (almost) completely from the blood, argues 
against non-neutrophil-bound transportation of 99mTc-IL-8 to the abscess. Furthermore, 
quantitative analysis of the images at various timepoints revealed that the 
accumulation of 99mTc-IL-8 in the abscess is accompanied by a simultaneous clearance 
of activity from the lungs, suggesting that neutrophil associated 99mTc-IL-8 that is 
trapped in the lungs initially migrates to the abscess at later timepoints, favoring 
neutrophil-bound transportation from the lungs to the abscess. It has been shown that 
IL-8 can induce stiffening of neutrophils by reorganisation of intracellular actin, and 
this could explain the leukosequestration in the lungs. These cells loose their flexibility 
and consequently can not pass the narrow microcapillaries of the lungs anymore 
(19,20). As leukosequestration is a transient phenomenon, neutrophils (with radiolabel 
adhered) gradually re-enter circulation and subsequently migrate to the inflamed tissue 
due to their enhanced chemotactic status induced by IL-8. Between injection and the 
final imaging, the lung uptake decreased by 10%, while the abscess uptake increased 
by 12%. It is tempting to speculate that increasing abscess uptake could (partly) be 
ascribed to a continuous supply of radiolabeled neutrophils from the lungs.  
Furthermore, several studies have shown that infiltrated (phagocytosing) 
neutrophils (21) in inflamed tissue in an environment of high concentrations of 
chemotactic cytokines (22) (and micro-organisms (23) or products thereof (24)) have 
downregulated their CXCR1 and CXCR2 expression and express relatively low 
numbers of these receptors, further arguing against direct targeting of infiltrated 
neutrophils by 99mTc-IL-8. It is most plausible that 99mTc-IL-8 targets predominantly 
peripheral neutrophils and not neutrophils within the inflammatory lesion.  
 Based on these considerations, we would propose the following hypothesis. 
Upon intravenous injection 99mTc-IL-8 is partly bound to peripheral neutrophils and 
the major fraction of 99mTc-IL-8 remains unbound. The fast blood clearance of the 
radiolabel is mainly reflecting the fast pharmacokinetics of the unbound 99mTc-IL-8 
fraction. Unbound 99mTc-IL-8 is rapidly cleared predominantly by the kidneys. Not 
surprisingly, the blood clearance patterns in normal versus neutropenic rabbits are 
essentially congruent, as these are both reflecting unbound 99mTc-IL-8. The neutrophils 
that bind 99mTc-IL-8 stiffen and are trapped in the microcapillaries of the lungs. 
Following release from the lungs, these cells migrate to the inflamed tissue and 
extravasate at the site of infection in a highly selective way. As the release of the cells 
from the lungs is a gradual process, the analysis of blood samples reveals only a low 
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percentage of the radiolabel attached to white blood cells. Analysis of blood samples 
mainly reflects unbound 99mTc-IL-8. Quantitative analysis of images reveals the 
comparitively slow pharmacokinetics of the cell-bound 99mTc-IL-8 fraction. 
Accumulation of 99mTc-IL-8 in the abscess is a neutrophil-driven gradual 
process, highly specific and efficient. 99mTc-IL-8 accumulated in abscesses of 
immunocompetent rabbits to a very high degree as determined by quantitative analysis 
of images and ex vivo quantification. In vivo biodistribution data did not conflict with ex 
vivo biodistribution data, showing the reliability of both approaches. The results showed 
that in previous studies (11,14) the total ex vivo abscess uptake of 99mTc-IL-8 was 
underestimated. Apparently, in the earlier studies only a part of the inflamed tissue 
was dissected and analyzed.  
 
 
CONCLUSION 
 
In this study substantial support is provided in favor of the hypothesis that 99mTc-IL-8 
localizes in the abscess mainly due to neutrophil-bound transportation. Accumulation 
of 99mTc-IL-8 in the abscess is a neutrophil-driven process, highly specific and 
efficient: Abscess uptake in immunocompetent rabbits with intramuscular infection is 
extremely high (up to over 15% ID) as confirmed by in vivo and ex vivo analysis. 
Based on experimental data, 99mTc-IL-8 meets virtually all desiderata for successful 
imaging of infection and inflammation: High and highly specific uptake in abscesses, 
fast clearance from non-target tissues and low protein doses are promising features for 
the introduction of 99mTc-IL-8 into the clinic.  
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ABSTRACT 
 
The complement anaphylatoxin C5a and its natural metabolite C5a des Arg74 (C5adR) 
are involved in several stages of the inflammatory process. Both act on a common 
receptor expressed on different cell types, including neutrophils and monocytes. The 
receptor binding affinity of C5a is in the nanomolar range and exceeds that of C5adR 
by 1-2 orders of magnitude. The biologic potency of C5a is considerably higher than 
that of C5adR. Here we tested both proteins labeled with 99mTc for imaging of 
infection.  
Methods: The proteins were labeled  with 99mTc via the hydrazinonicotinamide 
(HYNIC) chelator. The preparations were tested for imaging of infection in a rabbit 
model of intramuscular infection. Biodistribution of the radiolabel was determined by 
γ-camera imaging and by counting dissected tissues at 5 h p.i..  
Results: C5a and C5adR showed in vivo abscess uptakes of 0.12 and 0.025 %ID/g, 
abscess/muscle ratios of 76 and 14, abscess/blood ratios of 9.1 and 2.6, and ROI 
derived target-to-background ratios of 5.9 and 2.1, respectively at 5 h p.i..  
Conclusion: For infection imaging 99mTc-labeled C5a showed excellent in vivo 
characteristics. However, C5a is a very bioactive protein, impeding its clinical use as 
an infection imaging agent. The naturally occurring partial agonist C5adR has less 
biological effect but showed suboptimal imaging characteristics. The present study 
showed that for adequate localization of a receptor binding ligand affinities for the 
receptor in the nanomolar range are required. 
 
 
INTRODUCTION 
 
Leukocytes, particularly neutrophils and monocytes, accumulate in high numbers at 
sites of infection. They function as the primary line of defense in the destruction of 
microorganisms and initiate the repair of tissue. Leukocytes preferentially target 
infection by chemotaxis and can therefore be used to transport radionuclides to the 
infected area. Scintigraphic detection of infection can be accomplished by direct 
labeling of leukocytes (ex vivo labeling) or by labeling leukocytes indirectly, i.e. in 
vivo (for a recent review: (1)).  
Ex vivo labeling requires withdrawal of blood from the patient, purification of 
leukocytes, labeling and reinjection of the radiolabeled cells. The ex vivo leukocyte 
labeling approach has been developed in the seventies and eighties of the previous 
century and is still considered the “gold standard” nuclear medicine technique for 
infection imaging, but is time-consuming and bears the risk of cross contamination.  
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In vivo labeling of leukocytes can be based on antibody-antigen interactions 
(e.g. radiolabeled antigranulocyte antibodies) and on leukocyte receptor binding. 
Recent studies in our laboratory focussed on the use of small leukocyte receptor 
binding peptides such as chemotactic peptides (formyl-Met-Leu-Phe) (2) and 
cytokines (interleukin-1 and interleukin-8 (3-5)). Especially 99mTc-labeled interleukin-
8 appeared to be a highly promising candidate for infection imaging in several 
preclinical studies (3;6-8).  
The present study investigated the potential of two selected components of the 
complement system, C5a and its natural metabolite C5a des Arg74 (C5adR), for 
infection imaging. C5a is involved in several stages of the inflammatory response to 
tissue injury (for a review: (9;10)). C5a is a highly potent activator of a wide variety of 
cell types, including mast cells, neutrophils, monocytes, endothelial and epithelial 
cells. C5a causes chemotaxis and degranulation of neutrophils, enhances vascular 
permeability and stimulates the release of cytokines from macrophages and 
monocytes. In vivo, the C-terminal Arginine-residue of C5a is rapidly degraded by 
serum carboxypeptidase resulting in C5adR. The des-Arg form of C5a has a different 
pattern of activity as compared to intact C5a, being less active in general and having 
little spasmogenic or anaphylactic activity. Both C5a and its one aminoacid shortened 
version C5adR act on a common receptor on neutrophils, monocytes and other cell 
types, but the receptor affinity of C5a is in the nanomolar range, whereas the receptor 
affinity of C5adR is considerably lower (11). Yancey and coworkers reported 
monocyte binding affinities of 1.2 nM and 30 nM and neutrophil binding affinities of 
2.6 nM and 68 nM for fluorescein-conjugated C5a and C5adR, respectively (12). In 
the present study C5a and C5adR were labeled  with 99mTc via the 
hydrazinonicotinamide (HYNIC) coupling agent. The preparations were compared for 
their potential to image infections in a rabbit model of soft-tissue infection. 
 
 
MATERIALS AND METHODS 
 
Preparation of proteins and of HYNIC-protein-conjugates  
Human recombinant C5a and human C5adR were produced in E. coli and purified by 
the methods described by Bubeck et al (13). The propylaldehyde hydrazone derivative 
of succinimidyl-hydrazinonicotinamide (HYNIC) was synthesized essentially as 
described by Abrams, Schwartz et al. (14;15). The C5a-HYNIC and C5adR-HYNIC 
conjugates were prepared as described previously (3). Briefly, in a 1.5 ml vial 4 µl  1 
M NaHCO3,  pH 8.2 was added to 35-40 µl of protein (4-5 mg/ml). Subsequently, a 
three-fold molar excess of HYNIC in 5 µl dry DMSO  was added dropwise to the 
 
140     Chapter 9  
mixture. After incubation for  five minutes at room temperature, the reaction was 
stopped by adding an excess of 200 µl 1 M glycine in PBS. To remove excess 
unbound HYNIC the mixture was extensively dialyzed against PBS (0.1-0.5 ml 
dialysis cell 3.5 MWCO, Pierce, Rockford, IL). Dialyzed samples of circa 5 µg  
protein-HYNIC were stored at –20 0C. 
  
Technetium-99m labeling of HYNIC conjugated proteins 
20 mg tricine (N-[Tris(hydroxymethyl)-methyl]glycine, Fluka, Buchs, Switzerland) in 
0.2 ml PBS, 20 µl of a solution containing SnSO4  (1 mg/ml in 0.1M HCl) and 0.5 ml 
200-300 MBq 99mTcO4-  in saline were added to 5 µg thawed HYNIC-C5a or HYNIC-
C5adR and incubated at room temperature for 30 minutes. The radiochemical purity 
was determined by instant thin-layer chromatography  (ITLC) on ITLC-SG strips 
(Gelman Laboratories, Ann Arbor, MI) with 0.1 M citrate, pH 6.0, as the mobile 
phase. Following the labeling reaction the reaction mixture was applied to a Sephadex 
G-25 column (PD-10; Pharmacia, Uppsala, Sweden) and eluted with 0.5 % BSA in 
PBS to purify the radiolabeled conjugates.  
 
Receptor binding assay 
Human neutrophils were isolated from heparinized whole blood obtained from healthy 
donors. Receptor binding assays were performed essentially as described previously 
(4). Briefly, heparinized human whole blood (20 ml) was mixed with 2.5 ml 5% 
Dextran (Sigma, St. Louis, MO). After removing the red blood cell bulk by 
sedimentation during 1 hr at room temperature, the remainder of the blood sample was 
washed in incubation buffer (1 mM NaH2PO4, 5 mM Na2HPO4, 140 mM NaCl, 0.5 
mM MgCl2, 0.15 mM CaCl2, 0.5% HSA, pH 7.4) and centrifuged at 500xg for 20 min. 
The cell pellet was then resuspended in 7 ml incubation buffer and layered on 5 ml 
Ficoll-Hypaque (Pharmacia, Uppsala, Sweden), followed by centrifugation at 500xg 
for 20 min. The pellet, rich of polymorphonuclear cells (PMNs), was washed once and 
subsequently resuspended in incubation buffer. A series of serially diluted PMN 
suspensions (0.5 - 8 x 106 PMN/ml) was incubated with 10,000 cpm of  99mTc-labeled 
C5a and another series similarly with 99mTc-labeled C5adR. Duplicates of the lowest 
cell concentration were incubated in the presence of a 100-fold molar excess of 
unlabeled C5a to correct for nonspecific binding. After 3 h incubation at 4 0C, PMNs 
were centrifuged (5 min, 2000xg) and the radioactivity in the pellet (total bound 
activity) was measured in a shielded well-type gamma counter (Wizard, Pharmacia-
LKB, Sweden). The data were graphically analyzed in a modified Lineweaver-Burk 
plot: a double inverse plot of the conventional binding plot (specifically bound fraction 
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versus cell concentration) (16). The receptor-binding fraction at infinite cell excess 
was calculated by linear extrapolation to the ordinate. 
 
Animal studies 
Animal studies were carried out in accordance with the guidelines of the local animal 
welfare committee. Abscesses were induced in the left thigh muscle of ten female New 
Zealand white rabbits (2.4-2.7 kg) with 1011 colony forming units (cfu) of Escherichia 
coli in 0.5 ml. During the procedure, the rabbits were sedated with a subcutaneous 
injection of a 0.6 ml mixture of fentanyl 0.315 mg/ml and fluanisone 10 mg/ml 
(Hypnorm, Janssens Pharmaceutical, Buckinghamshire, UK). After 24 hours, when 
swelling of the muscle was apparent, five rabbits were  injected with 18 MBq 99mTc-
HYNIC-C5a (protein dose 2 µg) via the ear vein. The five other rabbits received 16 
MBq 99mTc-HYNIC-C5adR (protein dose 2 µg) intravenously. Three rabbits of each 
group were used for gamma camera imaging. For imaging, rabbits were  immobilized, 
placed prone on the gamma camera and injected with either 99mTc-HYNIC-C5a or 
99mTc-HYNIC-C5adR in the lateral ear vein. Images were recorded at 1 min, 1, 3 and 5 
h p.i. with a single-head gamma camera (Orbiter, Siemens Medical Systems Inc., 
Hoffman Estates, IL) equipped with a parallel-hole low-energy all purpose collimator. 
Images (100,000-200,000 counts per image) were obtained and digitally stored in a 
256 x 256 matrix. 
The scintigraphic results were analyzed quantitatively by drawing regions of 
interest (ROI) over the abscess and  the uninfected contralateral thigh muscle 
(background). Abscess-to-background ratios were calculated. 
After completion of the final imaging and blood sampling (5 h p.i.), the rabbits 
were killed with a lethal dose of sodium phenobarbital. Samples of blood, infected 
thigh muscle, uninfected contralateral thigh muscle, lung, spleen, liver, kidneys and 
intestines were collected. The dissected tissues were weighed and counted in a gamma 
counter. Injection standards were counted simultaneously to correct for radioactive 
decay. The measured activity in samples was expressed as percentage of injected dose 
per gram tissue (%ID/g). Abscess-to-contralateral muscle ratios and abscess-to-blood 
ratios were calculated. 
 
Statistical analysis 
All mean values are given as %ID/g or ratios ± one standard error of the mean (s.e.m.). 
The data were analyzed statistically using unpaired two-tailed t tests (GraphPad Instat 
3.00 Win 95, San Diego, CA, USA). 
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RESULTS 
 
Radiolabeling and characterization of 99mTc-HYNIC-C5a and 99mTc-HYNIC-C5adR 
The specific activities of the radiolabeled purified C5a and C5adR preparations were 9 
MBq/µg and 8 MBq/µg, respectively. The radiochemical purity of both preparations 
was higher than 95% after gel filtration as determined by ITLC. The fraction of the 
radiolabeled preparation binding to receptors on granulocytes was 40% for 99mTc-
HYNIC-C5a and 50% for 99mTc-HYNIC-C5adR. 
  
Animal studies in rabbits with E. coli infection  
Table 1 shows the biodistribution of 99mTc-HYNIC-C5a and 99mTc-HYNIC-C5adR in 
rabbits with E. coli infections at 5 h p.i. For C5a significantly higher values were 
observed for radioactivity uptake in the abscess (P<0.01), lungs (P<0.01) and  spleen 
(P<0.001). Kidney uptake of C5a was significantly lower as compared to C5adR 
(P<0.05). Abscess/muscle and abscess/blood ratios were significantly higher  for C5a 
(P<0.05, P<0.01 resp.): 75 ± 24 and 9.1 ± 1.8 vs 14 ± 2 and 2.6 ± 0.3 for C5adR resp. 
For both preparations the radiolabel was excreted almost exclusively via the kidneys.  
Gamma camera imaging rapidly visualized the abscesses in the thigh muscles from 1 h 
p.i. onwards for C5a (Fig. 1). The C5adR preparation showed only modest results in 
delineating infectious foci from 3 h p.i. onwards. Quantitative analysis of the images 
revealed abscess/background ratios improving with time up to 5.9 ± 1.0 for C5a vs 2.1 
± 0.1 for C5adR at 5 h p.i. (Fig. 2). Abscess/background ratios were significantly 
higher for C5a as compared to C5adR from 1 h p.i. onwards (P<0.05). Immediately 
after injection high kidney uptake was observed for both preparations, remaining 
prominent throughout the study.  
 
Table 1. Biodistribution of 99mTc-HYNIC-C5a and 99mTc-HYNIC-C5adR in rabbits with E. coli  
infections at 5 h p.i. (mean values ± s.e.m.). * P<0.05, ** P<0.01, *** P<0.001 (unpaired two- 
tailed t tests).  
 
%ID/g  99mTc-C5a  P 99mTc-C5adR 
  N=5  N=5 
blood  0.013 ± 0.001 0.010 ± 0.001 
muscle    0.002 ± 0.0004   0.002 ± 0.0004 
abscess  0.12 ± 0.02 ** 0.025 ± 0.003 
lung  0.13 ± 0.02 ** 0.032 ± 0.005 
spleen  0.26 ± 0.03 *** 0.093 ± 0.010 
kidney   1.88 ± 0.09 * 2.44 ± 0.19 
liver  0.046 ± 0.004  0.045 ± 0.006 
intestine  0.028 ± 0.002  0.029 ± 0.002 
abscess/muscle 75 ± 24 * 14 ± 2 
abscess/blood 9.1 ± 1.8 **    2.6 ± 0.3 
%ID kidneys                             33 ± 1 ** 40 ± 1 
%ID abscess  1.63 ± 0.22 ***   0.37 ± 0.06 
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Figure 1. Scintigraphic images of rabbits with an E. coli abscess in the left thigh muscle at 1 
min, 1, 3 and 5 h after injection of 99mTc-HYNIC-C5a (upper panel) or 99mTc-HYNIC-C5adR 
(lower panel). 
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Figure 2. The abscess-to-background ratios as determined by quantitative analysis of the 
images of rabbits with E. coli infection injected with 99mTc-HYNIC-C5a or 99mTc-HYNIC-
C5adR. The error bars indicate s.e.m. * P<0.05 (unpaired two-tailed t tests). 
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DISCUSSION 
 
In this study the imaging potential of two small leukocyte receptor binding proteins 
was explored: The complement factor C5a and its natural metabolite C5adR. The 
difference between the two proteins is that C5a has just one additional C-terminal 
aminoacid residue but the in vivo behavior of the peptides in the rabbit model was 
totally different. Theoretically, for infection imaging one would prefer a protein that 
binds its receptor with high affinity, while inducing marginal biologic effects. C5a has 
a relatively high affinity for its receptor  (in the nanomolar range) resulting in superior 
image quality of  99mTc-labeled C5a over C5adR. However, the spasmogenic and 
anaphylactic potencies of C5a make it unsuitable for use as a clinical diagnostic agent. 
C5adR has less undesirable biological effect, but the characteristics for infection 
imaging are far from optimal, presumably due to the lower binding affinity for the 
C5a-receptor. In fact, we investigated two other C5a receptor antagonists: the C5adR 
mutant with Lys68 substituted by Glu68 (C5adR E68) (17) and a C5adR mutant with a 
C-terminus heptapeptide substitution (18). Like C5adR, these low affinity antagonists 
also showed relatively low uptake in the abscess and thus are unsuitable for infection 
imaging (data not shown).  
In order to block inappropriate activation of the complement system in human 
disease numerous C5a receptor antagonists have been developed. Such agents include 
high molecular weight C5a receptor antagonists derived from C5a (18;19) and low 
molecular weight (<1000 Da) cyclic and linear peptides (20-29). Some of these 
antagonists have been shown to be potentially valuable complement therapeutics 
showing potent anti-inflammatory antagonist properties. In general, however, these 
antagonists bind with lower affinity to the C5a-receptor (affinities one to two orders of 
magnitude lower than C5a). The present study showed that for adequate localization of 
a receptor binding ligand an affinitiy for the receptor in the nanomolar range is 
required. However, the only C5a derivative meeting this demand is C5a itself. A C5a 
protein dose of 1 µg/kg of body weight as used in this study is reported to induce a 
serious but transient neutropenia followed by a prolonged neutrophilia (30). 
Theoretically, biological effects could be avoided by reducing the C5a administration 
doses below the biological threshold. In order to decrease protein doses, the specific 
activity of radiolabeled C5a (as expressed in MBq/µg) should be increased. By 
adopting alternative labeling strategies, specific activities could be substantially 
increased as demonstrated by our studies with 99mTc-labeled interleukin-8 (8). In the 
case of labeling interleukin-8 with 99mTc, different coligand formulations were used to 
enhance the specific activity of the preparation. The use of (iso-)nicotinic acid as 
coligand resulted in a dramatic improvement of the specific activity of the 99mTc-
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labeled interleukin-8 preparation. However, in case of labeling C5a with 99mTc we did 
not succeed in generating specific activities that were high enough to exclude potential 
biological effects.  
In conclusion, as an infection imaging agent 99mTc-labeled C5a is an excellent 
agent yielding high target-to-background ratios and is clearly better than C5adR, but 
its use in the clinic is impeded due to its biological activity. C5adR is less bioactive 
but its imaging quality is inferior. Binding affinities for the receptor in the nanomolar 
range appeared to be critical for effective accumulation in receptor rich tissue. To our 
knowledge no C5a receptor antagonist exists which combines high binding affinity 
with low biological activity. In the absence of such an antagonist the only solution to 
circumvent biological effects on i.v. administration of labeled C5a is to reduce protein 
doses by enhancing the specific activity of 99mTc-labeled C5a (in MBq/µg). So far, the 
applied radiolabeling procedures could not put C5a protein doses below the biological 
threshold. 
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ABSTRACT 
 
The CXC-chemokines are a family of closely related chemoattractant cytokines, which 
bind to, attract and activate neutrophils to variable degrees. In this study the relationship 
between neutrophil binding affinity and suitability for infection imaging was investigated 
in a selected group of CXC-chemokines. Neutrophil-activating-peptide-2 (NAP-2, 70 
residues, also called CXCL7) binds with high affinity to the CXCR2 receptor on 
neutrophils. Recently, C-terminally truncated NAP-2-variants have been described that 
have enhanced neutrophil binding affinity and neutrophil-stimulating capacity. Here, 
NAP-2 and its C-terminal shortened variants NAP-2(1-68), NAP-2(1-66) and NAP-2(1-
63) were labeled with 99mTc via the hydrazinonicotinamide (HYNIC) chelator and their 
potential for imaging of infection was investigated in a rabbit model of infection. The 
CXC-chemokine interleukin-8 (IL-8) was used as a reference. In addition, a series of 
99mTc-labeled CXC-chemokines were screened for their potential to image infection 
including CTAP-III, GCP-2, ENA-78, PF-4 and IP-10. 
Methods: The receptor binding affinity of HYNIC-conjugated NAP-2 and its analogues 
was compared in competitive binding assays on Jurkat cells transfected with the CXCR2 
receptor gene. Biodistribution of  labeled NAP-2 (analogues) and other CXC-chemokines 
in rabbits with intramuscular E.coli infections was determined both by γ-camera imaging 
and by counting dissected tissues at 6 h p.i. 
Results: The CXCR2 binding affinity of the HYNIC-conjugated NAP-2 analogues 
relative to NAP-2 was:  NAP-2(1-68) 2.5-fold, NAP-2 (1-66) 10-fold and NAP-2(1-63) 
3-fold. In the rabbit model, uptake in the abscess (in %ID/g ± s.e.m.) was for NAP-2 
0.084 ± 0.015, for NAP-2(1-68) 0.098 ± 0.010, for NAP-2(1-66) 0.189 ± 0.044 and for 
NAP-2(1-63) 0.114 ± 0.017 at 6 h p.i. respectively. In comparison, higher uptake in the 
abscess was found for labeled IL-8, a modest uptake for GCP-2 and ENA-78, and a low 
uptake for CTAP-III, PF-4 and IP-10.  
Conclusion: This study showed a clear relationship between affinity to receptors on 
neutrophils and suitability for infection imaging. Of the NAP-2 variants, NAP-2(1-66) 
combined highest affinity to CXCR2 with best characteristics for imaging. IL-8 binds to 
both CXCR1 and CXCR2 with high affinity and showed a superior imaging quality. The 
other CXC-chemokines tested bind to neutrophils with lower affinity and showed to be 
less suitable for infection imaging in this study. 
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INTRODUCTION 
 
White blood cells, particularly neutrophils and monocytes, accumulate in high 
numbers at sites of infection. They function as the primary line of defense in the 
destruction of microorganisms and initiate the repair of tissue. A variety of 
chemotactic peptides and proteins orchestrate the directed migration of leukocytes to 
inflammatory sites. Potentially these leukocyte-binding proteins can be used as an 
infection imaging agent, labeled either in their original natural form or in the 
sophisticated disguise of a receptor antagonist (for a review see (1)). This study 
focusses on a selection of chemokines for infection imaging.  
The “chemokines” (short for chemoattractant cytokines) are a superfamily of 
closely related and conserved cytokines. Most of the chemokines are small, with 
molecular weights in the range of 8 to 12 kDa. The chemokine superfamily is divided 
into subfamilies depending on the position of the highly conserved cysteines (2). One 
major subfamily is designated “CXC” because the two cysteines (C) nearest the N-
termini of these proteins are separated by a single, nonconserved amino acid residue 
(X). The other major subfamily is called “CC” because these two cysteines are 
adjacent. The CXC-chemokines act predominantly on neutrophils, whereas the CC-
chemokines act on lymphocytes, monocytes, mastcells and eosinophils (3). The CXC 
chemokine subfamily can be further divided into ELR+ and ELR- CXC chemokines 
depending on the presence or absence of a Glu-Leu-Arg (ELR) motif, respectively. 
This motif is positioned in the NH2-terminal region just in front of the first cysteine of 
the CXC-motif. The ELR+ CXC chemokines are the most selective chemotactic factors 
for neutrophil migration. Interleukin-8 (IL-8, recently renamed CXC chemokine ligand 
8 (CXCL8) (4)) is the prototype of this group and is the most potent neutrophil 
activating protein of the CXC chemokines in the human system. Other members of this 
group include growth regulated oncogene (GROα (CXCL1), GROβ (CXCL2) and 
GROγ (CXCL3)), connective tissue activating peptide-III (CTAP-III), neutrophil 
activating protein-2 (NAP-2 (CXCL7)), epithelial cell derived neutrophil attractant-78 
(ENA-78 (CXCL5)) and granulocyte chemotactic protein-2 (GCP-2 (CXCL6)). The 
ELR- CXC chemokines include platelet factor-4 (PF-4 (CXCL4)) and interferon γ-
inducible protein (IP-10 (CXCL10)). There are two high affinity G protein-coupled 
CXC chemokine receptors on neutrophils: CXC chemokine receptor 1 (CXCR1) and 
CXCR2 (5). IL-8 and GCP-2 bind to both CXCR1 and CXCR2, whereas the other 
ELR+ CXC chemokines are specific ligands for CXCR2 (6;7). The ELR- CXC 
chemokines PF-4 and IP-10 lack significant CXCR1 and CXCR2 binding (8;9). PF-4 
is reported to be active on many different cell types, including neutrophils (10), but no 
G protein-coupled receptor has been identified for PF-4 so far.  
150     Chapter 10 
In this study we aimed to select the most promising candidates within the 
family of the CXC-chemokines. Is there a clear relationship between biological 
properties such as neutrophil chemoattractant activity (as can be assessed in Boyden 
chamber assays), neutrophil activating properties (e.g., elastase release) and neutrophil 
binding affinity on the one side and suitability for infection imaging on the other side? 
We hypothesize that neutrophil binding affinity is a useful criterion for selecting the 
most suitable CXC-chemokine for infection imaging. This study focusses on NAP-2 
and three C-terminally truncated NAP-2 variants. NAP-2 is a member of a group of 
CXC-chemokines collectively termed β-thromboglobulins (10). These are platelet α-
granule-derived proteins, which differ only in the length of the termini. Platelet basic 
protein (PBP, 94 residues) and CTAP-III (85 residues) were shown to become 
converted into NAP-2 (70 residues) by N-terminal truncation through limited 
proteolysis (11;12). Although structurally closely related, the β-thromboglobulins PBP 
and CTAP-III do not exhibit neutrophil-stimulatory activity in contrast to their 
proteolytic daughter compound NAP-2. Recently, C-terminally truncated NAP-2-
variants have been described that have enhanced affinity for receptors on neutrophils and 
enhanced neutrophil-stimulating capacity (13;14). NAP-2(1-68) is also named 
thrombocidin-1 (TC-1) and has bactericidal properties (15). Here, NAP-2 and its C-
terminally shortened variants NAP-2(1-68), NAP-2(1-66) and NAP-2(1-63) were labeled 
with 99mTc and their potential for imaging of infection was investigated in rabbits with 
intramuscular E.coli infection. IL-8,  binding to both CXCR1 and CXCR2 with high 
affinity, has already been studied in detail for infection imaging purposes and was used 
as a reference (16-18). 
In addition, a broad inventarisation of the CXC-chemokines for infection 
imaging was made. CTAP-III, GCP-2, ENA-78 (ELR+ CXC-chemokines) and PF-4, 
IP-10 (ELR- CXC-chemokines) are a representative selection of the CXC-chemokines 
and were tested in our laboratory using the same rabbit model of intramuscular 
infection as used above.  
 
 
MATERIALS AND METHODS 
 
Chemokines 
The following human recombinant proteins were used: NAP-2 was purchased from RDI 
(Flanders, NJ, USA). NAP-2(1-68) (also named thrombocidin-1 (TC-1)), NAP-2(1-66) 
and NAP-2(1-63) were produced by recombinant methods as described previously (12). 
IL-8 was kindly provided by Dr I. Lindley (Novartis, Vienna, Austria). GCP-2, ENA-78 
and IP-10 were purchased from RDI (Flanders, NJ, USA). CTAP-III and PF-4 were 
Infection imaging with 99mTc-NAP-2 analogues     151 
kindly provided by Dr A. Waltz (Theodor-Kocher Institute, University of Bern, Bern, 
Switzerland).  
 
Conjugation of HYNIC to chemokine  
The propylaldehyde hydrazone of succinimidyl-hydrazinonicotinamide (HYNIC) was 
synthesized essentially as described previously (3;19). The HYNIC-chemokine conjugate 
was prepared as described previously (16). Briefly, in a 1.5 ml vial 5 µl  1 M NaHCO3,  
pH 8.2 was added to 35 µl of chemokine (5 mg/ml). Subsequently, a three-fold molar 
excess of HYNIC in 5 µl dry DMSO  was added dropwise to the mixture. After 
incubation for ten to thirty minutes at room temperature, the reaction was stopped by 
adding an excess of glycine (200 µl, 1 M in PBS). To remove excess unbound HYNIC 
the mixture was extensively dialyzed against PBS (0.1-0.5 ml dialysis cell 3.5 MWCO, 
Pierce, Rockford, IL). Dialyzed samples of circa 8 µg  HYNIC-conjugated chemokine 
were stored at –20 0C.  
 
Technetium-99m labeling of HYNIC conjugated chemokine  
Tricine (N-[Tris(hydroxymethyl)-methyl]glycine) was purchased from Fluka (Buchs, 
Switzerland), nicotinic acid from Sigma-Aldrich (St. Louis, MO). For labeling of the 
HYNIC-conjugated chemokines with 99mTc, tricine and nicotinic acid were used as 
coligands as described previously (17). To a thawed sample of 8 µg HYNIC-
chemokine was added 0.2 ml of a solution of tricine and nicotinic acid (125 mg/ml and 
12.5 mg/ml respectively, in PBS, adjusted to pH 7.0 with 2M NaOH), 20 µL of a 
freshly prepared tin (II) solution (10 mg SnSO4 in 10 ml nitrogen-purged 0.1 N HCl) 
and 300-400 MBq 99mTcO4-  in saline. The mixture was incubated at 70 0C for 30 
minutes.  
 The radiochemical purity was determined by instant thin-layer chromatography  
(ITLC) on ITLC-SG strips (Gelman Laboratories, Ann Arbor, MI) with 0.1 M citrate, 
pH 6.0, as the mobile phase. In case of a labeling-efficiency smaller than 96%, the 
reaction mixture was applied to a Sephadex G-25 column (PD-10; Pharmacia, 
Uppsala, Sweden) and eluted with PBS, 0.5% BSA to purify the radiolabeled 
chemokine. For animal experiments, the reaction mixture was diluted with PBS, 0.5% 
BSA to a concentration of 40 MBq/mL, ready for i.v. administration in the rabbits.  
 
Receptor binding competition assays 
The interaction of HYNIC conjugated NAP-2, its variants and IL-8 with chemokine 
receptor CXCR2 was investigated in binding competition assays using 99mTc-labeled 
IL-8 as a tracer. These assays were performed using Jurkat cells transfected with the 
CXCR2 receptor, a kind gift of Drs. Loetscher and Baggiolini (Theodor Kocher 
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Institute, University of Bern, Bern, Switserland) (20). The Jurkat cells were cultured at 
37 oC in a humidified atmosphere of air/CO2 (95:5) in RPMI 1640 medium (GIBCO, 
Gaithersburg, MD) containing 10% fetal calf serum and 1% glutamine, amino acids and 
pyruvate. The medium also contained Pen/Strep, 5 x 10-5 M of β-mercaptoethanol and 
1.5 µg/ml puromycin for selection. Live Jurkat cells were centrifuged (5 min, 2000xg) 
and washed once with assay buffer (RPMI 1640, 0.5% BSA, 0.05% NaN3). For the 
receptor binding competition assays CXCR2 bearing Jurkat cells were suspended at 
~4x108 cells/ml (final concentration) in RPMI 1640 medium containing 0.5% BSA. 
Duplicate samples of ~2x108 cells were incubated on ice for 3 h with a constant amount 
of 99mTc-labeled IL-8 (~0.014 nM IL-8, ~50,000 counts of radioactivity) as a tracer, in 
the presence or absence of increasing concentrations (0.25 nM – 400 nM) of HYNIC-
conjugated NAP-2, its variants and IL-8 in a total volume of 0.5 ml. To correct for 
nonspecific binding of 99mTc-labeled IL-8 a sample was incubated in the presence of a 
30,000 fold excess of native IL-8. After an incubation of 3 h on ice, cells were 
centrifuged (5 min, 2000xg), washed twice with incubation buffer and the radioactivity in 
the pellet (total bound radioactivity) was measured in a shielded well-type gamma 
counter (Wizard; Pharmacia, Uppsala, Sweden). Nonspecific binding of 99mTc-labeled 
IL-8 was subtracted. Each assay was performed in duplo. The concentration of HYNIC-
conjugated NAP-2 that caused 50% displacement was set at 1 and the IC50 
concentrations of the HYNIC-conjugated NAP-2 variants and IL-8 were expressed 
relative to that of  HYNIC-conjugated NAP-2.  
 
Animal studies 
For a direct comparison between 99mTc-labeled NAP-2, its three C-terminally 
truncated variants and IL-8 in imaging intramuscular infection, abscesses were 
induced in the left thigh muscle of 25 female New Zealand rabbits (2.4-2.7 kg) with 1-
2 x 1011 colony forming units (cfu) of Escherichia coli in 0.5 ml. During the 
procedure, rabbits were anaesthetized with a subcutaneous injection of a 0.6 ml 
mixture of fentanyl 0.315 mg/ml and fluanisone 10 mg/ml (Hypnorm, Janssens 
Pharmaceutical, Buckinghamshire, UK). The rabbits were divided into five groups of 
five animals (five animals per 99mTc-labeled chemokine). After 24 hours, when 
swelling of the muscle was apparent, the rabbits were injected with 20 MBq 99mTc-
labeled chemokine (protein dose 0.5 µg) via the ear vein. Three rabbits out of each 
group were used for gamma camera imaging. These rabbits were  immobilized, placed 
prone on the gamma camera and images were recorded at 1-5 min, 1½, 3, 4½ and 6 h 
p.i. with a single-head gamma camera (Orbiter, Siemens Medical Systems Inc., 
Hoffman Estates, IL) equipped with a parallel-hole low-energy all purpose collimator. 
Images were obtained with a 15% symmetrical window over the 140 keV energy peak 
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of 99mTc. After acquisition of 200,000-300,000 counts, the images were digitally stored 
in a 256 x 256 matrix. Scintigraphic images were analyzed quantitatively by drawing 
regions of interest (ROI) over the abscess and  the uninfected contralateral thigh 
muscle (background). Abscess-to-background ratios were calculated. 
 After completion of the final imaging session (6 h p.i.), all rabbits were killed with 
a lethal dose of pentobarbital (euthesate, Ceva Sante Animale, Naaldwijk, The 
Netherlands). Samples of blood, infected thigh muscle, uninfected contralateral thigh 
muscle, lung, spleen, liver, kidneys and intestines were collected. The dissected tissues 
were weighed and counted in a gamma counter. To correct for radioactive decay 
injection standards were counted simultaneously. The measured activity in samples was 
expressed as percentage of injected dose per gram tissue (%ID/g). Abscess-to-
contralateral muscle ratios and abscess-to-blood ratios were calculated. 
 Using the same rabbit model of intramuscular infection, the 99mTc-labeled CXC-
chemokines CTAP-III, GCP-2, ENA-78, PF-4 and IP-10 were tested for infection 
imaging at a smaller scale. 
 
Statistical analysis 
All mean values are given as %ID/g, %ID or ratios ± 1 standard error of the mean 
(s.e.m.). The data were analyzed statistically using the one-way ANOVA with Dunnett’s 
posttest (GraphPad Instat 3.00 Win 95, San Diego, CA, USA) comparing data for the 
99mTc-labeled NAP-2 derivatives with data for 99mTc-labeled NAP-2.  
 
 
RESULTS 
 
99mTc-labeling of the chemokines 
The radiochemical purities of 99mTc-labeled NAP-2, its variants and IL-8 exceeded 
98% in all cases, as determined by instant thin-layer chromatography, excluding the 
need for further purification. This is in line with our previous findings for IL-8, where 
the same labeling strategy using tricine and nicotinic acid as coligands was adopted 
(17). The specific activities of the preparations of 99mTc-labeled NAP-2, its variants 
and IL-8 were high, approximately 40-50 MBq per microgram of protein. The specific 
activities of the preparations of 99mTc-labeled CTAP-III, GCP-2, ENA-78, PF-4 and IP-
10 ranged from 20-40 MBq per microgram of protein. 
 
Receptor binding competition assays 
The receptor binding competition assays involved a direct comparison in binding to 
the CXCR2 receptor between HYNIC-conjugated proteins, i.e., chemically modified 
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proteins. The relative potencies of HYNIC-conjugated NAP-2 and its three C-
terminally truncated variants for binding to CXCR2 receptors transfected on Jurkat 
cells is depicted in figure 1. A two to three fold higher binding potency was found for 
the HYNIC-conjugated forms of NAP-2(1-68) and NAP-2(1-63) as compared to NAP-
2. HYNIC-conjugated NAP-2(1-66) showed a ten-fold higher binding potency relative 
to NAP-2. For comparison, the binding potency of HYNIC-conjugated IL-8 was 
seventy-five fold higher. 
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Figure 1. Relative potencies of HYNIC-conjugated NAP-2 and three C-terminally 
truncated variants to compete with 99mTc-labeled IL-8 for binding to Jurkat cells 
transfected with the CXCR2 receptor. The potency of HYNIC-conjugated NAP-2 is set at 
1. 
 
 
Animal studies 
Table 1 summarizes the biodistribution results of the four radiolabeled chemokine 
preparations in rabbits with an E.coli infection at 6 h p.i. Figure 2 presents uptake of the 
four radiolabeled chemokines in neutrophil-rich tissues, i.e., the abscess, the lungs and 
the spleen. 99mTc-labeled NAP-2(1-66) showed higher uptake in the abscess (P<0.05) 
as compared to 99mTc-labeled NAP-2. Physiologic uptake in the lungs was 
significantly higher for 99mTc-labeled NAP-2(1-66) as well (P<0.01). Abscess/muscle 
and abscess/blood ratios showed no significant differences. The agents cleared 
predominantly via the kidneys  and the residual amount of radioactivity in the kidneys 
was significantly lower (P<0.01) for the two shortest labeled NAP-2 variants, NAP-2(1-
66) and NAP-2(1-63 ) as compared to NAP-2. In comparison to 99mTc-labeled NAP-2, 
IL-8 showed significantly higher uptake in the abscess (0.39 ± 0.09 %ID/g), the lungs 
(0.12 ± 0.01 %ID/g), the spleen (0.55 ± 0.13 %ID/g) and higher ratios of 
abscess/muscle (215 ± 90) and abscess/blood (24 ± 4).  
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Table 1. Biodistribution of 99mTc-labeled NAP-2 and three C-terminally truncated 
variants in rabbits with E.coli induced intramuscular infection. Rabbits were injected 
with 20 MBq 99mTc-labeled chemokine, sacrificed at six hours after injection and 
dissected. Tissue samples were weighed and counted in a gamma counter. Values are 
expressed as percentages of the injected dose per gram tissue (%ID/g) ± one standard 
error of the mean or as ratios thereof.  
_____________________________________________________________________ 
99mTc-NAP-2 99mTc-NAP-2(1-68) 99mTc-NAP-2(1-66) 99mTc-NAP-2(1-63) 
blood 0.015 ± 0.001 0.013 ± 0.002 0.017 ± 0.003 0.013 ± 0.002
muscle 0.0017 ± 0.0002 0.0016 ± 0.0002 0.0024 ± 0.0001 0.0018 ± 0.0003
abscess 0.084 ± 0.015 0.098 ± 0.010 0.189 ± 0.044 0.114 ± 0.017
lung 0.057 ± 0.005 0.081 ± 0.015 0.171 ± 0.026 0.074 ± 0.016
spleen 0.15 ± 0.02 0.20 ± 0.05 0.30 ± 0.06 0.17 ± 0.03
kidney 3.1 ± 0.1 3.0 ± 0.1 1.9 ± 0.1 2.3 ± 0.1
liver 0.032 ± 0.001 0.035 ± 0.001 0.048 ± 0.006 0.043 ± 0.007
intestine 0.011 ± 0.001 0.012 ± 0.001 0.016 ± 0.002 0.014 ± 0.001
    
abscess/muscle 52 ± 11 65 ± 11 80 ± 23 66 ± 14
abscess/blood 5.7 ± 1.3 8.0 ± 1.1 12 ± 3 8.8 ± 1.2
_____________________________________________________________________ 
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Figure 2. Uptake of 99mTc-labeled NAP-2 and three C-terminally truncated variants at 
six hours after injection in tissues with a high natural abundancy of neutrophils: 
abscess, lungs and spleen. Values are expressed as percentages of the injected dose 
per gram tissue (%ID/g) ± one standard error of the mean. 
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Figure 3 shows the scintigrams acquired between 0 and 6 h after injection of 99mTc-
labeled NAP-2 and its three C-terminally truncated variants. Gamma camera imaging 
rapidly visualized the abscess from a few h p.i. onwards for all preparations. Quantitative 
analysis of the images revealed that the abscess-to-background ratios improved with 
time for all labeled chemokines up to 9 ± 1 for NAP-2, 9 ± 2 for NAP-2(1-68), 13 ± 1 
for NAP-2(1-66) and 10 ± 1 for NAP-2(1-63) at 6 h p.i.. For comparison, 99mTc-IL-8 
generated an abscess-to-background ratio of 20 ± 4 in the same animal model. 
Immediately after injection high kidney uptake was observed for all preparations, 
remaining prominent throughout the study.  
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Figure 3. Images of rabbits with an E.coli induced abscess in the left thigh muscle (at 
the right side on the image) at 1½, 3, 4½ and 6 hour after injection of 99mTc-labeled 
NAP-2 and three C-terminally truncated variants. 
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An overview of the various radiolabeled CXC-chemokines studied in the same rabbit 
model of intramuscular infection is presented in Figure 4. This figure contains 
representative images of 99mTc-labeled IL-8 (high affinity for both CXCR1 and 
CXCR2), CTAP-III (no binding to CXCR2), NAP-2 and its variants (various affinities 
for CXCR2), GCP-2 (acts via both CXCR1 and CXCR2) and ENA-78 (high affinity 
for CXCR2). Two examples of ELR- CXC-chemokines with poor neutrophil attractant 
capacity and no binding to CXCR1 and CXCR2 are PF-4 and IP-10. This figure 
illustrates the good characteristics for infection imaging of various 99mTc-labeled ELR+ 
CXC-chemokines, especially for NAP-2(1-66) and IL-8. In comparison to abscess 
uptake of NAP-2(1-66) (0.189 %ID/g) and IL-8 (0.39 %ID/g), only modest uptake was 
found for GCP-2 (0.081 %ID/g) and ENA-78 (0.056 %ID/g), and low uptake for 
CTAP-III (0.016 %ID/g), PF-4 (0.016 %ID/g) and IP-10 (0.0052 %ID/g).  
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ELR+ ELR-
PF-4 IP-10IL-8 GCP-2 ENA-78CTAP-III NAP-2
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Figure 4. Overview of images of rabbits with E.coli induced intramuscular infection 
obtained 6 h after injection of various 99mTc-labeled CXC-chemokines: ELR+ CXC-
chemokines IL-8, CTAP-III, the NAP-2 analogues, GCP-2 and ENA-78; and ELR- 
CXC-chemokines PF-4 and IP-10. 
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DISCUSSION 
 
In order to select the most suitable candidate for infection imaging within the family of 
CXC-chemokines, we screened a series of 99mTc-labeled CXC-chemokines for infection 
imaging. In this study we focussed on the relationship between binding affinity towards 
the CXCR2 receptor and suitability for infection imaging in a selected group of CXC-
chemokines: NAP-2 (70 residues) and three C-terminally truncated variants NAP-2(1-
68), NAP-2(1-66) and NAP-2(1-63).  It was previously shown that limited and defined 
truncation at the C-terminus of native NAP-2 enhances receptor binding and 
degranulation activity (13;14). A most prominent increase in potency to stimulate 
neutrophil degranulation and to bind neutrophils was observed for isoforms of NAP-2 
with a C-terminal deletion of four (NAP-2(1-66))  and seven amino acids (NAP-2(1-63)). 
Here, NAP-2 and its three variants were conjugated with the bifunctional chelator 
HYNIC which links 99mTc to protein via primary aminogroups within the protein. In 
receptor binding competition assays the relative binding affinities of the HYNIC-
conjugated (i.e., chemically modified) proteins were determined and the highest binding 
potency for the CXCR2 receptor was found for NAP-2(1-66). This finding correlated 
well with the findings of the infection imaging experiments with 99mTc-labeled NAP-2 
and its variants. 99mTc-labeled NAP-2(1-66) showed highest uptake in the abscess and 
highest physiologic uptake in the lungs, an organ that accomodates large numbers of 
neutrophils. HYNIC-conjugated IL-8 had a higher affinity for the CXCR2 receptor and 
99mTc-labeled IL-8 displayed the highest uptake in the abscess. However, it can not be 
excluded that NAP-2 and its variants might be more vulnerable to loose receptor binding 
affinity due to the conjugation procedure than IL-8.  This (hypothetical) situation might 
explain, at least in part, the differences in affinity for the CXCR2 receptor of the various 
HYNIC-conjugated chemokines.  
A survey of the 99mTc-labeled CXC-chemokines PF-4, IP-10, CTAP-III, ENA-78 
and GCP-2 in infection imaging provided additional evidence for the close relationship 
between neutrophil binding affinity and suitability for infection imaging. The presence of 
an ELR sequence within the CXC-chemokine was associated with effective imaging of 
infection. The 99mTc-labeled non-ELR CXC-chemokines studied in this paper, PF-4 and 
IP-10, lack significant binding to the CXCR1 and the CXCR2 receptor (8;9) and showed 
a very low uptake in the abscess. The presence of an ELR-sequence may be a 
prerequisite, but does not guarantee effective infection imaging. The radiolabeled ELR+ 
CXC-chemokine CTAP-III showed very low uptake in the abscess as well. CTAP-III is 
an N-terminally extended precursor of NAP-2 . CTAP-III neither binds to nor activates 
neutrophils in sharp contrast to NAP-2. NAP-2 has one amino acid residue preceeding 
the ELR-sequence and CTAP-III has sixteen residues preceeding the ELR-sequence. It is 
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suggested that the fraying N-terminal end of CTAP-III is interfering with the binding 
(21). In this way the ELR-sequence is masked and functionally not present. The 
radiolabeled ELR+ CXC-chemokines ENA-78 and GCP-2 showed only a modest uptake 
in the abscess. ENA-78 has high affinity towards the CXCR2 receptor only, but this 
affinity was found to be lower than that of GCP-2 and considerably lower than that of IL-
8. GCP-2 is reported to be efficient in binding the CXCR1 receptor as well (7). In the 
present study 99mTc-labeled GCP-2 more clearly delineated infectious foci than ENA-78.   
In accordance with these findings are the findings of a comparative study in imaging 
infection using 99mTc-labeled C5a and C5a des Arg74 (C5adR) (22). The complement 
anaphylatoxin C5a (74 amino acids) differs from its natural metabolite C5adR in just one 
additional C-terminal amino acid residue for C5a. Both act on a common receptor on 
different cell types, including neutrophils and monocytes. The receptor binding affinity 
of C5a exceeds that of C5adR by 1-2 orders of magnitude. For infection imaging 99mTc-
labeled C5a showed much better characteristics than C5adR: uptake in the abscess was 
five-fold higher for C5a than for C5adR (22).  
The importance of the C-terminal domain in the function of CXC-chemokines 
was illustrated in the present study by radiolabeled NAP-2 and three C-terminally 
truncated isoforms. Differences in biologic (and scintigraphic) behavior are attributed to 
the physicochemical properties of the deleted residues (14). Full size NAP-2 bears three 
acidic amino acids in the C-terminal ending: D66, E67 and D70. The loss of particularly the 
acidic residues D70 and E67 caused subsequent increases in biologic activity and binding 
to neutrophils, and the loss of a third acidic residue in NAP-2 resulted in NAP-2(1-63), 
the most active NAP-2 isoform. Further deletion of the C-terminal L63 was associated 
with a threefold reduction of the capacity of NAP-2(1-63) to bind to and activate 
neutrophils (14). Apparently, L63 is a functionally important residue within the structure 
of NAP-2. The present study showed a discrepancy with these reported findings: here, 
the most suitable NAP-2 derivative for infection imaging was radiolabeled NAP-2(1-66) 
and not NAP-2(1-63). This difference might be ascribed to the diverse effects of 
chemical modification on receptor binding. The chemokines were labeled with 99mTc 
using a succinimidyl-hydrazinonicotinamide (S-HYNIC) derivative as bifunctional 
agent. S-HYNIC is reacted with primary aminogroups, i.e., the α-aminogroup of the N-
terminal amino acid residue or the ε-aminogroup of lysine residues within the protein. 
The conjugation of S-HYNIC might interfere with receptor binding. It is tempting to 
speculate that the fraying C-terminal end of NAP-2(1-66) might prevent effective 
reaction of S-HYNIC with the lysines at critical positions 61 and 62 near to L63. This 
might explain the preferential qualities for infection imaging of 99mTc-labeled NAP-2(1-
66) as compared to NAP-2(1-63).  
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The importance of the N-terminal domain in the function of the CXC-chemokines is 
exemplified in the pair of closely related proteins CTAP-III and NAP-2 in our study, and 
also in a comparison between two naturally existent isoforms of IL-8 (2). The most 
abundant form of naturally occurring IL-8 is 72 amino acids long. This form has three 
residues in front of the ELR-sequence. A 77 amino acid variant of IL-8 is produced by 
endothelial cells and is extended at the N-terminus by five amino acids. The longer 
protein is some ten-fold less potent than the shorter protein in attracting and activating 
neutrophils. The differences might, again, be attributed to the negative interference of the 
longer fraying N-terminal end of IL-8(77) in the binding of the protein to CXC-receptors. 
IL-8(72) has a high affinity for both the CXCR1 and CXCR2 receptor and its potency as 
a neutrophil chemoattractant has been estimated to be threefold higher than that of NAP-
2 (23). The potential of radiolabeled IL-8(72) for imaging infection has been extensively 
explored by us (16-18) and is, not surprisingly, superior to that of other CXC-
chemokines, including the NAP-2 analogues.  
It must be emphasized here that neutrophil receptor affinity is not the only factor 
determining the uptake of a radiolabeled chemokine in the abscess. In general, 
localization of radiolabeled proteins in the focus of infection is a result of both specific 
and non-specific mechanisms. For non receptor binding proteins it was shown in a rat 
model of S.aureus infection that abscess accumulation is mainly driven by sustained 
blood levels (24). Blood residence time appeared to be the principal factor that 
determines localization of a nonspecific tracer protein in infectious foci. In the rabbit 
models of intramuscular E.coli infection, blood levels for 99mTc-labeled IL-8 were twice 
as high as for the 99mTc-labeled NAP-2 analogues at six hours post injection and these 
sustained higher blood levels will contribute to the uptake in the abscess in addition to 
the specific receptor interactions of the protein. However, in case of 99mTc-IL-8 it was 
estimated that non-specific uptake accounts for less than 10% of the total uptake in the 
abscess. Accumulation of 99mTc-IL-8 in the abscess is a predominantly neutrophil-driven 
(i.e., receptor interaction driven) process as was shown in a comparison between abscess 
uptake in neutropenic rabbits and that in immunocompetent rabbits in which the 
immunocompetent rabbits showed a ten-fold higher abscess uptake than the neutropenic 
animals (25).  
 In conclusion, this study showed a clear relationship between affinity to receptors 
on neutrophils and suitability for infection imaging. Of the NAP-2 variants, NAP-2(1-66) 
combined highest affinity to CXCR2 with best characteristics for imaging. IL-8, having a 
clearly higher affinity for the CXCR1 and CXCR2 receptor than NAP-2(1-66), showed a 
superior imaging quality. The other CXC-chemokines tested showed to be less suitable 
for infection imaging. 
 
Infection imaging with 99mTc-NAP-2 analogues     161 
 REFERENCES 
 
1.  Rennen HJ, Boerman OC, Oyen WJ, Corstens FH. Imaging infection/inflammation in the new millennium. Eur J 
Nucl Med. 2001;28:241-252. 
2.  Rollins BJ. Chemokines. Blood. 1997;90:909-928. 
3.  Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, Fuccello AJ, Rubin RH, Strauss HW, 
Fischman AJ. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for 
imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022-2028. 
4.  Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 
2000;12:121-127. 
5.  Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI. Characterization of two high affinity human 
interleukin-8 receptors. J Biol Chem. 1992;267:16283-16287. 
6.  Ahuja SK, Murphy PM. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, 
neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for 
the type B, but not the type A, human interleukin-8 receptor. J Biol Chem. 1996;271:20545-20550. 
7.  Wuyts A, Proost P, Lenaerts JP, Ben Baruch A, Van Damme J, Wang JM. Differential usage of the CXC 
chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell- derived 
neutrophil attractant-78. Eur J Biochem. 1998;255:67-73. 
8.  Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M. Platelet factor 4 binds to interleukin 8 receptors and 
activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci U S A. 
1993;90:3574-3577. 
9.  Dewald B, Moser B, Barella L, Schumacher C, Baggiolini M, Clark-Lewis I. IP-10, a gamma-interferon-inducible 
protein related to interleukin-8, lacks neutrophil activating properties. Immunol Lett. 1992;32:81-84. 
10. Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD. The beta-thromboglobulins and platelet factor 4: 
blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol. 
2000;67:471-478. 
11. Walz A, Baggiolini M. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or 
connective tissue-activating peptide III through monocyte proteases. J Exp Med. 1990;171:449-454. 
12. Brandt E, Van Damme J, Flad HD. Neutrophils can generate their activator neutrophil-activating peptide 2 by 
proteolytic cleavage of platelet-derived connective tissue- activating peptide III. Cytokine. 1991;3:311-321. 
13. Ehlert JE, Petersen F, Kubbutat MH, Gerdes J, Flad HD, Brandt E. Limited and defined truncation at the C 
terminus enhances receptor binding and degranulation activity of the neutrophil-activating peptide 2 (NAP-2). 
Comparison of native and recombinant NAP-2 variants. J Biol Chem. 1995;270:6338-6344. 
14. Ehlert JE, Gerdes J, Flad HD, Brandt E. Novel C-terminally truncated isoforms of the CXC chemokine beta- 
thromboglobulin and their impact on neutrophil functions. J Immunol. 1998;161:4975-4982. 
15. Krijgsveld J, Zaat SA, Meeldijk J, van Veelen PA, Fang G, Poolman B, Brandt E, Ehlert JE, Kuijpers AJ, 
Engbers GH, Feijen J, Dankert J. Thrombocidins, microbicidal proteins from human blood platelets, are C- 
terminal deletion products of CXC chemokines. J Biol Chem. 2000;275:20374-20381. 
16. Rennen HJ, Boerman OC, Oyen WJ, van der Meer JW, Corstens FH. Specific and rapid scintigraphic detection 
of infection with 99mTc- labeled interleukin-8. J Nucl Med. 2001;42:117-123. 
17. Rennen HJ, van Eerd JE, Oyen WJ, Corstens FH, Edwards DS, Boerman OC. Effects of coligand variation on the 
in vivo characteristics of  99mTclabeled interleukin-8 in detection of infection. Bioconjug Chem. 2002;13:370-377. 
18. Gratz S, Rennen HJ, Boerman OC, Oyen WJ, Corstens FH. Rapid imaging of experimental colitis with (99m)Tc-
interleukin-8 in rabbits. J Nucl Med. 2001;42:917-923. 
19. Schwartz DA, Abrams MJ, Giadomenico CM, Zubieta JA.  Certain pyridyl hydrazines and hydrazides useful for 
protein labeling. US patent nr.  5,206,370. 27-4-1993. 
20. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Both interleukin-8 receptors independently mediate 
chemotaxis. Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GRO alpha and NAP-2. 
FEBS Lett. 1994;341:187-192. 
21. Malkowski MG, Lazar JB, Johnson PH, Edwards BF. The amino-terminal residues in the crystal structure of 
connective tissue activating peptide-III(des10) block the ELR chemotactic sequence. J Mol Biol.1997;266:367-80 
22. Rennen HJ, Oyen WJ, Cain SA, Monk PN, Corstens FH, Boerman OC. Tc-99m-labeled C5a and C5a des 
Arg(74) for infection imaging. Nucl Med Biol. 2003;30:267-272. 
23. Leonard EJ, Yoshimura T, Rot A, Noer K, Walz A, Baggiolini M, Walz DA, Goetzl EJ, Castor CW. Chemotactic 
activity and receptor binding of neutrophil attractant/activation protein-1 (NAP-1) and structurally related host 
defense cytokines: interaction of NAP-2 with the NAP-1 receptor. J Leukoc Biol. 1991;49:258-265. 
24. Rennen HJ, Makarewicz J, Oyen WJ, Laverman P, Corstens FH, Boerman OC. The effect of molecular weight 
on nonspecific accumulation of (99m)T- labeled proteins in inflammatory foci. Nucl Med Biol. 2001;28:401-408. 
25. Rennen HJ, Boerman OC, Oyen WJ, Corstens FH. Kinetics of 99mTc-labeled interleukin-8 in experimental 
inflammation and infection. J Nucl Med. 2003;44:1502-1509.           

 
 
 
 
Chapter 11 
 
 
 
 
 
 
Conclusions and future prospects 
  
164     Chapter 11 
 
Imaging of infection and inflammation by targeting receptors on leukocytes 
Scintigraphic imaging of microbial and nonmicrobial foci of inflammation is a 
powerful diagnostic tool in the management of patients with inflammatory disorders. 
Rapid and accurate diagnosis of an inflammatory process allows early and adequate 
treatment and may prevent the onset of complications. Most inflammatory foci can be 
visualized accurately with ex vivo radiolabeled autologous leukocytes. The use of ex 
vivo labeled white blood cells is the standard nuclear medicine technique for imaging of 
inflammatory foci. However, this technique has several disadvantages: a.o., laborious 
preparation; requirement of specialized equipment and skills; handling of potentially 
contaminated blood. Therefore there is a continued search for an alternative agent with 
similar diagnostic power. After the relatively poor results obtained with large size 
monoclonal antibodies directed against surface antigens of leukocytes, radiolabeled 
small molecules that specifically bind to receptors on circulating leukocytes appeared 
to have more promise.  
As the leukocyte subpopulation of neutrophils play a prominent role in 
inflammatory disorders, especially in their acute phases, targeting receptors on 
neutrophils is of particular importance and involves several interesting features and 
choices for selection and optimization. 
 
The choice of the receptor(s).   
In this thesis three different neutrophil receptors for high-affinity binding were tested 
as target for imaging of inflammatory foci with radiolabeled receptor binding peptides 
and proteins: C5a and C5adR target the C5a-receptor (Chapter 9); the chemokines IL-
8, NAP-2 and others target the chemokine receptor CXCR2 (Chapters 4-8, 10); IL-8 
targets the chemokine receptor CXCR1 as well. The CXC-receptors, expressed in high 
numbers on neutrophils, appeared to be suitable targets for infection imaging with 
radiolabeled chemokines, especially with IL-8. IL-8 binds with high affinity to both 
CXCR1 and CXCR2 (Chapters 4-5). Alternative receptors for radiolabeled 
compounds, not investigated in this thesis, include the N-formyl-peptide receptors 
(FPR), which are high affinity binding receptors for chemotactic peptides such as 
Formyl-Met-Leu-Phe (fMLF) and its derivatives, and the Leukotriene B-4 (LTB-4) 
receptor BLT1, to which LTB-4 analogues bind with high affinity. These targets on 
the neutrophil proved to be suitable targets for radiolabeled compounds such as 
fMLFK and the LTB-4 receptor antagonists RP517 and DPC11870.  
High and exclusive expression of receptors on neutrophils is a prerequisite for 
specific targeting of neutrophils in vivo. The choice of the proper ligand for such a 
receptor opens a myriad of possibilities. This choice may be guided principally by two 
main characteristics of a candidate compound: affinity for the receptor and induction 
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of biologic effects (“side-effects”) following i.v. administration. In addition, finetuning 
of radiolabeling conditions may be applied in order to improve receptor binding and to 
improve the clearance (rate and route) of the radiolabeled compound from the blood 
and from non-target tissues.  
 
High affinity receptor binding  
High affinity for the receptor of choice should be in the nanomolar range and is 
definitely a requirement for effective imaging of inflammation as described in 
Chapters 9 and 10. A clear relationship between affinity for the receptor on neutrophils 
and suitability for infection imaging was found in an experimental study in which the 
targeting characteristics of radiolabeled NAP-2 and NAP-2 derivatives were compared 
(Chapter 10). The NAP-2 variant NAP-2(1-66) combined highest affinity to CXCR2 
with best characteristics for imaging. IL-8 binds to both CXCR1 and CXCR2 with high 
affinity and showed a superior imaging quality. The receptor binding affinity of C5a is in 
the nanomolar range and exceeds that of C5adR by 1-2 orders of magnitude.  For 
infection imaging 99mTc-labeled C5a showed considerable uptake in the focus but C5adR 
showed suboptimal imaging characteristics (Chapter 9). From the point of view of high 
(nanomolar) affinity for the receptor, IL-8, fMLF analogues, LTB-4 antagonists and, to 
some lesser degree, NAP-2(1-66) and C5a are interesting candidates for imaging of 
infection. 
 
Induction of side-effects 
The choice of the most suitable ligand is further also determined by the concern that most 
of the neutrophil receptor binding compounds elicit a biologic response after binding to 
the receptor. Side-effects such as leukopenia, leukocytosis, fever, hypotension, etc,  are 
undesirable for a diagnostic utility in routine clinical practice. The biologic activities of 
high-affinity binding compounds as C5a and also the fMLF analogues prevent the 
clinical use of these agents as infection imaging agents. The induction of side-effects can 
be addressed in several ways. First, a receptor antagonist can be applied as replacement 
for the agonist. However, in most cases receptor affinity and agonistic activity are closely 
related, resulting in lower affinity with less biological activation. Apparantly, the LTB-4 
receptor antagonists RP517 and DPC11870 are an exception to this rule. These agents 
appear not to trigger signal transduction following binding to the receptor. In most cases, 
however, high affinity binding receptor antagonists are not available and radiochemistry 
has to overcome potential side-effects. The biologic effect of the agent can be reduced by 
substantially increasing the specific activity of the radiolabeled agent. Successful efforts 
were made using state-of-the-art radiochemical approaches to increase the specific 
activity of 99mTc-labeled IL-8, thereby reducing the biologic effect of a diagnostic dose of 
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99mTc-IL-8 (Chapter 5). Using the bifunctional coupling agent S-HYNIC and a selected 
set of coligands, the protein administration dose was lowered a factor 350 compared to 
the iodinated IL-8 preparation used previously (Van der Laken et al., J Nucl Med 
2000;41:463-9). Based on pharmacokinetic data, at the low protein doses of 99mTc-
labeled IL-8, side-effects are not expected in humans.  
 
99mTc-HYNIC-IL-8 for imaging of infection and inflammation 
99mTc-HYNIC-IL-8 has excellent characteristics as an infection and inflammation 
imaging agent. As demonstrated in the animal experiments presented in this thesis, it 
surpasses the current standard, labeled white blood cells, in ease and safety of 
preparation, preparation time and quality of imaging (Target-to-Background ratios). 
Patient studies with 99mTc-HYNIC-IL-8 will have to demonstrate its safety (side-effects) 
and its value as a diagnostic tool in various clinical settings. None of the other 
chemotactic proteins for infection imaging described in this thesis could match the 
characteristics of IL-8 as infection imaging agent.  
Competitive new agents are positron emission tomography (PET) using 18F-
fluorodeoxyglucose (FDG) and the recently described LTB-4 receptor antagonist, 
DPC11870 (Van Eerd et al., J Nucl Med 2003;44:1087-91). In various clinical studies in 
patients with inflammatory disorders FDG-PET has already proved to be useful. The 
mechanism of accumulation is based on the fact that granulocytes and macrophages at 
the site of infection have an enhanced glucose metabolism. However, FDG-PET does not 
allow the discrimination between tumor lesions and inflammatory lesions. Moreover, 
FDG-PET is a rather expensive imaging modality and is not yet widely available.  
The 111In-labeled LTB-4 receptor antagonist, DPC11870, also has great potential 
as a new infection imaging agent. DPC11870, a small (3 kDa) nonpeptide compound, 
clearly delineated infectious foci in various rabbit models of infection and inflammation. 
It was reported to induce no biologic effects after intravenous administration. A 
disadavantage here is the choice of 111In as radiometal. 99mTc has much more favorable 
physical characteristics. In future studies the 111In chelating DTPA moiety of DPC11870 
will be replaced by a 99mTc chelating HYNIC moiety.  
 
Alternative labeling strategies for IL-8 
The IL-8 molecule is an ideal playground for the radiochemist. It offers opportunities for 
alternative labeling strategies with 99mTc and 18F. It offers opportunities for more 
selective, site-directed labeling strategies which do not impede binding of labeled IL-8 to 
the receptors on neutrophils. A further development, not limited to IL-8 for its 
application, is the modification of the bifunctional coupling agent S-HYNIC, which 
might facilitate clearance of the radiolabel from the body and the kidneys.  
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IL-8 is a 72 amino acid protein and contains 9 lysine residues. The 9 primary ε-
amino groups of the lysine residues and the N-terminal α-amino group of serine are 
potential sites for reaction with activated esters as the succinimidyl moiety in 
succinimidyl-hydrazinonicotinamide (S-HYNIC), the bifunctional coupling agent most 
extensively applied in this thesis. A careful selection of conditions for the conjugation 
reaction of S-HYNIC with IL-8 resulted in a HYNIC-IL-8 conjugate that could be 
labeled with 99mTc with high specific activity in combination with preservation of the 
neutrophil binding capacity (Chapters 4 and 5).  
 
The tricarbonyl approach: labeling IL-8 with [99mTc(CO)3(H2O)3]+ 
The two histidine residues of IL-8 might be used in an alternative method to label IL-8 
with 99mTc: labeling with 99mTc using the tricarbonyl method. In this method an 
organometallic aquaion [99mTc(CO)3(H2O)3]+ is formed as a precursor. This precursor 
complex can be used to label IL-8 with 99mTc presumably via the histidine residues of IL-
8. Preliminary experiments, not reported in this thesis, indicated that 99mTc-IL-8 
preparations prepared according to the tricarbonyl method showed distinctive differences 
in biodistribution in rabbits with infection as compared to 99mTc-IL-8 using S-HYNIC as 
bifunctional coupling agent. Relatively modest specific activities were obtained with the 
99mTc-tricarbonyl method and future experiments will focus on the modification of IL-8 
with an Nα-histidinyl acetate group to facilitate complexation with the 99mTc-aquaion 
complex and in order to produce a radiochemically better defined product. However, in 
comparison to the labeling of proteins with 99mTc via HYNIC, the 99mTc-tricarbonyl 
approach in its current phase is more laborious and more time consuming. The 99mTc-
tricarbonyl approach takes two reaction steps involving radioactive 99mTc instead of one 
step in case of direct labeling of HYNIC-conjugated proteins with 99mTc. 
   
Site-specific conjugation of HYNIC to IL-8 
As mentioned above, the 10 primary amino groups of IL-8 can potentially react with S-
HYNIC. The HYNIC-moieties are more or less randomly linked to these primary amino 
groups and could potentially interfere with receptor binding. Introduction of a HYNIC-
group into IL-8 in a chemically well-defined manner, at a region of the molecule not 
involved in receptor binding, could potentially improve the characteristics of 99mTc-
labeled IL-8 for imaging of infection. IL-8 has a serine residue at the N-terminus of the 
protein, a distinctive and rather unique feature. The N-terminal serine residue can be 
selectively oxidized under mild conditions to give a reactive glyoxyl function. Peptides 
with an N-terminal cysteine residue can react with the glyoxyl function forming a 
thiazolidine-ring which is highly stable over a broad range of pH and temperature 
conditions. For site-specific conjugation of HYNIC to IL-8, small peptides containing an 
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N-terminal cysteine residue and a HYNIC-moiety as attached to an adjacent amino acid 
residue, were synthesized by solid-phase synthesis.  The in vivo characteristics of site-
specifically HYNIC-conjugated IL-8 are currently under investigation in experimental 
models of infection.  
 
Cleavable linkers for faster clearance and excretion 
As indicated in Chapters 4 and 5, 99mTc-HYNIC-IL-8 is cleared mainly via the kidneys, 
but is only partially excreted to the urine. It has been shown for bifunctional chelating 
agents linked to antibodies that the biodistribution of the radiolabeled antibody is 
strongly dependent on the nature of the linker. Antibody-conjugates containing cleavable 
linkers exhibit faster whole-body clearance and excretion from the body as compared to 
antibody-conjugates containing noncleavable linkers. Future efforts will be directed 
towards synthesis of an S-HYNIC derivative including additional ester groups between 
the hydrazinonicotinic (HYNIC) moiety and the succinimidyl (S) moiety for faster 
clearance and excretion. Such a derivative could find a broad range of applications, not 
restricted to conjugation to IL-8. 
  
Positron emission tomography (PET) using 18F-IL-8 
The 10 amino groups in IL-8 can potentially be used to label IL-8 with 18F for positron 
emission tomography (PET). For instance, N-succinimidyl 4-[18F]fluorobenzoate (SFB) 
contains a succinimidyl-group and can be coupled to IL-8 in a similar way as used for 
coupling of S-HYNIC to IL-8. PET using 18F-IL-8 is feasible because of rapid and high 
accumulation of radiolabeled IL-8 in foci of infection. PET-imaging is of particular 
interest for its high spatial resolution. High spatial resolution is of particular importance, 
e.g.,  when it is crucial to discriminate soft tissue infection from bone infection in cases 
of osteomyelitis.  
 
Limitations 
The utility of neutrophil binding compounds is limited, once a discrimination between 
infection and sterile inflammation is required such as in, e.g., the evaluation of infection 
of orthopaedic prostheses. For application in those cases, radiolabeled agents that 
specifically bind to micro-organisms have been proposed (Infecton, 99mTc-labeled 
antimicrobial peptides). Though an attractive concept, directly targeting micro-organisms 
is still in a premature state, and most radiopharmaceuticals currently under investigation 
show a lack of targeting and/or specificity. The utility of neutrophil binding compounds 
is also limited in diagnosing infection and inflammation in deeply neutropenic patients. 
In those cases, agents not relying on neutrophil receptor binding such as, e.g., 
radiolabeled polyclonal IgG, could be applied.     
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Patients with inflammatory disorders may pose a diagnostic problem to their 
physicians. Rapid and accurate detection of inflammatory foci is a challenging 
problem in clinical practice, because it may have important implications for the 
treatment of patients with presumed or established inflammatory disorders. Over the 
last 30 years various approaches to visualize inflammatory foci scintigraphically have 
been developed. Chapter 1 presents a survey of the different approaches currently in 
use or under investigation. In response to inflammation, white blood cells move 
massively to inflammatory foci and localize there in great numbers. The use of ex vivo 
labeled white blood cells is currently the gold standard nuclear medicine technique for 
imaging of inflammatory foci. The limitations of this approach have encouraged the 
continued search for an alternative agent with at least a similar diagnostic power.  
 
The aim of the studies described in this thesis is to investigate the potential of 99mTc-
labeled interleukin-8 (IL-8) for imaging infection and inflammation. IL-8 is a small 
protein that binds with high affinity to receptors on white blood cells in general and 
especially to receptors on the white blood cell subpopulation of neutrophils. IL-8 was 
labeled with the radionuclide 99mTc using a derivative of hydrazinonicotinamide 
(HYNIC) as bifunctional coupling agent. The HYNIC-derivative is first coupled to IL-
8 and is used subsequently to bind 99mTc. 
 
In two fundamental studies the chemistry of  labeling proteins with 99mTc via HYNIC 
is investigated. The effects of conjugation ratio, reaction temperature, pH and protein 
concentration on HYNIC-substitution ratio, labeling efficiency and biologic activity 
were studied in a series of proteins (molecular weight between 6.5 and 17 kDa) 
(Chapter 2). It was found that HYNIC-conjugation was most efficient at 0 0C (as 
compared to 20 and 40 0C), at pH 8.2 (as compared to 6.0, 7.2 and 9.5) and at protein 
concentrations ≥ 2.5 mg/ml. Labeling efficiency improved with increasing molar 
conjugation ratio HYNIC/protein. For receptor binding proteins, biologic activity was 
best preserved under relatively mild conjugation conditions.  
 
In Chapter 3, the effect of molecular weight on non-specific accumulation of  99mTc 
labeled proteins in inflammatory foci is studied in a rat model. Eleven proteins in a 
broad molecular weight range from 2.5 kDa up to 800 kDa were labeled with 99mTc via 
HYNIC. Rats with an intramuscular S. aureus infection were injected intravenously 
with the 99mTc-labeled proteins and scintigraphic images were acquired. Proteins of 
intermediate size (66 kDa – 206 kDa) showed moderate hepatic and moderate renal 
clearance with sustained high blood levels and showed highest localization in 
inflammatory foci. This study showed that the circulatory half-life is the main 
characteristic of a non-specific tracer protein that determines its suitability for 
infection imaging. From the proteins tested here, IgG and serum albumin showed the 
best characteristics.  
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In Chapter 4 the first in vivo characterization of 99mTc-HYNIC-IL-8 in rabbits with an 
intramuscular infection is described. It was shown that the white blood cell receptor 
binding capacity was preserved after labeling. Gamma camera imaging rapidly visualized 
the abscess from 1 hour after injection onwards, with abscess/background ratios 
improving with time up to 22 at 8 hour after injection versus 2.7 for a 99mTc-labeled 
control protein lysozyme. The only mild transient drop of white blood cell counts shortly 
after injection suggested that 99mTc-HYNIC-IL-8 may be suitable as an imaging agent 
with only mild and  transient side-effects.  
 
In Chapter 5 a further optimization of the labeling of IL-8 with 99mTc is described. The 
propylaldehyde hydrazone formulation of HYNIC was introduced to enhance the shelf-
life of HYNIC-IL-8. 99mTc-HYNIC-IL-8 was prepared using 5 different coligands. The 
effects of these coligands on the in vitro characteristics and in vivo behavior of 99mTc-
HYNIC-IL-8 in rabbits with E.coli induced intramuscular infection were investigated. 
The most optimal infection imaging characteristics were obtained when nicotinic 
acid/tricine was used as coligand system. This preparation combined a high specific 
activity (up to 80 MBq/µg) with a high in vitro stability and high abscess/background 
ratios (>20) at 6 hour after injection. As a result of the high specific activity, protein 
doses to be administered were as low as 70 ng/kg bodyweight. At these low protein doses 
side effects are not to be expected in the human system.  
 
The importance of the careful choice of the radiolabeling conditions for the imaging 
characteristics was stressed once more in the Addendum to Chapter 5.   
 
In addition to its suitability to delineate infectious and inflammatory foci in rabbits with 
intramuscular infection, 99mTc-HYNIC-IL-8 demonstrated its utility as an imaging agent 
in rabbit models of colitis and pulmonary infection.  
In rabbits with chemically-induced acute colitis, inflammatory lesions were visualized 
scintigraphically after injection of 99mTc-HYNIC-IL-8 (Chapter 6). Within 4 hour after 
injection, 99mTc-labeled IL-8 allowed a meticulous evaluation of the severity of 
inflammatory bowel disease.  
99mTc-labeled IL-8 was tested for imaging of pulmonary infection in three 
experimental rabbit models: aspergillosis in immunocompromised rabbits, 
pneumococcal (gram-positive) pneumonia and E.coli-induced (gram-negative) 
pneumonia in immunocompetent rabbits (Chapter 7). 99mTc-HYNIC-IL-8 enabled 
early (within 2 hour after injection) and excellent visualization of localization and 
extent of pulmonary infection in each of the three models of pulmonary infection. 
99mTc-labeled IL-8 offers many advantages over the conventionally used 
radiopharmaceuticals to image pulmonary infection, 67Ga-citrate and radiolabeled 
white blood cells, i.e., rapid and easy preparation, short time span between injection 
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and imaging, low radiation burden and, most importantly, a clear delineation of the 
infectious foci. 
 
The pharmacokinetics of 99mTc-HYNIC-IL-8 are studied in detail in Chapter 8. To 
address specificity of uptake of 99mTc-labeled IL-8 in the abscess, uptake in turpentine-
induced abscesses in neutropenic rabbits was compared to uptake in turpentine-
induced abscesses in normal rabbits. Abscess uptake in immunocompetent rabbits was 
ten times higher than that in neutropenic rabbits, demonstrating specificity of the target 
uptake of 99mTc-IL-8. Substantial support is provided for the hypothesis that 99mTc-
labeled IL-8 localizes in the abscess mainly by binding to peripheral neutrophils. As 
assessed by in vivo and ex vivo analysis, the total fraction that accumulates in the 
inflamed tissue was extremely high (more than 15% of the injected dose).    
 
In Chapters 9 and 10 other leukocyte receptor binding ligands were investigated. 
The complement factor C5a and its natural metabolite C5a des Arg74 (C5adR) both act on 
a common receptor expressed on neutrophils. The receptor binding affinity of C5a is in 
the nanomolar range and exceeds that of C5adR ten to hundred fold. 99mTc-labeled C5a 
and C5adR were tested for imaging of infection in a rabbit model of intramuscular 
infection (Chapter 9).  For infection imaging 99mTc-labeled C5a showed excellent in 
vivo characteristics. However, C5a is an extremely bioactive protein, impeding its 
clinical use as an infection imaging agent. C5adR is biologically less active but showed 
suboptimal imaging characteristics. This study suggested that for adequate localization of 
a receptor binding ligand affinities for the receptor in the nanomolar range are required. 
 
The CXC-chemokines are a family of closely related chemotactic cytokines, which bind 
to, attract and activate neutrophils. In Chapter 10 the relationship between neutrophil 
binding affinity and suitability for infection imaging was investigated in a selected group 
of CXC-chemokines, including NAP-2, three NAP-2 variants, IL-8, CTAP-III, GCP-2, 
ENA-78, PF-4 and IP-10. The 99mTc-labeled CXC-chemokines were tested for imaging 
of infection in rabbits with intramuscular E.coli infections. This study showed a clear 
relationship between neutrophil receptor affinity and suitability for infection imaging. Of 
the NAP-2 variants, NAP-2(1-66) combined highest affinity to CXCR2 with best 
characteristics for imaging.  
 
Conclusion 
99mTc-HYNIC-IL-8 has almost ideal characteristics as an infection imaging agent. As 
demonstrated in the animal experiments presented in this thesis, it surpasses the current 
standard, labeled white blood cells, in ease and safety of preparation, preparation time 
and quality of imaging. Patient studies with 99mTc-HYNIC-IL-8 will have to demonstrate 
its safety and its value as a new diagnostic tool in various clinical settings. 
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De diagnose van ontstekingen bij patiënten is vaak moeilijk. Snel en adequaat 
detecteren van ontstekingshaarden is een ware uitdaging in de klinische praktijk, met 
belangrijke gevolgen voor de behandeling van patiënten met een mogelijke dan wel 
reeds vastgestelde ontsteking. De afgelopen 30 jaar zijn er diverse methodes 
ontwikkeld om ontstekingshaarden zichtbaar te maken met gebruik van radioactieve 
stoffen en detectie met behulp van gammacamera’s. In Hoofdstuk 1 wordt een 
overzicht gegeven van de diverse technieken die momenteel in de kliniek worden 
toegepast en van technieken die in ontwikkeling zijn. In reactie op de ontsteking 
bewegen witte bloedcellen zich massaal naar de ontstekingshaard en verblijven daar in 
groten getale. Het gebruik van radioactief gelabelde witte bloedcellen vormt nog altijd 
de gouden standaard binnen het vakgebied van de nucleaire geneeskunde voor het 
scintigrafisch zichtbaar maken van ontstekingshaarden. Deze techniek kent zijn 
beperkingen en er wordt dan ook naarstig gezocht naar een alternatief middel met een 
op zijn minst gelijkwaardige diagnostische kwaliteit.   
 
Het doel van de studies zoals beschreven in dit proefschrift is om Technetium-99m 
(99mTc) gelabeld interleukine-8 (IL-8) te onderzoeken op zijn kwaliteiten om 
ontstekingen zichtbaar te maken. IL-8 is een klein eiwit dat met hoge affiniteit bindt 
aan receptoren op witte bloedcellen in het algemeen en aan receptoren op een 
subpopulatie van witte bloedcellen, de neutrofielen, in het bijzonder. Om IL-8 te 
labelen met het radionuclide 99mTc werd gebruik gemaakt van een 
hydrazinonicotinamide (HYNIC) derivaat als bifunctioneel koppelingsreagens. Het 
HYNIC derivaat wordt eerst aan IL-8 gekoppeld en wordt vervolgens benut om 99mTc 
te binden. 
 
In twee fundamentele studies wordt de chemie van het labelen van eiwitten met 99mTc 
via HYNIC nader bekeken. De effecten van de conjugatieratio, de reactietemperatuur, 
pH en eiwitconcentratie op de HYNIC-substitutie ratio, de labelingsefficiëntie en de 
biologische activiteit werden onderzocht in een reeks eiwitten met een 
molecuulgewicht tussen de 6.5 en 17 kDa (Hoofdstuk 2). De conjugatie bleek het 
meest efficiënt te verlopen bij 0 0C (in vergelijking met 20 en 40 0C), bij pH 8.2 (in 
vergelijking met pH 6.0, 7.2 en 9.5) en bij eiwitconcentraties boven 2.5 mg/ml. De 
labelingsefficiëntie nam toe bij een toenemende molaire conjugatie ratio HYNIC/eiwit. 
In geval van receptor bindende eiwitten bleek de biologische activiteit het beste 
behouden te blijven onder relatief milde conjugatie condities. 
 
Hoofdstuk 3 beschrijft het effect van het molecuulgewicht van het eiwit op de niet-
specifieke opname van 99mTc-gelabelde eiwitten in ontstekingshaarden in ratten. Elf 
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eiwitten variërend in molecuul gewicht tussen de 2.5 en 800 kDa werden gelabeld met 
99mTc via HYNIC. Ratten met een door S.aureus bacteriën geïnduceerde infectie in de 
dijbeenspier werden intraveneus geïnjecteerd met de radioactief gelabelde eiwitten. 
Vervolgens werden op verschillende tijdstippen opnames van de ratten gemaakt met 
een gamma-camera. Eiwitten van gemiddelde grootte (66 kDa – 206 kDa) vertoonden 
een bescheiden mate van klaring door de lever en de nieren, een aanhoudend hoge 
bloedspiegel en de hoogste opname in de ontstekingshaarden. Deze studie toonde aan 
dat de circulatietijd voor niet-specifieke tracer eiwitten de belangrijkste factor is ter 
bepaling van de geschiktheid voor scintigrafische detectie van ontstekingen. Van de 
geteste eiwitten bleken polyclonaal immunoglobuline G en serum albumine het meest 
geschikt. 
 
In Hoofdstuk 4 wordt de eerste in vivo karakterisering van 99mTc-HYNIC-IL-8 in 
konijnen met een spierontsteking beschreven. Uit deze studies bleek dat dit preparaat 
ook na labeling nog in staat was om te binden aan receptoren op witte bloedcellen. 
Reeds vanaf 1 uur na de injectie konden de ontstekingen met een gamma-camera 
zichtbaar gemaakt worden. De verhouding tussen de opname in de ontsteking en de 
achtergrond (abces/achtergrond ratio) nam geleidelijk aan toe tot een waarde van 22, 8 
uur na toediening van het preparaat. Ter vergelijking, de abces/achtergrond ratio van 
een controle eiwit, 99mTc-gelabeld lysozyme, bedroeg 2,7. Als gevolg van de injectie 
met 99mTc-HYNIC-IL-8 werd een slechts geringe en tijdelijke daling van het aantal 
witte bloedcellen gezien, hetgeen aangeeft dat de bijwerkingen van toediening van 
99mTc-HYNIC-IL-8 mild en tijdelijk zijn. 
 
In Hoofdstuk 5 wordt een verdere optimalisatie van de labeling van IL-8 met 99mTc 
beschreven. Om de houdbaarheid van HYNIC-IL-8 te vergroten werd de 
propylaldehyde hydrazon formulering van HYNIC geïntroduceerd. Vervolgens werden 
99mTc-HYNIC-IL-8 preparaten met behulp van vijf verschillende coliganden gelabeld. 
Het effect van deze coliganden op de in vitro karakteristieken en het in vivo gedrag 
van 99mTc-HYNIC-IL-8 werd bestudeerd in konijnen met ontstekingen in de 
dijbeenspier geïnduceerd door E.coli bacteriën. Het gebruik van nicotinezuur/tricine 
als coliganden gaf de meest optimale eigenschappen om ontstekingen te visualiseren. 
Dit preparaat combineerde een hoge specifieke activiteit (tot 80 MBq/µg) met een 
goede in vitro stabiliteit en hoge abces/achtergrond ratio’s (>20), 6 uur na toediening. 
Als gevolg van de hoge specifieke activiteit komt de toegediende hoeveelheid eiwit in 
mensen niet boven de 70 ng/kg lichaamsgewicht uit. Bij deze lage eiwitdoses worden 
geen bijwerkingen verwacht. 
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Het belang van een zorgvuldige keuze van de radiolabeling condities voor de kwaliteit 
van de scintigrafische detectie wordt nogmaals benadrukt in het Addendum bij 
Hoofdstuk 5.  
 
99mTc-HYNIC-IL-8 is niet alleen bruikbaar om ontstekingen in spieren in konijnen te 
visualiseren, maar bleek ook geschikt als diagnosticum in experimentele modellen van 
colitis en longontsteking in konijnen. 
In konijnen met chemisch geïnduceerde acute colitis werden de ontstekingshaarden 
scintigrafisch zichtbaar gemaakt met behulp van 99mTc-HYNIC-IL-8 (Hoofdstuk 6). 
Binnen 4 uur na injectie van 99mTc-HYNIC-IL-8 is een nauwgezette beoordeling van 
de ernst van de ontsteking in de darm mogelijk.  
99mTc-HYNIC-IL-8 werd getest als diagnosticum voor longontstekingen in drie 
experimentele modellen in konijnen: aspergillosis in konijnen met een verzwakt 
afweersysteem, pneumococcen (gram-positieve) pneumonie en E.coli geïnduceerde 
(gram-negatieve) pneumonie in konijnen met een normaal afweersysteem (Hoofdstuk 
7). Met behulp van 99mTc-HYNIC-IL-8 kon binnen twee uur na toediening de plaats en 
ernst van de ontsteking uitstekend bepaald worden in elk van de drie modellen. 99mTc-
HYNIC-IL-8 biedt diverse voordelen boven de conventionele radiofarmaca voor de 
detectie van longontsteking, namelijk 67Ga-citraat en radioactief gelabelde witte 
bloedcellen. Deze voordelen zijn een snelle en eenvoudige bereiding, een korte 
tijdsspanne tussen het injecteren en het maken van de opnames, een lage 
stralingsbelasting en, niet onbelangrijk, een scherpere aftekening van de 
ontstekingshaarden op de opnames. 
 
De farmacokinetiek van 99mTc-HYNIC-IL-8 wordt in detail bestudeerd in Hoofdstuk 
8. Om te onderzoeken in welke mate de aanwezigheid van neutrofielen een rol speelt 
bij de opname van 99mTc-gelabeld IL-8 in een ontsteking, werd de opname van 99mTc-
HYNIC-IL-8 in steriele ontstekingen in konijnen met zeer weinig neutrofielen 
(neutropene konijnen) vergeleken met de opname in steriele ontstekingen in konijnen 
met normale aantallen neutrofielen (normale konijnen). De opname van 99mTc-
HYNIC-IL-8 in ontstekingen in normale konijnen was tien keer hoger dan de opname 
in ontstekingen in neutropene konijnen, een goede demonstratie van de (neutrofiel 
afhankelijke) specificiteit van opname van 99mTc-IL-8 in ontstekingen. Verder wordt 
aannemelijk gemaakt dat 99mTc-gelabeld IL-8 in de ontstekingshaard terechtkomt 
hoofdzakelijk middels binding aan neutrofielen in de bloedbaan. Uit zowel in vivo als 
ex vivo analyses bleek de totale fractie van het geïnjecteerde preparaat dat uiteindelijk 
in het ontstoken weefsel terecht komt extreem hoog (meer dan 15%) te zijn.   
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In de Hoofdstukken 9 en 10 worden andere eiwitten die binden aan receptoren op 
witte bloedcellen onderzocht.  
C5a, een eiwit dat deel uit maakt van het complementsysteem, en zijn natuurlijke 
metaboliet C5a des Arg74 (C5adR) binden beide de zelfde receptor op witte 
bloedcellen. De bindingsaffiniteit van C5a is in de orde van grootte van 10-9 M, een 
factor 10-100 hoger dan in geval van C5adR. 99mTc-gelabeld C5a en C5adR werden 
getest op hun vermogen om ontstekingen zichtbaar te maken in konijnen met 
spierontstekingen (Hoofdstuk 9). 99mTc-gelabeld C5a vertoonde uitstekende 
eigenschappen om ontstekingen te visualiseren. C5a is echter biologisch zeer actief, 
hetgeen een gebruik in de kliniek als beeldvormend middel voor ontstekingen 
belemmert. C5adR is een biologisch minder actief eiwit maar is als diagnosticum 
suboptimaal. Deze studie gaf aan dat voor een adequate lokalisatie van een receptor 
bindend eiwit bindingsaffiniteiten in de orde van grootte van 10-9 M vereist zijn. 
 
De CXC-chemokines zijn een familie van nauw verwante chemotactische cytokinen, 
die binden aan neutrofielen, deze aantrekken en activeren. In Hoofdstuk 10 wordt de 
relatie tussen bindingsaffiniteit voor neutrofielen en mate van geschiktheid voor het 
zichtbaar maken van ontstekingen onderzocht in een selectie van CXC-chemokines, 
waaronder NAP-2, drie NAP-2 varianten, IL-8, CTAP-III, GCP-2, ENA-78, PF-4 en 
IP-10. De 99mTc-gelabelde CXC-chemokines werden getest op hun vermogen om 
ontstekingen zichtbaar te maken in konijnen met spierontstekingen geïnduceerd door 
E.coli. Deze studie toonde een duidelijk verband aan tussen receptoraffiniteit voor 
neutrofielen en de mate van geschiktheid voor het zichtbaar maken van ontstekingen. 
Van de NAP-2-varianten combineerde NAP-2(1-66) een hoogste affiniteit voor de 
CXCR2 receptor met de beste eigenschappen voor beeldvorming.  
 
Conclusie  
De dierexperimentele studies zoals beschreven in dit proefschrift laten zien dat 99mTc-
HYNIC-IL-8 beter is dan de huidige standaard, gelabelde witte bloedcellen, voor het 
scintigrafisch zichtbaar maken van ontstekingen. De bereiding is sneller en 
eenvoudiger en er bestaat geen kans op besmetting door bloedproducten. Tevens is de 
kwaliteit van de scintigrafische opnames veel beter dan die van gelabelde witte 
bloedcellen. De veiligheid van 99mTc-HYNIC-IL-8 voor de patiënt en de klinische 
toepasbaarheid dienen nog nader onderzocht te worden.  
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